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. INTRODUCTION
hese guidelines address the diagnosis and management
f atherosclerotic, aneurysmal, and thromboembolic pe-
ipheral arterial diseases (PADs). The clinical manifesta-
ions of PAD are a major cause of acute and chronic
llness, are associated with decrements in functional
apacity and quality of life, cause limb amputation, and
ncrease the risk of death. Whereas the term “peripheral
rterial disease” encompasses a large series of disorders
hat affect arterial beds exclusive of the coronary arteries,
his writing committee chose to limit the scope of the
ork of this document to include the disorders of the
bdominal aorta, renal and mesenteric arteries, and lower
xtremity arteries. The purposes of the full guidelines are
o (a) aid in the recognition, diagnosis, and treatment of
AD of the aorta and lower extremities, addressing its
revalence, impact on quality of life, cardiovascular isch-
mic risk, and risk of critical limb ischemia (CLI); (b) aid
n the recognition, diagnosis, and treatment of renal and
isceral arterial diseases; and (c) improve the detection
nd treatment of abdominal and branch artery aneurysms.
linical management guidelines for other arterial beds
e.g., the thoracic aorta, carotid and vertebral arteries,
nd upper-extremity arteries) have been excluded from
he current guidelines to focus on the infradiaphragmatic
rterial system and in recognition of the robust evidence
ase that exists for the aortic, visceral, and lower extrem-
ty arteries.
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nd tables included in this executive summary represent a
uccinct summary of the more extensive evidence base,
ritical evaluation, tables, and references that are included in
he full-text document. Readers are strongly encouraged to
efer to this source document to gain full access to the 65
ables, more than 1300 references, and supporting text
ssembled by the writing committee. The full-text docu-
ent can be accessed at http://www.acc.org/clinical/
uidelines/pad/index.pdf.
A classification of recommendation and level of evi-
ence have been assigned to each recommendation.
lassifications of recommendations and levels of evidence
re expressed in the American College of Cardiology
ACC)/American Heart Association (AHA) format as
ollows.
lassification of Recommendations
lass I: Conditions for which there is evidence for and/or
general agreement that a given procedure or treatment is
beneficial, useful, and effective.
lass II: Conditions for which there is conflicting evidence
and/or a divergence of opinion about the usefulness/
efficacy of a procedure or treatment.
Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well established by
evidence/opinion.
lass III: Conditions for which there is evidence and/or
general agreement that a procedure/treatment is not
useful/effective and in some cases may be harmful.
evel of Evidence
evel of Evidence A: Data derived from multiple random-
ized clinical trials or meta-analyses.
evel of Evidence B: Data derived from a single random-
ized trial or nonrandomized studies.
evel of Evidence C: Only consensus opinion of experts,
case studies, or standard of care. (Please refer to Table 1
in the full-text guidelines for more details.)
. Definitions
or the purposes of these guidelines, the term “peripheral
rterial disease” broadly encompasses the vascular dis-
ases caused primarily by atherosclerosis and thrombo-
mbolic pathophysiological processes that alter the nor-
al structure and function of the aorta, its visceral
rterial branches, and the arteries of the lower extremity.
eripheral arterial disease is the preferred clinical term
hat should be used to denote stenotic, occlusive, and
neurysmal diseases of the aorta and its branch arteries,
xclusive of the coronary arteries.. Vascular History and Physical Examination
ECOMMENDATIONS
lass I
. Individuals at risk for lower extremity PAD (see
Section 2.1.1 of the full-text guidelines) should un-
dergo a vascular review of symptoms to assess walk-
ing impairment, claudication, ischemic rest pain,
and/or the presence of nonhealing wounds. (Level of
Evidence: C)
. Individuals at risk for lower extremity PAD (see
Section 2.1.1 of the full-text guidelines) should un-
dergo comprehensive pulse examination and inspec-
tion of the feet. (Level of Evidence: C)
. Individuals over 50 years of age should be asked if
they have a family history of a first-order relative with
an abdominal aortic aneurysm. (Level of Evidence: C)
The full-text guidelines offer suggestions for creation of a
ascular review of systems as outlined below.
Key components of the vascular review of systems (not
sually included in the review of systems of the extremities)
nd family history include the following:
Any exertional limitation of the lower extremity muscles
or any history of walking impairment. The characteristics
of this limitation may be described as fatigue, aching,
numbness, or pain. The primary site(s) of discomfort in
the buttock, thigh, calf, or foot should be recorded, along
with the relation of such discomfort to rest or exertion.
Any poorly healing or nonhealing wounds of the legs or
feet.
Any pain at rest localized to the lower leg or foot and its
association with the upright or recumbent positions.
Postprandial abdominal pain that reproducibly is pro-
voked by eating and is associated with weight loss.
Family history of a first-degree relative with an abdom-
inal aortic aneurysm.
he Vascular Physical Examination
ey components of the vascular physical examination are as
ollows:
Measurement of blood pressure in both arms and nota-
tion of any interarm asymmetry.
Palpation of the carotid pulses and notation of the carotid
upstroke and amplitude and presence of bruits.
Auscultation of the abdomen and flank for bruits.
Palpation of the abdomen and notation of the presence of
the aortic pulsation and its maximal diameter.
Palpation of pulses at the brachial, radial, ulnar, femoral,
popliteal, dorsalis pedis, and posterior tibial sites. Per-
form Allen’s test when knowledge of hand perfusion is
needed.
Auscultation of both femoral arteries for the presence of
bruits.
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numerically as follows: 0, absent; 1, diminished; 2,
normal; and 3, bounding.
The shoes and socks should be removed; the feet in-
spected; the color, temperature, and integrity of the skin
and intertriginous areas evaluated; and the presence of
ulcerations recorded.
Additional findings suggestive of severe PAD, including
distal hair loss, trophic skin changes, and hypertrophic
nails, should be sought and recorded.
I. LOWER EXTREMITY PAD
. Epidemiology
. Risk Factors. The major cause of lower extremity PAD
s atherosclerosis. Risk factors for atherosclerosis such as
igarette smoking, diabetes, dyslipidemia, hypertension, and
yperhomocysteinemia increase the likelihood of develop-
ng lower extremity PAD (Fig. 1).
. Prevalence. Lower extremity PAD is a common syn-
rome that affects a large proportion of most adult popula-
ions worldwide (1,2). Peripheral arterial disease can be
resent in subclinical forms that can be detected by use of
ensitive vascular imaging techniques, which may reveal
arly manifestations of arterial disease before it is detected
y either limb-pressure measurements or clinical symptoms.
hen so defined, as, for example, by measurement of the
ntimal-medial thickness (IMT) in the carotid or femoral
rtery, early forms of PAD are easily detected in populations
t risk (3). Claudication, a symptomatic expression of lower
igure 1. Risk of developing lower extremity peripheral arterial disease.
he range for each risk factor is estimated from epidemiologic studies
see text). The relative risks take into consideration current smokers vs.
ormer smokers and nonsmokers; the presence vs. the absence of
iabetes and hypertension; and the highest vs. the lowest quartile of
omocysteine and C-reactive protein. The estimate for hypercholester-
lemia is based on a 10% risk for each 10 mg/dl rise in total cholesterol.
dapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the
ransAtlantic Inter-Society Consensus (TASC) Working Group,
anagement of peripheral arterial disease (PAD), S1–S296, Copyright
000, with permission from Elsevier (16).xtremity PAD, defines a significantly smaller subset of the
otal population with the disease.
. Prognosis and Natural History
. Coprevalence of Coronary Arterial Disease and Ca-
otid Disease. The prognosis of patients with lower ex-
remity PAD is characterized by an increased risk for
ardiovascular ischemic events due to concomitant coronary
rtery disease and cerebrovascular disease (1,4). These car-
iovascular ischemic events are more frequent than ischemic
imb events in any lower extremity PAD cohort, whether
ndividuals present without symptoms or with atypical leg
ain, classic claudication, or CLI (Fig. 2) (5).
. Other Causes of Lower Extremity PAD
eripheral arterial disease has a diversity of causes beyond
therosclerosis. Aneurysms may be associated with atheroscle-
osis, may be due to underlying hereditary (familial) reasons, or
ay be of acquired (e.g., due to smoking or trauma) origin.
enal arterial disease may be due to atherosclerosis, fibromus-
ular dysplasia, or arteritides. Lower extremity PAD may be
aused by atherosclerotic, thromboembolic, inflammatory, or
neurysmal disease; by trauma, adventitial cysts, or entrapment
yndromes; or by congenital abnormalities. Establishment of
n accurate diagnosis is necessary if individual patients are to
eceive ideal pharmacological, endovascular, surgical, or reha-
ilitative interventions.
. Clinical Presentation
. Asymptomatic.
ECOMMENDATIONS
lass I
. A history of walking impairment, claudication, isch-
emic rest pain, and/or nonhealing wounds is recom-
mended as a required component of a standard review
of systems for adults 50 years and older who have
atherosclerosis risk factors and for adults 70 years and
older. (Level of Evidence: C)
. Individuals with asymptomatic lower extremity
PAD should be identified by examination and/or
measurement of the ankle-brachial index (ABI) so
that therapeutic interventions known to diminish
their increased risk of myocardial infarction (MI),
stroke, and death may be offered. (Level of Evi-
dence: B)
. Smoking cessation, lipid lowering, and diabetes and
hypertension treatment according to current national
treatment guidelines are recommended for individuals
with asymptomatic lower extremity PAD. (Level of
Evidence: B)
. Antiplatelet therapy is indicated for individuals with
asymptomatic lower extremity PAD to reduce the risk
of adverse cardiovascular ischemic events. (Level of
Evidence: C)
C1
2
C
1
c
i
t
d
t
i
m
f
F
m
c
s
w indiv
i 6;94:
T
A
1244 Hirsch et al. JACC Vol. 47, No. 6, 2006
ACC/AHA Guidelines for the Management of PAD March 21, 2006:1239–312lass IIa
. An exercise ABI measurement can be useful to
diagnose lower extremity PAD in individuals who are
at risk for lower extremity PAD (Table 1) who have a
normal ABI (0.91 to 1.30), are without classic clau-
dication symptoms, and have no other clinical evi-
dence of atherosclerosis. (Level of Evidence: C)
. A toe-brachial index or pulse volume recording mea-
surement can be useful to diagnose lower extremity
PAD in individuals who are at risk for lower extrem-
ity PAD who have an ABI greater than 1.30 and no
other clinical evidence of atherosclerosis. (Level of
Evidence: C)
lass IIb
. Angiotensin-converting enzyme (ACE) inhibition
may be considered for individuals with asymptomatic
lower extremity PAD for cardiovascular risk reduc-
igure 2. The natural history of atherosclerotic lower extremity periphera
ay be: (a) asymptomatic (without identified ischemic leg symptoms, a
laudication or atypical leg symptoms); or (c) present with critical limb
ymptoms, as well as a high short-term cardiovascular ischemic event rate a
ith claudication or critical limb ischemia (CLI), and less well defined for
nfarction. Adapted with permission from Weitz JL et al. Circulation 199tion. (Level of Evidence: C)Current data document that lower extremity PAD is
ommon, that the traditional term “asymptomatic” may
naccurately imply that limb function is normal, and
hat lower extremity PAD is invariably and indepen-
ently associated with impaired lower extremity func-
ioning (6 – 8). Thus, most individuals with lower extrem-
ty PAD do not have classic (typical) claudication but
ay have more subtle impairments of lower extremity
unction.
ial disease (PAD). Individuals with atherosclerotic lower extremity PAD
with a functional impairment); (b) present with leg symptoms (classic
mia. All individuals with PAD face a risk of progressive limb ischemic
reased mortality. These event rates are most clearly defined for individuals
iduals with asymptomatic PAD. CV  cardiovascular; MI  myocardial
3026–49 (5).
able 1. Individuals at Risk for Lower Extremity Peripheral
rterial Disease
● Age less than 50 years, with diabetes and one other atherosclerosis risk
factor (smoking, dyslipidemia, hypertension, or hyperhomocysteinemia)
● Age 50 to 69 years and history of smoking or diabetes
● Age 70 years and older
● Leg symptoms with exertion (suggestive of claudication) or ischemic
rest pain
● Abnormal lower extremity pulse examinationl arter
lbeit
ische
nd inc● Known atherosclerotic coronary, carotid, or renal artery disease
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haracterized by a risk factor profile comparable to that of
hose with symptomatic lower extremity PAD (9,10). The
igh prevalence of diabetes, a history of past or current
moking, hypertension, and/or hypercholesterolemia place
uch individuals at a markedly increased risk of atheroscle-
otic ischemic events, including MI and stroke (9,11) and
igher degrees of internal carotid artery stenosis (12,13).
iven these data, current U.S. national hypertension, lipid,
nd antiplatelet treatment guidelines include all patients
ith lower extremity PAD, regardless of symptom status, as
“high-risk” category. All patients with lower extremity
AD should achieve risk reduction and specific treatment
argets comparable to those of individuals with established
oronary artery disease (14,15).
The responsibility for the detection of lower extremity
AD should be with the primary care provider. Programs
f lower extremity PAD detection, whether applied in
ffice practice or in community-based detection pro-
rams, should ideally utilize the epidemiological database
o apply the detection tool to a population “at risk.” The
ost cost-effective tool for lower extremity PAD detec-
ion is the ABI, which has been used in numerous field
urveys and cross-sectional practice surveys, as cited in
he full-text guidelines.
. Claudication.
ECOMMENDATIONS
lass I
. Patients with symptoms of intermittent claudication
should undergo a vascular physical examination, includ-
ing measurement of the ABI. (Level of Evidence: B)
. In patients with symptoms of intermittent claudica-
tion, the ABI should be measured after exercise if the
resting index is normal. (Level of Evidence: B)
. Patients with intermittent claudication should have
significant functional impairment with a reasonable
likelihood of symptomatic improvement and absence
of other disease that would comparably limit exercise
even if the claudication was improved (e.g., angina,
Table 2. Classification of Peripheral Arterial D
Categories
Fontaine
Stage Clinical
I Asymptomatic
IIa Mild claudication
IIb Moderate-severe claudication
III Ischemic rest pain
IV Ulceration or gangrene
Reprinted from J Vasc Surg, 31, Dormandy JA, Rutherfo
Working Group, Management of peripheral arterial disease (PAD
(16).heart failure, chronic respiratory disease, or orthope-
dic limitations) before undergoing an evaluation for
revascularization. (Level of Evidence: C)
. Individuals with intermittent claudication who are
offered the option of endovascular or surgical thera-
pies should (a) be provided information regarding
supervised claudication exercise therapy and pharma-
cotherapy; (b) receive comprehensive risk factor mod-
ification and antiplatelet therapy; (c) have a signifi-
cant disability, either being unable to perform normal
work or having serious impairment of other activities
important to the patient; and (d) have lower extremity
PAD lesion anatomy such that the revascularization
procedure would have low risk and a high probability
of initial and long-term success. (Level of Evidence: C)
lass III
. Arterial imaging is not indicated for patients with a
normal postexercise ABI. This does not apply if other
causes (e.g., entrapment syndromes or isolated inter-
nal iliac artery occlusive disease) are suspected. (Level
of Evidence: C)
Vascular claudication due to lower extremity PAD is
roduced consistently by exercise and is relieved with rest
nd is therefore traditionally referred to as “intermittent”
laudication, or simply “claudication.” The severity of the
ymptoms can be classified according to either the Fontaine
r Rutherford categories (Table 2).
Vascular claudication must be distinguished from other
isorders that cause exertional leg pain, which has been called
pseudoclaudication.” Distinguishing features of these various
auses of leg pain are summarized in Table 3 (16).
The ABI should be measured in all patients with claudi-
ation. For individuals who present with classic claudication
nd in whom the ABI is borderline or normal (0.91 to 1.30)
r supranormal (greater than 1.30), alternative diagnostic
trategies should be used (including the toe-brachial index,
egmental pressure examination, or duplex ultrasound), to
onfirm the lower extremity PAD diagnosis (see Section 2.5
f the full-text guidelines).
e: Fontaine’s Stages and Rutherford’s
Rutherford
e Category Clinical
0 Asymptomatic
1 Mild claudication
2 Moderate claudication
3 Severe claudication
4 Ischemic rest pain
5 Minor tissue loss
6 Ulceration or gangrene
, for the TransAtlantic Inter-Society Consensus (TASC)iseas
Grad
0
I
I
I
II
III
IV
rd RB
), S1–S296, Copyright 2000, with permission from Elsevier
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ACC/AHA Guidelines for the Management of PAD March 21, 2006:1239–312Most individuals with claudication benefit from a com-
rehensive medical approach that includes risk factor mod-
fication, antiplatelet therapy, exercise rehabilitation, and
se of claudication medications (see Sections 2.6.1 and
.6.2). In these individuals, more complex imaging studies
re not required for effective management. Decisions re-
arding revascularization of individuals with claudication
hould be based on the severity of symptoms, a significant
isability as assessed by the patient, failure of medical
herapies, lack of significant comorbid conditions, vascular
natomy suitable for the planned revascularization, and a
avorable risk-benefit ratio. These recommendations are
able 3. Differential Diagnosis of Intermittent Claudication
Condition
Location of Pain
or Discomfort
Characteristic
Discomfort
Onset
to Ex
ntermittent
claudication
Buttock, thigh, or
calf muscles
and rarely the
foot
Cramping,
aching, fatigue,
weakness, or
frank pain
After sa
degre
exerci
erve root
compression
(e.g.,
herniated
disc)
Radiates down
leg, usually
posteriorly
Sharp lancinating
pain
Soon, if
imme
after
pinal stenosis Hip, thigh,
buttocks
(follows
dermatome)
Motor weakness
more
prominent
than pain
After w
stand
variab
length
time
rthritic,
inflammatory
processes
Foot, arch Aching pain After va
degre
exerci
ip arthritis Hip, thigh,
buttocks
Aching
discomfort,
usually
localized to
hip and gluteal
region
After va
degre
exerci
ymptomatic
Baker’s cyst
Behind knee,
down calf
Swelling,
soreness,
tenderness
With ex
enous
claudication
Entire leg, but
usually worse
in thigh and
groin
Tight, bursting
pain
After w
hronic
compartment
syndrome
Calf muscles Tight, bursting
pain
After m
exerci
joggin
dapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic In
PAD), S1–S296, Copyright 2000, with permission from Elsevier (16).ummarized in Table 4 (16). Patients selected for possibleevascularization may then undergo additional imaging studies
s required to determine whether their arterial anatomy is
uitable for percutaneous or surgical revascularization.
. Critical Limb Ischemia.
ECOMMENDATIONS
lass I
1. Patients with CLI should undergo expedited evalu-
ation and treatment of factors that are known to
increase the risk of amputation (see text). (Level of
ive
e
Effect of
Rest
Effect of
Body Position
Other
Characteristics
Quickly relieved None Reproducible
y
Not quickly
relieved (also
often present
at rest)
Relief may be
aided by
adjusting back
position
History of back
problems
or
r
Relieved by
stopping only
if position
changed
Relief by lumbar
spine flexion
(sitting or
stooping
forward)
Frequent history of
back problems,
provoked by
intra-abdominal
pressure
Not quickly
relieved (and
may be
present at
rest)
May be relieved
by not bearing
weight
Variable, may
relate to activity
level
Not quickly
relieved (and
may be
present at
rest)
More comfortable
sitting, weight
taken off legs
Variable, may
relate to activity
level, weather
changes
Present at rest None Not intermittent
Subsides slowly Relief speeded by
elevation
History of
iliofemoral deep
vein thrombosis,
signs of venous
congestion,
edema
g.,
Subsides very
slowly
Relief speeded by
elevation
Typically occurs in
heavy muscled
athletes
ciety Consensus (TASC) Working Group, Management of peripheral arterial diseaseRelat
ercis
me
e of
se
not
diatel
onset
alking
ing fo
le
s of
riable
e of
se
riable
e of
se
ercise
alking
uch
se (e.
g)
ter-SoEvidence: C)
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PAD2. Patients with CLI in whom open surgical repair is
anticipated should undergo assessment of cardio-
vascular risk. (Level of Evidence: B)
3. Patients with a prior history of CLI or who have
undergone successful treatment for CLI should be
evaluated at least twice annually by a vascular
specialist owing to the relatively high incidence of
recurrence. (Level of Evidence: C)
4. Patients at risk of CLI (ABI less than 0.4 in a
nondiabetic individual, or any diabetic individual
with known lower extremity PAD) should undergo
regular inspection of the feet to detect objective
signs of CLI. (Level of Evidence: B)
5. The feet should be examined directly, with shoes
and socks removed, at regular intervals after suc-
cessful treatment of CLI. (Level of Evidence: C)
6. Patients with CLI and features to suggest athero-
embolization should be evaluated for aneurysmal
disease (e.g., abdominal aortic, popliteal, or com-
mon femoral aneurysms). (Level of Evidence: B)
7. Systemic antibiotics should be initiated promptly in
patients with CLI, skin ulcerations, and evidence of
limb infection. (Level of Evidence: B)
8. Patients with CLI and skin breakdown should be
referred to healthcare providers with specialized
expertise in wound care. (Level of Evidence: B)
9. Patients at risk for CLI (those with diabetes, neu-
ropathy, chronic renal failure, or infection) who
develop acute limb symptoms represent potential
vascular emergencies and should be assessed imme-
diately and treated by a specialist competent in
treating vascular disease. (Level of Evidence: C)
0. Patients at risk for or who have been treated for CLI
should receive verbal and written instructions re-
garding self-surveillance for potential recurrence.
able 4. Indications for Revascularization in Intermittent
laudication
Before offering a patient with intermittent claudication the option of any
invasive revascularization therapy, whether endovascular or surgical, the
following considerations must be taken into account:
● A predicted or observed lack of adequate response to exercise
therapy and claudication pharmacotherapies
● Presence of a severe disability, either being unable to perform
normal work or having very serious impairment of other activities
important to the patient
● Absence of other disease that would limit exercise even if the
claudication was improved (e.g., angina or chronic respiratory
disease)
● The individual’s anticipated natural history and prognosis
● The morphology of the lesion (must be such that the appropriate
intervention would have low risk and a high probability of initial
and long-term success)
dapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic
nter-Society Consensus (TASC) Working Group, Management of peripheral arterial
isease (PAD), S1–S296, Copyright 2000, with permission from Elsevier (16).(Level of Evidence: C)Critical limb ischemia is defined by most vascular clini-
ians in patients who present with lower extremity ischemic
est pain, ulceration, or gangrene. In these individuals, the
ntreated natural history of severe PAD would lead to major
imb amputation within 6 months. The Rutherford clinical
ategories (described earlier) are used to classify the degree
f ischemia and salvageability of the limb. Critical limb
schemia is also a component of the Fontaine clinical
lassification system (Table 2).
Patients with CLI usually present with limb pain at rest,
ith or without trophic skin changes or tissue loss. The
iscomfort is often worse when the patient is supine (e.g., in
ed) and may lessen when the limb is maintained in the
ependent position. Typically, narcotic medications are
equired for analgesia. Those factors that are known to
ncrease the risk of limb loss in patients with CLI are
elineated in Table 5.
It is fundamentally important for the clinician to
etermine the time course of development of the isch-
mia. If the clinical history and physical examination
uggest relatively rapid progression, then early or “semi-
rgent” revascularization may be required to prevent
urther deterioration and irreversible tissue loss. A vas-
ular history should also be obtained. This should include
valuation for arterial disease in other territories, assess-
ent of global risk factors for atherosclerosis, and clari-
cation of any specific precipitating factors or events
e.g., trauma or infection) that may have caused initial
kin ulceration. The objectives for the diagnostic evalu-
tion of patients with CLI are summarized in Table 6.
pecific investigations that are helpful in evaluating
atients with CLI are summarized in Table 7.
Distinctions should be made between ulcers that are
rterial and those that are venous or neurotrophic (Tables 8,
, and 10).
The evaluation of patients presenting with CLI should
nclude a complete blood count, chemistries (including
lood glucose and renal function tests), electrocardiogram,
nd ABI. In the absence of “noncompressible vessels,”
easurement of an absolute systolic blood pressure 50 mm
g or lower at the ankle and 30 mm Hg at the toe will often
mply that amputation may be required in the absence of
uccessful revascularization (16,17). Individuals with CLI
able 5. Factors That Increase Risk of Limb Loss in Patients
ith Critical Limb Ischemia
Factors that reduce blood flow to the microvascular bed:
● Diabetes
● Severe renal failure
● Severely decreased cardiac output (severe heart failure or shock)
● Vasospastic diseases or concomitant conditions (e.g., Raynaud’s
phenomenon, prolonged cold exposure)
● Smoking and tobacco use
Factors that increase demand for blood flow to the microvascular bed:
● Infection (e.g., cellulitis, osteomyelitis)
● Skin breakdown or traumatic injury
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ACC/AHA Guidelines for the Management of PAD March 21, 2006:1239–312ho present with clinical features to suggest atheroemboli-
ation should be evaluated for more proximal aneurysmal
isease (e.g., abdominal aortic, popliteal, or common fem-
ral aneurysms). Atheroembolism is suggested by the onset
f signs and symptoms of CLI after recent endovascular
atheter manipulation, the onset of associated systemic
atigue or muscle discomfort, symmetrical bilateral limb
ymptoms, livido reticularis, or rising creatinine values.
Treatment of CLI is dependent on increasing blood flow
o the affected extremity to relieve pain, heal ischemic
lcerations, and avoid limb loss. Individuals with minimal or
o skin breakdown or in whom comorbid conditions pre-
ent consideration of revascularization can occasionally be
reated by medical therapies in the absence of revasculariza-
ion. Medical care strategies have included the use of
ntiplatelet agents, anticoagulant medications, intravenous
rostanoids, rheologic agents, and maintenance of the limb
n a dependent position. However, none of these clinical
nterventions has been adequately evaluated or proven in
rospective clinical trials to offer predictable improve-
ents in limb outcomes. Recent investigation of angio-
enic therapies, via administration of gene or protein, to
nhance collateral blood flow has offered promise as a
otential strategy to treat CLI; however, these are not yet
roven interventions and are not available as established
herapies.
In the absence of revascularization, most patients with
LI are expected to require amputation within 6 months.
herefore, timely referral to a vascular specialist is indicated.
etailed arterial mapping requires vascular expertise to (a)
dentify the cause of the ischemia and (b) define the options
vailable for revascularization.
. Acute Limb Ischemia.
ECOMMENDATIONS
lass I
. Patients with acute limb ischemia and a salvageable
extremity should undergo an emergent evaluation
that defines the anatomic level of occlusion and that
leads to prompt endovascular or surgical revascular-
able 6. Objectives for Diagnostic Evaluation of Patients With
ritical Limb Ischemia
The diagnostic evaluation of patients with critical limb ischemia should
be directed toward the following objectives:
● Objective confirmation of the diagnosis
● Localization of the responsible lesion(s) and a gauge of relative
severity
● Assessment of the hemodynamic requirements for successful
revascularization (vis-à-vis proximal versus combined
revascularization of multilevel disease)
● Assessment of individual patient endovascular or operative risk
dapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic
nter-Society Consensus (TASC) Working Group, Management of peripheral arterial
isease (PAD), S1–S296, Copyright 2000, with permission from Elsevier (16).ization. (Level of Evidence: B)
I
dlass III
. Patients with acute limb ischemia and a nonviable
extremity should not undergo an evaluation to define
vascular anatomy or efforts to attempt revasculariza-
tion. (Level of Evidence: B)
Acute limb ischemia arises when a rapid or sudden
ecrease in limb perfusion threatens tissue viability. This
orm of CLI may be the first manifestation of arterial
isease in a previously asymptomatic patient or may occur as
n acute event that causes symptomatic deterioration in a
atient with antecedent lower extremity PAD and intermit-
ent claudication. Although attempts have been made to
efine various levels of ischemia (18), it is frequently not
ossible to precisely delineate the status of the patient with
n acutely ischemic limb, because many of the classification
chemes are based on subjective clinical criteria and not
iscrete end points. Table 11 displays the Society for
ascular Surgery/International Society for Cardiovascular
urgery classification scheme and provides the most useful
linical method to describe this entity.
The hallmark clinical symptoms and physical examination
igns of acute limb ischemia include the 5 “Ps” that suggest
imb jeopardy: pain, paralysis, paresthesias, pulseless, and pal-
or. Some clinicians would also include a sixth “P,” polar, to
ndicate a cold extremity. However, arterial embolism can
ccur without symptoms, whereas thrombosis can produce
udden, severe limb ischemia. The clinical diagnosis of arterial
mbolism is suggested by (a) the sudden onset or sudden
orsening of symptoms, (b) a known embolic source, (c) the
bsence of antecedent claudication or other manifestations of
bstructive arterial disease, or (d) the presence of normal
rterial pulses and Doppler systolic blood pressures in the
ontralateral limb. Acute limb ischemia is a situation that
able 7. Investigations for Evaluating Patients With Critical
imb Ischemia (CLI)
To achieve the objectives listed in Table 6, the following investigations
should be used in patients with CLI:
● Clinical history and examination, including the coronary and
cerebral circulation
● Hematologic and biochemical tests: complete blood count, platelet
count, fasting blood glucose, hemoglobin A1c, creatinine, fasting
lipid profile, and urinalysis (for glycosuria and proteinuria)
● Resting electrocardiogram
● Ankle or toe pressure measurement or other objective measures for
the severity of ischemia
● Imaging of the lower-limb arteries in patients considered for
endovascular or surgical intervention
● Duplex scan of the carotid arteries should be considered in selected
patients at high risk (defined as individuals with cerebrovascular
ischemic symptoms or in whom the risk of carotid revascularization
is less than the short-term risk of stroke)
● A more detailed coronary assessment may be performed in selected
patients in whom coronary ischemic symptoms would otherwise
merit such an assessment if CLI were not present (such coronary
assessments should usually not impede associated CLI care)
dapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic
nter-Society Consensus (TASC) Working Group, Management of peripheral arterial
isease (PAD), S1–S296, Copyright 2000, with permission from Elsevier (16).
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PADequires prompt diagnosis and treatment to preserve the limb
nd prevent the systemic illness or death that might result from
he metabolic abnormalities associated with tissue necrosis.
lthough the technical ability to recanalize or revascularize
ccluded arteries that perfuse ischemic tissues has improved
ignificantly, the pathophysiology of the local and systemic
linical sequelae associated with reperfusion of an ischemic
imb is only partially understood. Revascularization of an
schemic extremity may be complicated by reperfusion injury to
he damaged tissues and precipitate systemic responses, includ-
ng cardiac, renal, and pulmonary dysfunction.
. Prior Limb Arterial Revascularization.
ECOMMENDATIONS
lass I
. Long-term patency of infrainguinal bypass grafts
should be evaluated in a surveillance program, which
should include an interval vascular history, resting
ABIs, physical examination, and a duplex ultrasound
at regular intervals if a venous conduit has been used.
(Level of Evidence: B)
lass IIa
. Long-term patency of infrainguinal bypass grafts may
be considered for evaluation in a surveillance pro-
able 8. Differential Diagnosis of Common Foot and Leg Ulcers
Origin Cause
ain arteries Atherosclerotic lower extremity PAD, Buerger’s
disease, acute arterial occlusion
enous Venous disease
kin infarct Systemic disease, embolism, hypertension
eurotrophic Neuropathy
dapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic In
PAD), S1–S296, Copyright 2000, with permission from Elsevier (16).
PAD  peripheral arterial disease.
able 9. Foot Physical Examination and Differential Diagnosis
f Neuropathic and Neuroischemic Ulcers
Neuropathic Ulcer Neuroischemic Ulcer
ainless Painful
ormal pulses Absent pulses
ypically punched-out appearance Irregular margins
ften located on sole or edge of
foot or metatarsal head
Commonly located on toes
resence of calluses Calluses absent or infrequent
oss of sensation, reflexes, and
vibration sense
Variable sensory findings
ncrease in blood flow
(arteriovenous shunting)
Decrease in blood flow
ilated veins Collapsed veins
ry, warm foot Cold foot
one deformities No bony deformities
ed appearance Pale, cyanotic
dapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic
nter-Society Consensus (TASC) Working Group, Management of peripheral
rterial disease (PAD), S1–S296, Copyright 2000, with permission from Elsevier
16).
(gram, which may include conducting exercise ABIs
and other arterial imaging studies at regular intervals
(see duplex ultrasound recommendations, Section 2.5.5
of the full-text guidelines). (Level of Evidence: B)
. Long-term patency of endovascular sites may be
evaluated in a surveillance program, which may in-
clude conducting exercise ABIs and other arterial
imaging studies at regular intervals (see duplex ultra-
sound recommendations, Section 2.5.5 of the full-
text guidelines). (Level of Evidence: B)
Location Pain Appearance
Toes, foot Severe Irregular, pink base
Malleolar Mild Irregular, pink base
Lower third of leg Severe Small after infarction,
often multiple
Foot sole None Often deep, infected
ciety Consensus (TASC) Working Group, Management of peripheral arterial disease
able 10. Etiologic Classification of Foot and Leg Ulcers
Venous obstruction and insufficiency
Arterial etiologies
Larger arteries
Atherosclerotic lower extremity PAD
Thromboemboli, atheroemboli
Thromboangiitis obliterans
Microcirculatory
Diabetic microangiopathy
Vasculitis
Collagen vascular diseases
Neuropathic
Diabetes mellitus
Infectious
Leprosy
Mycotic
Hematologic
Sickle cell anemia
Polycythemia
Leukemia
Thalassemia
Thrombocytosis
Malignancy
Squamous cell carcinoma
Kaposi’s sarcoma
Secondary metastases
Lymphosarcoma, mycosis fungoides
Miscellaneous
Gout
Pyoderma gangrenosum
Necrobiosis lipoidica
Vitamin B12 deficiency
Drugs
Artifactual or factitious
dapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic
nter-Society Consensus (TASC) Working Group, Management of peripheral
rterial disease (PAD), S1–S296, Copyright 2000, with permission from Elsevierter-So16).
PAD  peripheral arterial disease; PVR  pulse volume recording.
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ACC/AHA Guidelines for the Management of PAD March 21, 2006:1239–312Despite increasing short-term success rates for both
ndovascular and surgical revascularization procedures, the
ossibility of recurrence remains throughout the lifetime of
he patient. Early revascularization interventions for recur-
ent hemodynamic compromise are preferred, because delay
n detection or treatment can lead to higher morbidity and
oorer outcome (19–24). Participation in a follow-up sur-
eillance program is imperative for patients undergoing both
ercutaneous and surgical revascularization. There are in-
dequate data to permit creation of consensus-based stan-
ards to define exact time intervals for surveillance visits
fter each type of revascularization procedure. In the ab-
ence of evidence-based standards, the clinical timeframe
as customarily been based on the judgment of the vascular
pecialist, by evaluating the specific level and type of
evascularization procedure and taking into account specific
atient characteristics (Tables 12, 13, and 14).
Recommendations have been made that follow-up of au-
ogenous vein bypass grafts be performed with duplex ultra-
onography at intervals of 1, 3, 6, 12, 18, and 24 months after
urgery and then yearly thereafter (16). Prompt evaluation with
nvasive techniques (angiography) is then indicated when
oninvasive methods suggest hemodynamically significant le-
ions (e.g., greater than 50% stenosis) (25,26). Some patients
ith failing lower extremity grafts due to stenosis documented
y duplex ultrasound may proceed to have operative repair
ithout angiography. The benefit of surveillance with duplex
ltrasound is less well established for prosthetic grafts.
able 11. Clinical Categories of Acute Limb Ischemia
Category Description/Prognosis Sensory
iable Not immediately
threatened
None
hreatened marginally Salvageable if promptly
treated
Minimal (toes
hreatened immediately Salvageable with immediate
revascularization
More than toe
with rest pa
rreversible Major tissue loss or
permanent nerve damage
Profound, ane
eprinted from Katzen BT. Clinical diagnosis and prognosis of acute limb ischemia
able 12. Surveillance Program for Aortoiliac and Infrainguinal
ransluminal Angioplasty
Patients undergoing aortoiliac and infrainguinal transluminal angioplasty
for lower extremity revascularization should be entered into a
surveillance program, which consists of:
● Interval history (new symptoms)
● Vascular examination of the leg with palpation of proximal and
outflow vessel pulses
● Resting and, if possible, postexercise ABI recording
Surveillance programs should be performed in the immediate post-PTA
period and at intervals for at least 2 years
dapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic
nter-Society Consensus (TASC) Working Group, Management of peripheral
rterial disease (PAD), S1–S296, Copyright 2000, with permission from Elsevier
16).
ABI  ankle-brachial index; PTA  percutaneous transluminal angioplasty.
(Postprocedure surveillance after percutaneous or endovascu-
ar procedures is less well studied, and standards are less well
stablished. Regular visits, with assessment of interval change
n symptoms, vascular examination, and ABI measurement, is
onsidered the standard of care. Postexercise ABI determina-
ions may be useful in some individuals. These modalities are
learly useful for patients in whom there is evidence of
ecurrent narrowing at the interventional site. Similarly, distal
r small-caliber endovascular sites (with or without stenting) at
igh risk of restenosis may merit more careful noninvasive
valuation. Whereas the role of surveillance duplex imaging of
utogenous and prosthetic grafts has been evaluated (see
ull-text guidelines), the utility and role of duplex ultrasound
nd other noninvasive diagnostic modalities (magnetic reso-
ance angiography [MRA] and computed tomographic an-
iography [CTA]) for such routine surveillance of endovascu-
ar sites have yet to be determined.
There is no uniformly accepted threshold for repeat angiog-
aphy and intervention in the patient with evidence of recur-
ent stenosis. Patients who have recurrent symptoms in asso-
iation with evidence of hemodynamic compromise require
estudy and repeat intervention. Likewise, evidence of rapidly
rogressive restenosis, even in the absence of symptoms, should
rovide a clue that may identify individuals who might benefit
rom future invasive management. For grafts as well as native
essels, a stenosis of less than 50% appears to be associated with
s
Muscle
Weakness
Arterial Doppler
Signals
Venous Doppler
Signals
None Audible Audible
one None (Often) inaudible Audible
ociated Mild, moderate (Usually) inaudible Audible
c Profound paralysis
(rigor)
Inaudible Inaudible
Cardiovasc Med 2002;3 (Suppl 2):S2–S6 (18a).
able 13. Surveillance Program for Infrainguinal Vein Bypass
rafts
Patients undergoing vein bypass graft placement in the lower extremity
for the treatment of claudication or limb-threatening ischemia should be
entered into a surveillance program. This program should consist of:
● Interval history (new symptoms)
● Vascular examination of the leg with palpation of proximal, graft,
and outflow vessel pulses
● Periodic measurement of resting and, if possible, postexercise ABIs
● Duplex scanning of the entire length of the graft, with calculation of
peak systolic velocities and velocity ratios across all identified lesions
Surveillance programs should be performed in the immediate
postoperative period and at regular intervals for at least 2 years
● Femoral-popliteal and femoral-tibial venous conduit bypass at
approximately 3, 6, and 12 months and annually
dapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic
nter-Society Consensus (TASC) Working Group, Management of peripheral
rterial disease (PAD), S1–S296, Copyright 2000, with permission from ElsevierLos
) or n
s; ass
in
stheti16).
ABI  ankle-brachial index.
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PADavorable prognosis and patency, whereas a stenosis greater
han 70% is a harbinger of poor long-term patency, and thus,
eintervention may be warranted (27,28).
. Diagnostic Methods
atients with vascular disorders can usually be assured that
n accurate anatomic diagnosis will be established with
odern noninvasive vascular diagnostic techniques (e.g.,
nkle- and toe-brachial indices, segmental pressure mea-
urements, pulse volume recordings, duplex ultrasound im-
ging, Doppler waveform analysis, and exercise testing).
hese tests will usually provide adequate information for
reation of a therapeutic plan. When required, these phys-
ological and anatomic data can be supplemented by use of
RA or CTA and selective use of invasive aortic and lower
xtremity angiographic techniques. Table 15 summarizes
he evidence base that defines the benefits and limitations of
ach of these vascular diagnostic techniques. Table 16
ummarizes typical use of noninvasive tests based on clinical
resentation. For a detailed discussion of each of these
echniques, see the full text of the guidelines.
. Ankle-Brachial and Toe-Brachial Indices, Segmental
ressure Examination.
ECOMMENDATIONS
lass I
. The resting ABI should be used to establish the lower
extremity PAD diagnosis in patients with suspected
lower extremity PAD, defined as individuals with
exertional leg symptoms, with nonhealing wounds,
who are 70 years and older or who are 50 years and
older with a history of smoking or diabetes. (Level of
Evidence: C)
. The ABI should be measured in both legs in all new
patients with PAD of any severity to confirm the
diagnosis of lower extremity PAD and establish a
baseline. (Level of Evidence: B)
. The toe-brachial index should be used to establish
able 14. Surveillance Program for Infrainguinal Prosthetic
rafts
Patients undergoing prosthetic femoropopliteal or femorotibial bypass
for claudication or limb-threatening ischemia should be entered into a
graft surveillance program that consists of:
● Interval history (new symptoms)
● Vascular examination of the leg with palpation of proximal and
outflow vessel pulses
● Measurement of ABIs at rest and, if possible, after exercise testing
Surveillance programs should be performed in the immediate
postoperative period and at regular intervals (timing of surveillance and
efficacy have not been ideally defined) for at least 2 years
dapted from J Vasc Surg, 31, Dormandy JA, Rutherford RB, for the TransAtlantic
nter-Society Consensus (TASC) Working Group, Management of peripheral
rterial disease (PAD), S1–S296, Copyright 2000, with permission from Elsevier
16).
ABI  ankle-brachial index.the lower extremity PAD diagnosis in patients inwhom lower extremity PAD is clinically suspected
but in whom the ABI test is not reliable due to
noncompressible vessels (usually patients with
long-standing diabetes or advanced age). (Level of
Evidence: B)
. Leg segmental pressure measurements are useful to
establish the lower extremity PAD diagnosis when
anatomic localization of lower extremity PAD is
required to create a therapeutic plan. (Level of
Evidence: B)
. Pulse Volume Recording.
ECOMMENDATION
lass IIa
. Pulse volume recordings are reasonable to establish the
initial lower extremity PAD diagnosis, assess localiza-
tion and severity, and follow the status of lower extrem-
ity revascularization procedures. (Level of Evidence: B)
. Continuous-Wave Doppler Ultrasound.
ECOMMENDATION
lass I
. Continuous-wave Doppler ultrasound blood flow
measurements are useful to provide an accurate as-
sessment of lower extremity PAD location and sever-
ity, to follow lower extremity PAD progression, and
to provide quantitative follow-up after revasculariza-
tion procedures. (Level of Evidence: B)
. Treadmill Exercise Testing With and Without ABI
ssessments and 6-Minute Walk Test.
ECOMMENDATIONS
lass I
. Exercise treadmill tests are recommended to provide
the most objective evidence of the magnitude of the
functional limitation of claudication and to measure
the response to therapy. (Level of Evidence: B)
. A standardized exercise protocol (either fixed or
graded) with a motorized treadmill should be used to
ensure reproducibility of measurements of pain-free
walking distance and maximal walking distance.
(Level of Evidence: B)
. Exercise treadmill tests with measurement of pre-
exercise and postexercise ABI values are recommended
to provide diagnostic data useful in differentiating
arterial claudication from nonarterial claudication
(“pseudoclaudication”). (Level of Evidence: B)
. Exercise treadmill tests should be performed in indi-
viduals with claudication who are to undergo exercise
training (lower extremity PAD rehabilitation) so as to
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Diagnostic Tool Benefits Limitations
nkle-brachial
indices (ABIs)
● A quick and cost-effective way to establish or refute
the lower extremity PAD diagnosis (see text)
● May not be accurate when systolic blood pressure
cannot be abolished by inflation of an air-filled
blood pressure cuff (noncompressible pedal
arteries), as occurs in a small fraction of diabetic
or very elderly individuals
oe-brachial
indices
● A quick and cost-effective way to establish or refute
the lower extremity PAD diagnosis (see text)
● Can measure digital perfusion when small-vessel
arterial occlusive disease is present
● Useful in individuals with noncompressible posterior
tibial or dorsalis pedis arteries
● Requires small cuffs and careful technique to
preserve accuracy
egmental pressure
examination
● Useful to establish or refute the PAD diagnosis (see
text)
● Useful to provide anatomic localization of lower
extremity PAD when these data are required to
create a therapeutic plan
● Can provide data to predict limb survival, wound
healing, and patient survival
● Useful to monitor the efficacy of therapeutic
interventions
● May not be accurate when systolic blood pressure
cannot be measured by inflation of an air-filled
blood pressure cuff owing to noncompressible
pedal arteries, as occurs in a small fraction of
diabetic or very elderly individuals
ulse volume
recording
● Useful to establish the diagnosis of PAD in vascular
laboratories or office practice
● Usefulness maintained in patients with
noncompressible vessels (ABI value greater than
1.3)
● Helpful in predicting the outcome in CLI and risk
of amputation
● Can be used to monitor limb perfusion after
revascularization procedures
● Qualitative, not quantitative, measure of perfusion
● May not be accurate in more distal segments
● Less accurate than other noninvasive tests in
providing arterial anatomic localization of PAD
● May be abnormal in patients with low cardiac
stroke volume
ontinuous-wave
Doppler
ultrasound
● Useful to assess lower extremity PAD anatomy,
severity, and progression
● Can provide localizing information in patients with
poorly compressible arteries
● Can provide quantitative data after successful lower
extremity revascularization
● “Pulse normalization” downstream from stenoses
can diminish test sensitivity
● Test specificity greater for patent superficial femoral
arteries than for aortoiliac occlusive disease
● Does not provide visualization of arterial anatomy
● Limited accuracy in tortuous, overlapping, or
densely calcified arterial segments, and insensitive
for iliac arteries (in context of obesity, bowel gas,
and vessel tortuosity)
uplex ultrasound ● Can establish the lower extremity PAD diagnosis,
establish anatomic localization, and define severity
of focal lower extremity arterial stenoses
● Useful tool to provide graft surveillance after
femoral popliteal or femoral tibial or pedal
surgical bypass with venous (but not prosthetic)
conduit
● Can be useful to select candidates for endovascular
or surgical revascularization
● Accuracy is diminished in proximal aortoiliac
arterial segments in some individuals (e.g., due to
obesity or the presence of bowel gas)
● Dense arterial calcification can limit diagnostic
accuracy
● Sensitivity is diminished for detecting stenoses
downstream from a proximal stenosis
● Diminished predictive value in surveillance of
prosthetic bypass grafts
oe-tip exercise
testing, with pre-
exercise and
postexercise ABIs
● Useful to diagnose lower extremity PAD when
resting ABI values are normal
● Can be performed in the absence of a treadmill,
with increased convenience and low cost
● Provides qualitative (rather than quantitative)
exercise diagnostic results
● Lower workload may not elicit symptoms in all
individuals with claudication
readmill exercise
testing, with and
without pre-
exercise and
postexercise ABIs
● Helps differentiate claudication from
pseudoclaudication in individuals with exertional leg
symptoms
● Useful to diagnose lower extremity PAD when
resting ABI values are normal
● Objectively documents the magnitude of symptom
limitation in patients with claudication, especially
when used with a standardized treadmill protocol
● Requires use of a motorized treadmill, with or
without continuous electrocardiogram monitoring,
as well as staff familiar with exercise testing
protocolsContinued on next page
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exercise limitations, and demonstrate the safety of
exercise. (Level of Evidence: B)
Class IIb
. A 6-minute walk test may be reasonable to provide an
objective assessment of the functional limitation of
claudication and response to therapy in elderly indi-
viduals or others not amenable to treadmill testing.
(Level of Evidence: B)
able 15. Continued
Diagnostic Tool Benefits
readmill exercise
testing, with and
without pre-
exercise and
postexercise ABIs
(continued)
● Demonstrates the safety of exercise and
data to individualize exercise prescriptio
individuals with claudication before ini
formal program of therapeutic exercise
● Useful to measure the objective functio
to claudication therapeutic intervention
agnetic resonance
angiography
(MRA)
● Useful to assess PAD anatomy and pre
significant stenoses
● Useful to select patients who are candid
endovascular or surgical revascularizatio
omputed
tomographic
angiography
(CTA)
● Useful to assess PAD anatomy and pre
significant stenoses
● Useful to select patients who are candid
endovascular or surgical revascularizatio
● Helpful to provide associated soft tissu
information that may be associated wit
presentation (e.g., aneurysms, popliteal
and cystic adventitial disease)
● Patients with contraindications to MRA
pacemakers or defibrillators) may be sa
● Metal clips, stents, and metallic prosth
cause significant CTA artifacts
● Scan times are significantly faster than
ontrast
angiography
● Definitive method for anatomic evaluat
when revascularization is planned
ools are listed in order from least to most invasive and from least to most costly.
CLI  critical limb ischemia; PAD  peripheral arterial disease.. Duplex Ultrasound.ECOMMENDATIONS
lass I
. Duplex ultrasound of the extremities is useful to
diagnose anatomic location and degree of stenosis of
PAD. (Level of Evidence: A)
. Duplex ultrasound is recommended for routine
surveillance after femoral-popliteal or femoral-
tibial-pedal bypass with a venous conduit. Mini-
mum surveillance intervals are approximately 3, 6,
and 12 months, and then yearly after graft place-
Limitations
ides
of a
ng
sponse
of
for
● Tends to overestimate the degree of stenosis
● May be inaccurate in arteries treated with metal
stents
● Cannot be used in patients with contraindications
to the magnetic resonance technique (e.g.,
pacemakers, defibrillators, intracranial metallic
stents, clips, coils, and other devices)
of
for
nostic
D
pment,
.,
aged
o not
RA
● Single-detector computed tomography lacks
accuracy for detection of stenosis
● Spatial resolution lower than digital subtraction
angiography
● Venous opacification can obscure arterial filling
● Asymmetrical opacification of the legs may
obscure arterial phase in some vessels
● Accuracy and effectiveness not as well determined
as MRA
● Treatment plans based on CTA have not been
compared with those of catheter angiography
● Requires iodinated contrast and ionizing radiation
(although radiation exposure is less than with
catheter angiography)
● Because CTA requires administration of
iodinated contrast, use is limited in individuals
with established renal dysfunction
f PAD ● Invasive evaluation is associated with risk of
bleeding, infection, vascular access complications
(e.g., dissection or hematoma),
atheroembolization, contrast allergy, and contrast
nephropathy
● May provide limited visualization of tibial-pedal
vessels in patients with CLI with poor inflow to
the leg
● Below-knee vessels may be difficult to identify by
digital subtraction angiography
● Multiple projections may be necessary to visualize
eccentric lesionsprov
ns in
tiation
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s
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. Duplex ultrasound of the extremities can be useful to
select patients as candidates for endovascular inter-
vention. (Level of Evidence: B)
. Duplex ultrasound can be useful to select patients as
candidates for surgical bypass and to select the sites
of surgical anastomosis. (Level of Evidence: B)
lass IIb
. The use of duplex ultrasound is not well established
to assess long-term patency of percutaneous translu-
minal angioplasty. (Level of Evidence: B)
. Duplex ultrasound may be considered for routine
surveillance after femoral-popliteal bypass with a
synthetic conduit. (Level of Evidence: B)
. Computed Tomographic Angiography.
ECOMMENDATIONS
lass IIb
. Computed tomographic angiography of the ex-
tremities may be considered to diagnose anatomic
location and presence of significant stenosis in
patients with lower extremity PAD. (Level of Evi-
dence: B)
. Computed tomographic angiography of the extremi-
ties may be considered as a substitute for MRA for
those patients with contraindications to MRA. (Level
of Evidence: B)
able 16. Typical Noninvasive Vascular Laboratory Tests for
ower Extremity PAD Patients by Clinical Presentation
Clinical Presentation Noninvasive Vascular Test
symptomatic lower extremity
PAD
ABI
laudication ABI, PVR, or segmental
pressures
Duplex ultrasound
Exercise test with ABI to assess
functional status
ossible pseudoclaudication Exercise test with ABI
ostoperative vein graft
follow-up
Duplex ultrasound
emoral pseudoaneurysm; iliac
or popliteal aneurysm
Duplex ultrasound
uspected aortic aneurysm;
serial AAA follow-up
Abdominal ultrasound, CTA,
or MRA
andidate for revascularization Duplex ultrasound, MRA, or
CTA
dapted from Primary Cardiology, 2nd ed., Braunwald E, Goldman L, eds., “Recognition
nd management of peripheral arterial disease,” Hirsch AT, 659–71, Philadelphia, PA:
B Saunders, Copyright 2003, with permission from Elsevier (30a).
AAA  abdominal aortic aneurysm; ABI  ankle-brachial index; CTA 
omputed tomographic angiography; MRA  magnetic resonance angiography;
AD  peripheral arterial disease; PVR  pulse volume recording.. Magnetic Resonance Angiography.ECOMMENDATIONS
lass I
. Magnetic resonance angiography of the extremities is
useful to diagnose anatomic location and degree of
stenosis of PAD. (Level of Evidence: A)
. Magnetic resonance angiography of the extremities
should be performed with gadolinium enhancement.
(Level of Evidence: B)
. Magnetic resonance angiography of the extremities is
useful in selecting patients with lower extremity PAD
as candidates for endovascular intervention. (Level of
Evidence: A)
lass IIb
. Magnetic resonance angiography of the extremities
may be considered to select patients with lower
extremity PAD as candidates for surgical bypass and
to select the sites of surgical anastomosis. (Level of
Evidence: B)
. Magnetic resonance angiography of the extremities
may be considered for postrevascularization (endo-
vascular and surgical bypass) surveillance in patients
with lower extremity PAD. (Level of Evidence: B)
. Contrast Angiography.
ECOMMENDATIONS
lass I
1. Contrast angiography provides detailed information
about arterial anatomy and is recommended for
evaluation of patients with lower extremity PAD
when revascularization is contemplated. (Level of
Evidence: B)
2. A history of contrast reaction should be documented
before the performance of contrast angiography and
appropriate pretreatment administered before con-
trast is given. (Level of Evidence: B)
3. Decisions regarding the potential utility of invasive
therapeutic interventions (percutaneous or surgical)
in patients with lower extremity PAD should be
made with a complete anatomic assessment of the
affected arterial territory, including imaging of the
occlusive lesion, as well as arterial inflow and out-
flow with angiography or a combination of angiog-
raphy and noninvasive vascular techniques. (Level of
Evidence: B)
4. Digital subtraction angiography is recommended for
contrast angiographic studies because this tech-
nique allows for enhanced imaging capabilities com-
pared with conventional unsubtracted contrast an-
giography. (Level of Evidence: A)
5. Before performance of contrast angiography, a full
history and complete vascular examination should
be performed to optimize decisions regarding the
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catheter manipulation. (Level of Evidence: C)
6. Selective or superselective catheter placement dur-
ing lower extremity angiography is indicated be-
cause this can enhance imaging, reduce contrast
dose, and improve sensitivity and specificity of the
procedure. (Level of Evidence: C)
7. The diagnostic lower extremity arteriogram should
image the iliac, femoral, and tibial bifurcations in
profile without vessel overlap. (Level of Evidence: B)
8. When conducting a diagnostic lower extremity ar-
teriogram in which the significance of an obstructive
lesion is ambiguous, transstenotic pressure gradi-
ents and supplementary angulated views should be
obtained. (Level of Evidence: B)
9. Patients with baseline renal insufficiency should
receive hydration before undergoing contrast an-
giography. (Level of Evidence: B)
0. Follow-up clinical evaluation, including a physical
examination and measurement of renal function, is
recommended within 2 weeks after contrast angiog-
raphy to detect the presence of delayed adverse
effects such as atheroembolism, deterioration in
renal function, or access site injury (e.g., pseudoaneu-
rysm or arteriovenous fistula). (Level of Evidence: C)
lass IIa
. Noninvasive imaging modalities, including MRA,
CTA, and color flow duplex imaging, may be used in
advance of invasive imaging to develop an individu-
alized diagnostic strategic plan, including assistance
in selection of access sites, identification of signifi-
cant lesions, and determination of the need for
invasive evaluation. (Level of Evidence: B)
. Treatment with n-acetylcysteine in advance of con-
trast angiography is suggested for patients with base-
line renal insufficiency (creatinine greater than 2.0
mg per dl). (Level of Evidence: B)
. Treatment
. Cardiovascular Risk Reduction.
. LIPID-LOWERING DRUGS.
ECOMMENDATIONS
lass I
. Treatment with a hydroxymethyl glutaryl coenzyme-A
reductase inhibitor (statin) medication is indicated for
all patients with PAD to achieve a target low-density
lipoprotein (LDL) cholesterol level of less than 100 mg
per dl. (Level of Evidence: B)
lass IIa
. Treatment with a hydroxymethyl glutaryl coenzyme-A
reductase inhibitor (statin) medication to achieve a
target LDL cholesterol level of less than 70 mg per dl is hreasonable for patients with lower extremity PAD at
very high risk of ischemic events. (Level of Evidence: B)
. Treatment with a fibric acid derivative can be useful
for patients with PAD and low high-density lipopro-
tein (HDL) cholesterol, normal LDL cholesterol,
and elevated triglycerides. (Level of Evidence: C)
It is recommended that patients with PAD and LDL
holesterol of 100 mg per dl or greater be treated with a
tatin, but when risk is very high, an LDL cholesterol goal
f less than 70 mg per dl is a therapeutic option (29,30).
mong the factors that define very high risk in individuals
ith established PAD are (a) multiple major risk factors
especially diabetes), (b) severe and poorly controlled risk
actors (especially continued cigarette smoking), (c) multiple
isk factors of the metabolic syndrome (especially high
riglycerides; i.e., greater than or equal to 200 mg per dl plus
on-HDL cholesterol greater than or equal to 130 mg per
l with low HDL cholesterol [less than or equal to 40 mg
er dl]), and (d) individuals with acute coronary syndromes.
he efficacy of this treatment with fibric acid derivatives in
atients with PAD is not known. In patients with coronary
rtery disease and low HDL cholesterol levels, one study
ound that gemfibrozil reduced the risk of nonfatal myocar-
ial infarction or cardiovascular death by 22% (31).
. ANTIHYPERTENSIVE DRUGS.
ECOMMENDATIONS
lass I
. Antihypertensive therapy should be administered to
hypertensive patients with lower extremity PAD to
achieve a goal of less than 140 mm Hg systolic over
90 mm Hg diastolic (nondiabetics) or less than 130
mm Hg systolic over 80 mm Hg diastolic (diabetics
and individuals with chronic renal disease) to reduce
the risk of MI, stroke, congestive heart failure, and
cardiovascular death. (Level of Evidence: A)
. Beta-adrenergic blocking drugs are effective antihy-
pertensive agents and are not contraindicated in
patients with PAD. (Level of Evidence: A)
lass IIa
. The use of ACE inhibitors is reasonable for symp-
tomatic patients with lower extremity PAD to reduce
the risk of adverse cardiovascular events. (Level of
Evidence: B)
lass IIb
. Angiotensin-converting enzyme inhibitors may be
considered for patients with asymptomatic lower
extremity PAD to reduce the risk of adverse cardio-
vascular events. (Level of Evidence: C)
Treatment of high blood pressure is indicated to reduce
he risk of cardiovascular events (32). Beta-blockers, which
ave been shown to reduce the risk of MI and death in
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ffect walking capacity (34). Angiotensin-converting en-
yme inhibitors reduce the risk of death and nonfatal
ardiovascular events in patients with coronary artery disease
nd left ventricular dysfunction (35,36). The Heart Out-
omes Prevention Evaluation (HOPE) trial found that in
atients with symptomatic PAD, ramipril reduced the risk
f MI, stroke, or vascular death by approximately 25%, a
evel of efficacy comparable to that achieved in the entire
tudy population (37). There is currently no evidence base
or the efficacy of ACE inhibitors in patients with asymp-
omatic PAD, and thus, the use of ACE-inhibitor medica-
ions to lower cardiovascular ischemic event rates in this
opulation must be extrapolated from the data on symp-
omatic patients.
. DIABETES THERAPIES.
ECOMMENDATIONS
lass I
. Proper foot care, including use of appropriate foot-
wear, chiropody/podiatric medicine, daily foot in-
spection, skin cleansing, and use of topical moistur-
izing creams should be encouraged, and skin lesions
and ulcerations should be addressed urgently in all
diabetic patients with lower extremity PAD. (Level of
Evidence: B)
lass IIa
. Treatment of diabetes in individuals with lower
extremity PAD by administration of glucose control
therapies to reduce the hemoglobin A1C to less than
7% can be effective to reduce microvascular compli-
cations and potentially improve cardiovascular out-
comes. (Level of Evidence: C)
Aggressive treatment of diabetes is known to decrease the
isk for microvascular events such as nephropathy and
etinopathy (38,39). Patients with lower extremity PAD
nd diabetes should be treated to reduce their glycosylated
emoglobin to less than 7%, per the American Diabetes
ssociation recommendation (40). Frequent foot inspection
y patients and physicians will enable early identification of
oot lesions and ulcerations and facilitate prompt referral for
reatment (41).
. SMOKING CESSATION.
ECOMMENDATION
lass I
. Individuals with lower extremity PAD who smoke
cigarettes or use other forms of tobacco should be
advised by each of their clinicians to stop smoking
and should be offered comprehensive smoking cessa- (tion interventions, including behavior modification
therapy, nicotine replacement therapy, or bupropion.
(Level of Evidence: B)
Physician advice coupled with frequent follow-up
chieves 1-year smoking cessation rates of approximately
% compared with only 0.1% in those attempting to quit
moking without a physician’s intervention (42). Phar-
acological interventions such as nicotine replacement
herapy and bupropion achieve 1-year smoking cessation
ates of approximately 16% and 30%, respectively (43).
obacco cessation interventions are particularly critical in
ndividuals with thromboangiitis obliterans, because con-
inued use is associated with a particularly adverse out-
ome (44).
. HOMOCYSTEINE-LOWERING DRUGS.
ECOMMENDATION
lass IIb
. The effectiveness of the therapeutic use of folic acid
and B12 vitamin supplements in individuals with
lower extremity PAD and homocysteine levels greater
than 14 micromoles per liter is not well established.
(Level of Evidence: C)
. ANTIPLATELET AND ANTITHROMBOTIC DRUGS.
ECOMMENDATIONS
lass I
. Antiplatelet therapy is indicated to reduce the risk of
MI, stroke, or vascular death in individuals with
atherosclerotic lower extremity PAD. (Level of Evi-
dence: A)
. Aspirin, in daily doses of 75 to 325 mg, is recom-
mended as safe and effective antiplatelet therapy to
reduce the risk of MI, stroke, or vascular death in
individuals with atherosclerotic lower extremity
PAD. (Level of Evidence: A)
. Clopidogrel (75 mg per day) is recommended as an
effective alternative antiplatelet therapy to aspirin to
reduce the risk of MI, stroke, or vascular death in
individuals with atherosclerotic lower extremity
PAD. (Level of Evidence: B)
lass III
. Oral anticoagulation therapy with warfarin is not
indicated to reduce the risk of adverse cardio-
vascular ischemic events in individuals with ath-
erosclerotic lower extremity PAD. (Level of Evi-
dence: C)
In the Antithrombotic Trialists’ Collaboration (ATC)
45), patients treated with antiplatelet therapy had a 32%
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50 mg daily, 26% with 160 to 325 mg daily, and 19%
ith 500 to 1500 mg daily. There was a significantly
maller (13%) reduction in cardiovascular events in pa-
ients being treated with less than 75 mg of aspirin per
ay. In the CAPRIE trial (Clopidogrel Versus Aspirin in
atients at Risk of Ischemic Events), clopidogrel reduced
he risk of MI, stroke, or vascular death by 23.8%
ompared with aspirin in patients with PAD (46). To
ate, there is no evidence to support the efficacy of
ombined aspirin and clopidogrel treatment versus a
ingle antiplatelet agent in patients with lower extremity
AD. Information regarding the efficacy of oral antico-
gulants (i.e., coumarin derivatives such as warfarin) in
educing adverse cardiovascular events in patients with
therosclerosis is derived primarily from studies of pa-
ients with coronary artery disease. Among patients with
oronary artery disease, moderate- and high-intensity
ral anticoagulation with coumarin derivatives reduces
he risk of MI and death but with an increased rate of
leeding (47,48).
. Claudication.
. EXERCISE AND LOWER EXTREMITY PAD REHABILITATION.
ECOMMENDATIONS
lass I
. A program of supervised exercise training is rec-
ommended as an initial treatment modality for
patients with intermittent claudication. (Level of
Evidence: A)
. Supervised exercise training should be performed for
a minimum of 30 to 45 minutes, in sessions per-
formed at least 3 times per week for a minimum of 12
weeks. (Level of Evidence: A)
Class IIb
. The usefulness of unsupervised exercise programs is
not well established as an effective initial treatment
modality for patients with intermittent claudication.
(Level of Evidence: B)
Regular walking in a supervised claudication exercise
rogram can be expected to result in an increase in the
peed, distance, and duration walked, with decreased
laudication symptoms at each workload or distance
49 –55). Indeed, supervised exercise can induce increases
n maximal walking ability that exceed those attained
ith drug therapies, which have been estimated to result
n improvements in maximal walking distance of 20% to
5% with pentoxifylline and 40% to 60% with cilostazol
56,57). In a meta-analysis by Gardner and Poehlman
50), the greatest improvements in walking ability oc-
1urred when each exercise session lasted longer than 30
inutes, when sessions took place at least 3 times per
eek, when the exercise modality was walking to near-
aximal pain, and when the program lasted 6 months or
reater. The key elements of such a therapeutic claudi-
ation exercise program for patients with claudication are
ummarized in Table 17.
able 17. Key Elements of a Therapeutic Claudication Exercise
raining Program (Lower Extremity PAD Rehabilitation)
Primary Clinician Role
● Establish the PAD diagnosis using the ankle-brachial index
measurement or other objective vascular laboratory evaluations
● Determine that claudication is the major symptom limiting
exercise
● Discuss risk-benefit of claudication therapeutic alternatives including
pharmacological, percutaneous, and surgical interventions
● Initiate systemic atherosclerosis risk modification
● Perform treadmill stress testing
● Provide formal referral to a claudication exercise rehabilitation
program
Exercise Guidelines for Claudication*
● Warm-up and cool-down period of 5 to 10 minutes each
Types of Exercise
● Treadmill and track walking are the most effective exercise for
claudication.
● Resistance training has conferred benefit to individuals with other
forms of cardiovascular disease, and its use, as tolerated, for general
fitness is complementary to, but not a substitute for, walking.
Intensity
● The initial workload of the treadmill is set to a speed and grade that
elicits claudication symptoms within 3 to 5 minutes
● Patients walk at this workload until they achieve claudication of
moderate severity, which is then followed by a brief period of
standing or sitting rest to permit symptoms to resolve
Duration
● The exercise-rest-exercise pattern should be repeated throughout the
exercise session
● The initial duration will usually include 35 minutes of intermittent
walking and should be increased by 5 minutes each session until 50
minutes of intermittent walking can be accomplished
Frequency
● Treadmill or track walking 3 to 5 times per week
Role of Direct Supervision
● As patients improve their walking ability, the exercise workload
should be increased by modifying the treadmill grade or speed (or
both) to ensure that there is always the stimulus of claudication pain
during the workout
● As patients increase their walking ability, there is the possibility that
cardiac signs and symptoms may appear (e.g., dysrhythmia, angina,
or ST-segment depression). These events should prompt physician
re-evaluation.
dapted with permission from Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT.
edical progress: exercise training for claudication. N Engl J Med 2002;347:1941–51
2002 Massachusetts Medical Society. All rights reserved (62a). *These general
uidelines should be individualized and based on the results of treadmill stress testing
nd the clinical status of the patient. A full discussion of the exercise precautions for
ersons with concomitant diseases can be found elsewhere for diabetes (Ruderman N,
evlin JT, Schneider S, Kriska A. Handbook of Exercise in Diabetes. Alexandria,
A: American Diabetes Association, 2002) (62b), hypertension (ACSM’s Guidelines
or Exercise Testing and Prescription. In: Franklin BA, editor. Baltimore, MD:
ippincott, Williams, and Wilkins, 2000) (62c), and coronary artery disease (Guide-
ines for Cardiac Rehabilitation and Secondary Prevention/American Association of
ardiovascular and Pulmonary Rehabilitation. Champaign, IL: Human Kinetics,
999) (62d).
PAD  peripheral arterial disease.
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LAUDICATION.
ILOSTAZOL.
ECOMMENDATIONS
lass I
. Cilostazol (100 mg orally 2 times per day) is
indicated as an effective therapy to improve symp-
toms and increase walking distance in patients with
lower extremity PAD and intermittent claudica-
tion (in the absence of heart failure). (Level of
Evidence: A)
. A therapeutic trial of cilostazol should be consid-
ered in all patients with lifestyle-limiting claudica-
tion (in the absence of heart failure). (Level of
Evidence: A)
Cilostazol improves maximal walking distance by 40%
o 60% after 12 to 24 weeks of therapy (56 – 60).
ilostazol increases ABI modestly, but the hemodynamic
ffect cannot account for the improvement in claudication
56,57,59,61). A meta-analysis indicates that cilostazol
lso improves walking ability and health-related quality
f life (62). Cilostazol administered at 100 mg twice daily
s more effective than 50 mg twice daily (58,60). Al-
hough no trials have found a significant increase in major
ardiovascular events in patients treated with cilostazol,
his medication should not be used in individuals with
eart failure because of its potential adverse effect in this
opulation as a phosphodiesterase type 3 inhibitor.
ENTOXIFYLLINE.
ECOMMENDATIONS
lass IIb
. Pentoxifylline (400 mg 3 times per day) may be
considered as second-line alternative therapy to
cilostazol to improve walking distance in patients
with intermittent claudication. (Level of Evidence:
A)
. The clinical effectiveness of pentoxifylline as therapy
for claudication is marginal and not well established.
(Level of Evidence: C)
Meta-analyses of randomized, placebo-controlled,
ouble-blind clinical trials found that pentoxifylline
auses a marginal but statistically significant improve-
ent in pain-free and maximal walking distance (63,64);
owever, pentoxifylline does not increase the ABI at rest
r after exercise (64). Pentoxifylline may be considered to
reat patients with intermittent claudication; however,
he anticipated outcome is likely to be of marginal clinical
mportance.THER PROPOSED MEDICAL THERAPIES.
ECOMMENDATIONS
lass IIb
. The effectiveness of L-arginine for patients with
intermittent claudication is not well established.
(Level of Evidence: B)
. The effectiveness of propionyl-L-carnitine as a ther-
apy to improve walking distance in patients with
intermittent claudication is not well established.
(Level of Evidence: B)
. The effectiveness of ginkgo biloba to improve walk-
ing distance for patients with intermittent claudica-
tion is marginal and not well established. (Level of
Evidence: B)
lass III
. Oral vasodilator prostaglandins such as beraprost and
iloprost are not effective medications to improve
walking distance in patients with intermittent clau-
dication. (Level of Evidence: A)
. Vitamin E is not recommended as a treatment for
patients with intermittent claudication. (Level of Ev-
idence: C)
. Chelation (e.g., ethylenediaminetetraacetic acid) is
not indicated for treatment of intermittent claudica-
tion and may have harmful adverse effects. (Level of
Evidence: A)
. ENDOVASCULAR TREATMENT FOR CLAUDICATION.
ECOMMENDATIONS
lass I
. Endovascular procedures are indicated for individu-
als with a vocational or lifestyle-limiting disability
due to intermittent claudication when clinical fea-
tures suggest a reasonable likelihood of symptomatic
improvement with endovascular intervention and (a)
there has been an inadequate response to exercise or
pharmacological therapy and/or (b) there is a very
favorable risk-benefit ratio (e.g., focal aortoiliac oc-
clusive disease). (Level of Evidence: A)
. Endovascular intervention is recommended as the
preferred revascularization technique for Transatlan-
tic Inter-Society Consensus type A (see Tables 20
and 21 and Figure 8 of the full-text guidelines) iliac
and femoropopliteal arterial lesions. (Level of Evi-
dence: B)
. Translesional pressure gradients (with and without
vasodilation) should be obtained to evaluate the
significance of angiographic iliac arterial stenoses of
50% to 75% diameter before intervention. (Level of
Evidence: C)
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PAD. Provisional stent placement is indicated for use in the
iliac arteries as salvage therapy for a suboptimal or
failed result from balloon dilation (e.g., persistent
translesional gradient, residual diameter stenosis
greater than 50%, or flow-limiting dissection). (Level
of Evidence: B)
. Stenting is effective as primary therapy for common iliac
artery stenosis and occlusions. (Level of Evidence: B)
. Stenting is effective as primary therapy in external iliac
artery stenoses and occlusions. (Level of Evidence: C)
lass IIa
. Stents (and other adjunctive techniques such as la-
sers, cutting balloons, atherectomy devices, and ther-
mal devices) can be useful in the femoral, popliteal,
and tibial arteries as salvage therapy for a suboptimal
or failed result from balloon dilation (e.g., persistent
translesional gradient, residual diameter stenosis
greater than 50%, or flow-limiting dissection). (Level
of Evidence: C)
lass IIb
. The effectiveness of stents, atherectomy, cutting bal-
loons, thermal devices, and lasers for the treatment of
femoral-popliteal arterial lesions (except to salvage a
suboptimal result from balloon dilation) is not well
established. (Level of Evidence: A)
. The effectiveness of uncoated/uncovered stents,
atherectomy, cutting balloons, thermal devices,
and lasers for the treatment of infrapopliteal le-
sions (except to salvage a suboptimal result from
balloon dilation) is not well established. (Level of
Evidence: C)
lass III
. Endovascular intervention is not indicated if there is
no significant pressure gradient across a stenosis
despite flow augmentation with vasodilators. (Level of
Evidence: C)
. Primary stent placement is not recommended in the
femoral, popliteal, or tibial arteries. (Level of Evi-
dence: C)
. Endovascular intervention is not indicated as pro-
phylactic therapy in an asymptomatic patient with
lower extremity PAD. (Level of Evidence: C)
Outcomes of percutaneous transluminal angioplasty
PTA) and stents to improve results for individuals with
laudication depend on anatomic and clinical factors (Table
8). Durability of patency after PTA is greatest for lesions
n the common iliac artery and decreases distally and with
ncreasing length of the stenosis/occlusion, multiple and
iffuse lesions, poor-quality runoff, diabetes, renal failure,
moking, and CLI (65–80). Overall outcomes of PTA and
tenting of native vessels are summarized in Table 21 in the
ull-text guidelines. Percutaneous transluminal angioplasty sf vein bypass graft stenoses has also been reported, with 1-
o 3-year patency rates of the treated site of approximately
0% (81–83), comparable to surgical repair (81). Percuta-
eous transluminal angioplasty of multiple vein graft steno-
es has a much lower 3-year patency rate of only 6% (82).
herefore, patient selection is key in obtaining satisfactory
utcomes. For a full discussion of patient and lesion
election, see the full-text guidelines.
. SURGERY FOR CLAUDICATION.
NDICATIONS.
ECOMMENDATIONS
lass I
. Surgical interventions are indicated for individuals
with claudication symptoms who have a significant
functional disability that is vocational or lifestyle
limiting, who are unresponsive to exercise or phar-
macotherapy, and who have a reasonable likeli-
hood of symptomatic improvement. (Level of Evi-
dence: B)
lass IIb
. Because the presence of more aggressive atheroscle-
rotic occlusive disease is associated with less durable
results in patients younger than 50 years of age, the
effectiveness of surgical intervention in this popula-
tion for intermittent claudication is unclear. (Level of
Evidence: B)
lass III
. Surgical intervention is not indicated to prevent
progression to limb-threatening ischemia in pa-
tients with intermittent claudication. (Level of
Evidence: B)
Because claudication usually does not progress to limb-
hreatening ischemia, there is no automatic mandate to
roceed to surgical intervention. Surgical intervention is
sually reserved for individuals (a) who do not derive
dequate functional benefit from nonsurgical therapies, (b)
ho have limb arterial anatomy that is favorable to obtain-
ng a durable clinical result, and (c) in whom the cardiovas-
ular risk of surgical revascularization is low. The 2 tradi-
ional functional indications for surgical intervention are
xercise impairment sufficient to threaten the patient’s
mployment or to require significant alterations in the
atient’s lifestyle after failure of nonsurgical or endovascular
herapy. Patients who present with symptoms of claudica-
ion before 50 years of age may have a more virulent form of
therosclerosis and have a poorer response to vascular
urgical interventions, frequently requiring graft revisions or
eplacements (87,88). Surgery for these younger patients
hould be avoided if possible.
Table 18. Overview of Primary Patency and Limb Salvage Rates After Endovascular Procedures for Peripheral Arterial Disease of the Lower Extremities
Procedure Lesion Type
Severity of
Disease Reference
No. of
Limbs
% 30-Day
Mortality
(95% CI)
% Major
Complication
(95% CI)
% Technical
Success
(95% CI)
% Primary Patency (95% CI)*
1 yr 2 yrs 3 yrs 4 yrs 5 yrs
Iliac PTA 80% Stenoses,
20% occlusion
67% Claudication,
33% critical
ischemia
(84) 1473 1.0 (0–2.9) 4.3 (2.0–6.5) 91 (86–96) 74 (71–76) 66 (63–68) 61 (59–64) 58 (56–61) —
Stenoses Claudication ND ND 96 79 72 68 65 —
Stenoses Critical ischemia ND ND ND 72 61 56 53 —
Occlusion Claudication ND ND 80 66 60 57 54 —
Occlusion Critical ischemia ND ND ND 60 51 47 44 —
Iliac stent 72% Stenoses,
28% occlusion
85% Claudication,
15% critical
ischemia
(84) 901 0.8 (0.7–0.9) 5.2 (3.5–6.9) 96 (91–100) 86 (84–89) 79 (76–81) 75 (72–78) 74 (69–78) —
Stenoses Claudication ND ND 100 91 84 80 77 —
Stenoses Critical ischemia ND ND ND 87 76 70 67 —
Occlusion Claudication ND ND 80 72 67 64 61 —
Occlusion Critical ischemia ND ND ND 69 60 56 53 —
Femoropopliteal
PTA
64% Stenoses,
36% occlusion
65% Claudication,
35% critical
ischemia
(85,86) 4800/1003† 0.9 (0.7–1.1) 8.1 (7.3–8.9) 89 (87–91) 59 (56–62) 54 (51–57) 52 (48–55) 49 (45–52) 45 (4–49)
Stenoses Claudication ND ND 95 79 75 74 71 68
Stenoses Critical ischemia ND ND 90 62 57 54 51 47
Occlusion Claudication ND ND 87 52 46 43 40 35
Occlusion Critical ischemia ND ND 75 26 21 18 15 12
Femoropopliteal
stent
Stenoses and
occlusions
80% Claudication,
20% critical
ischemia
Meta-
analysis‡
600 — 5.9 (1.7–10) 98 (97–100) 62 (48–80) 52 (33–83) 43 (22–86) — —
Infrapopliteal
PTA
Stenoses and
occlusions
14% Claudication,
86% critical
ischemia
Meta-
analysis§
1282 — — 93 (90–96) 79 (68–90) 74 (65–83) — — —
*All patency rates and limb savage rates include initial technical failures. †Mortality and complication rates are based on n equals 4800, patency rates are based on n equals 1003. ‡Based on a random-effects meta-analysis of the results
from various sources, each weighted with the inverse of the variance (17–27). §Based on a random-effects meta-regression analysis of the results from various sources, each weighted with the inverse of the variance (28–46). Reprinted
from Kandarpa et al. J Vasc Interv Radiol 2001;12:683–95 (84a).
CI  confidence interval; ND  no difference by subgroup can be demonstrated; PTA  percutaneous transluminal angioplasty.
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PADREOPERATIVE EVALUATION.
ECOMMENDATION
lass I
. A preoperative cardiovascular risk evaluation should
be undertaken in those patients with lower extremity
PAD in whom a major vascular surgical intervention
is planned. (Level of Evidence: B)
Lower extremity PAD is associated with the presence of
oronary artery disease and marks high short-term and
ong-term coronary ischemic risk, and therefore, a preoper-
tive cardiovascular risk evaluation should be undertaken.
he specific testing strategy that might be used for a specific
atient is beyond the scope of this guideline. Perioperative
schemic risk is increased for all lower extremity vascular
urgical procedures (inclusive of aortic, femoral, and infra-
opliteal segments). This risk is further increased in those
atients with an established history of ischemic heart
isease, current angina, or an abnormal electrocardiogram
nd may be challenging to assess in those individuals in
hom a sedentary lifestyle limits assessment of functional
apacity. The preoperative cardiovascular risk evaluation is
ummarized in more detail in the ACC/AHA Guideline
pdate for Perioperative Cardiovascular Evaluation for
oncardiac Surgery (89).
ORRELATION OF SYMPTOMS AND LESIONS.
URGICAL PROCEDURES. For individuals with claudication,
nitial revascularization strategies will usually rely on
ndovascular techniques, with surgical intervention re-
erved for individuals in whom arterial anatomy is not
avorable for endovascular procedures. As noted in Sec-
ion 2.6.2.4 of the full-text guidelines, comparable effi-
acy can often be achieved, with less risk imposed by
ndovascular intervention when both procedures are fea-
ible (90 –92). Once the decision to proceed with surgical
ntervention has been made and the site and severity of
cclusive lesions have been defined through imaging
tudies, the type of revascularization must be chosen. In
atients with combined inflow and outflow disease,
nflow problems are corrected first. A significant im-
rovement in inflow may diminish the symptoms of
laudication to the extent that supervised exercise therapy
r pharmacotherapies may be effective and, if distal
evascularization is needed, reduce the likelihood of distal
raft thrombosis from low flow.
NFLOW PROCEDURES: AORTOILIAC OCCLUSIVE DISEASE.
ECOMMENDATIONS
lass I
. Aortobifemoral bypass is beneficial for patients
with vocational- or lifestyle-disabling symptoms Aand hemodynamically significant aortoiliac disease
who are acceptable surgical candidates and who are
unresponsive to or unsuitable for exercise, phar-
macotherapy, or endovascular repair. (Level of
Evidence: B)
. Iliac endarterectomy and aortoiliac or iliofemoral
bypass in the setting of acceptable aortic inflow
should be used for the surgical treatment of unilateral
disease or in conjunction with femoral-femoral by-
pass for the treatment of a patient with bilateral iliac
artery occlusive disease if the patient is not a suitable
candidate for aortobifemoral bypass grafting. (Level
of Evidence: B)
lass IIb
. Axillofemoral-femoral bypass may be considered
for the surgical treatment of patients with inter-
mittent claudication in very limited settings, such
as chronic infrarenal aortic occlusion associated
with symptoms of severe claudication in patients
who are not candidates for aortobifemoral bypass.
(Level of Evidence: B)
lass III
. Axillofemoral-femoral bypass should not be used
for the surgical treatment of patients with inter-
mittent claudication except in very limited settings
(see Class IIb recommendation above). (Level of
Evidence: B)
There are numerous patterns of aortoiliac occlusive
isease and procedures to surgically treat them (Table
9). Most commonly, patients demonstrate diffuse dis-
ase of the infrarenal aorta and iliac vessels, with the
esions of greatest hemodynamic consequence located in
he iliac arteries. The most effective surgical procedure
or the treatment for this pattern of atherosclerotic
cclusive disease and the resultant buttock and thigh
laudication is aortobifemoral bypass.
If the aortoiliac lesions are confined to the area of the
ortic bifurcation, localized aortoiliac endarterectomy may
e considered. A less invasive approach may be appropriate
or patients with adequate aortic flow but stenoses or
cclusions of both iliac vessels. Such patients may not be
onsidered acceptable candidates for aortobifemoral bypass
able 19. Vascular Surgical Procedures for Inflow Improvement
Inflow Procedure
Operative
Mortality
(%)
Expected
Patency Rates
(%) References
ortobifemoral bypass 3.3 87.5 (5 yrs) (93)
ortoiliac or aortofemoral
bypass
1–2 85–90 (5 yrs) (94–96)
liac endarterectomy 0 79–90 (5 yrs) (97–99)
emorofemoral bypass 6 71 (5 yrs) (100)
xillofemoral bypass 6 49–80 (3 yrs) (101,102)
xillofemoral-femoral bypass 4.9 63–67.7 (5 yrs) (103,104)
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ACC/AHA Guidelines for the Management of PAD March 21, 2006:1239–312ecause of comorbid cardiovascular disease. If endovascular
reatment of 1 iliac artery is feasible and can achieve patency
ith this less invasive approach, a subsequent endarterec-
omy, unilateral iliofemoral bypass, or a femoral-femoral
ypass can be constructed. In the absence of an inflow
tenosis within the donor iliac arterial segment, this proce-
ure can effectively provide flow to both lower extremities
nd eliminate the symptoms of claudication. Patients with
evere infrarenal aortic atherosclerosis who are at high
ardiovascular or surgical risk for open aortobifemoral by-
ass may be treated with axillofemoral-femoral bypass.
ecause of lower patency rates, such bypasses are reserved
or those who have no alternatives for revascularization.
nilateral iliac stenoses or occlusions that cannot be effec-
ively treated by angioplasty and stent placement can be
reated by iliac artery endarterectomy, aortoiliac bypass,
ortofemoral bypass, or iliofemoral bypass if the origin of
he iliac artery is free of disease.
UTFLOW PROCEDURES: INFRAINGUINAL DISEASE.
ECOMMENDATIONS
lass I
. Bypasses to the popliteal artery above the knee
should be constructed with autogenous vein when
possible. (Level of Evidence: A)
. Bypasses to the popliteal artery below the knee
should be constructed with autogenous vein when
possible. (Level of Evidence: B)
lass IIa
. The use of synthetic grafts to the popliteal artery
below the knee is reasonable only when no autoge-
nous vein from ipsilateral or contralateral legs or
arms is available. (Level of Evidence: A)
lass IIb
. Femoral-tibial artery bypasses constructed with au-
togenous vein may be considered for the treatment of
Table 20. Vascular Surgical Procedures for Ou
Outflow Procedure
Operative Mo
(%)
Fem-AK popliteal vein 1.3–6.3
Fem-AK popliteal prosthetic 1.3–6.3
Fem-BK popliteal vein 1.3–6.3
Fem-BK popliteal prosthetic 1.3–6.3
Fem-Tib vein 1.3–6.3
Fem-Tib prosthetic 1.3–6.3
Composite sequential bypass 0–4
Fem-Tib blind segment bypass 2.7–3.2
Profundaplasty 0–3AK  above the knee; BK  below the knee; Fem  femoral; Ticlaudication in rare instances for certain patients (see
text). (Level of Evidence: B)
. Because their use is associated with reduced patency
rates, the effectiveness of the use of synthetic grafts to
the popliteal artery above the knee is not well estab-
lished. (Level of Evidence: B)
lass III
. Femoral-tibial artery bypasses with synthetic graft
material should not be used for the treatment of
claudication. (Level of Evidence: C)
The most commonly performed infrainguinal bypass
or the treatment of claudication is the femoral-popliteal
rtery bypass (Table 20). There are, however, specific
actors that may modify the result of this procedure. The
major factors are the type of conduit and the site of
nastomosis to the popliteal artery, whether above or
elow the knee.
Nearly all studies that have compared vein with pros-
hetic conduit for arterial reconstruction of the lower
xtremity have demonstrated the superior patency of
ein. Four large, randomized, prospective studies sum-
arized in Table 21 demonstrate findings consistent with
he large body of evidence on the choice of graft material
or the construction of bypasses to the above-knee pop-
iteal artery (115–118). The superior rates of immediate
nd long-term patency at all time periods favor use of
utogenous vein, whether in situ or reversed. In its
bsence, polytetrafluoroethylene or polyester fiber may be
sed with an expected lower but acceptable patency rate.
he need for retreatment or revision is greater with
ynthetic material over time. With more distal anasto-
oses or the presence of hemodynamically significant
ibial arterial occlusive disease and poor outflow, there is
ccelerated failure of prosthetic grafts. Therefore, the use
f autogenous vein is also strongly favored for bypasses to
he popliteal artery below the knee. Femoral tibial bypass
rafting with autogenous vein should rarely be necessary
or the treatment of intermittent claudication because of
he increased risk of amputation associated with failure of
Improvement
y Expected Patency Rate
(%) References
66 (5 yrs) (85,105,106)
50 (5 yrs) (115–118)
66 (5 yrs) (105,106)
33 (5 yrs) (85,105,106)
74–80 (5 yrs) (107)
25 (3 yrs) (109)
28–40 (5 yrs) (110,111)
64–67 (2 yrs) (112)
49–50 (3 yrs) (113,114)tflow
rtalitb  tibial.
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PADuch grafts (119,120). Bypasses to the tibial arteries with
rosthetic material should be avoided at all costs for the
reatment of the claudicant because of very high risks of
raft failure and amputation.
OLLOW-UP AFTER VASCULAR SURGICAL PROCEDURES.
ECOMMENDATIONS
lass I
. Patients who have undergone placement of aorto-
bifemoral bypass grafts should be followed up with
periodic evaluations that record any return or pro-
gression of claudication symptoms, the presence of
femoral pulses, and ABIs at rest and after exercise.
(Level of Evidence: C)
. Patients who have undergone placement of a lower
extremity bypass with autogenous vein should un-
dergo periodic evaluations for at least 2 years that
record any claudication symptoms; a physical exami-
nation and pulse examination of the proximal, graft,
and outflow vessels; and duplex imaging of the entire
length of the graft, with measurement of peak systolic
velocities and calculation of velocity ratios across all
lesions. (Level of Evidence: C)
. Patients who have undergone placement of a syn-
thetic lower extremity bypass graft should, for at
least 2 years after implantation, undergo periodic
evaluations that record any return or progression of
claudication symptoms; a pulse examination of the
proximal, graft, and outflow vessels; and assess-
ment of ABIs at rest and after exercise. (Level of
Evidence: C)
. Critical Limb Ischemia and Treatment for Limb Salvage.
.MEDICALANDPHARMACOLOGICALTREATMENTFORCLI.
ECOMMENDATIONS
lass III
. Parenteral administration of pentoxifylline is not
able 21. Patency of Bypass Grafts to the Above-Knee Popliteal
First Author Reference Graft Material n
ohnson (117) SVG 226
PTFE 265
linkert (118) SVG 75
PTFE 76
buRahma (116) SVG 43
PTFE 43
reen (115) PTFE
Dacron
 number of patients; PTFE  polytetrafluoroethylene; SVG  saphenous veinuseful for the treatment of CLI. (Level of Evidence: B)ROSTAGLANDINS.
ECOMMENDATIONS
lass IIb
. Parenteral administration of prostaglandin E-1
(PGE-1) or iloprost for 7 to 28 days may be consid-
ered to reduce ischemic pain and facilitate ulcer
healing in patients with CLI, but its efficacy is likely
to be limited to a small percentage of patients. (Level
of Evidence: A)
lass III
. Oral iloprost is not an effective therapy to reduce the
risk of amputation or death in patients with CLI.
(Level of Evidence: B)
In the 8 short-term trials of parenteral administration of
GE-1 or prostacyclin in patients with CLI, the results
ave been inconsistent and for the most part have not
emonstrated efficacy, as defined by amelioration of pain or
ealing of ulcers (16,121–127). In addition, there have been
t least 11 randomized, placebo-controlled trials of intrave-
ous PGE-1 or iloprost (16). The majority of studies have
ound that parenteral administration of either PGE-1 or
loprost reduced pain, as assessed by analgesic consumption,
lcer size, and/or amputation (16,128–136). One study
valuated the efficacy of oral iloprost in patients with CLI.
loprost did not significantly affect the primary end point of
mputation or death at 1 year (137).
NGIOGENIC GROWTH FACTORS.
ECOMMENDATION
lass IIb
. The efficacy of angiogenic growth factor therapy for
treatment of CLI is not well established and is best
investigated in the context of a placebo-controlled
ry
% Patency (yrs)
2 5
Assisted
5 6
Assisted
6
81 73
69 39
75.6 79.7
51.9 57.2
76 83
68 68
43 68
45 68Artetrial. (Level of Evidence: C)
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ECOMMENDATIONS
lass I
. For individuals with combined inflow and outflow
disease with CLI, inflow lesions should be addressed
first. (Level of Evidence: C)
. For individuals with combined inflow and outflow
disease in whom symptoms of CLI or infection
persist after inflow revascularization, an outflow re-
vascularization procedure should be performed.
(Level of Evidence: B)
. If it is unclear whether hemodynamically significant
inflow disease exists, intra-arterial pressure measure-
ments across suprainguinal lesions should be mea-
sured before and after the administration of a vaso-
dilator. (Level of Evidence: C)
The optimal strategy for management of a patient with
LI must be determined on a case-by-case basis. Important
ssues to consider include the urgency of the clinical pre-
entation, the presence of comorbidity, and the arterial
natomy. A significant improvement in inflow may dimin-
sh the symptoms of rest pain, but pulsatile flow to the foot
s generally necessary for the treatment of ischemic ulcers or
schemic gangrene. Therefore, if infection, ischemic ulcers,
r gangrenous lesions persist and the ABI is less than 0.8
fter correction of inflow, an outflow procedure should be
erformed that bypasses all major distal stenoses and occlu-
ions (138). The angiographic evaluation may also suggest
he presence of arterial stenoses whose functional signifi-
ance may not be clear. In this situation, measurement of
rans-stenotic pressure gradients can guide therapy. How-
ver, in the presence of severe outflow disease, an inaccu-
ately low pressure gradient may exist. Severe outflow
isease may so limit arterial flow that gradients are not
eveloped, and in this context, use of a pharmacological
rterial vasodilator to augment flow may be useful.
. THROMBOLYSIS FORACUTEANDCHRONICLIMB ISCHEMIA.
ECOMMENDATIONS
lass I
. Catheter-based thrombolysis is an effective and ben-
eficial therapy and is indicated for patients with acute
limb ischemia (Rutherford categories I and IIa) of
less than 14 days’ duration. (Level of Evidence: A)
lass IIa
. Mechanical thrombectomy devices can be used as
adjunctive therapy for acute limb ischemia due to
peripheral arterial occlusion. (Level of Evidence: B)
lass IIb
. Catheter-based thrombolysis or thrombectomy may
be considered for patients with acute limb ischemia(Rutherford category IIb) of more than 14 days’
duration. (Level of Evidence: B)
Randomized controlled trials and registry reports in-
icate that the use of thrombolytic therapy for acute limb
schemia is effective as initial therapy (139 –142). (The
erms “thrombolysis” and “thrombolytic” are synonymous
ith the terms “fibrinolysis” and “fibrinolytic,” as used in
ther ACC/AHA guidelines.) These randomized trials
nd case series suggest that the use of intra-arterial
hrombolytic therapy for acute limb ischemia is reason-
bly effective and comparable to surgery. The advantage
f thrombolytic therapy is that it offers a low-risk
lternative to open surgery in complex patients with severe
omorbidities. Other advantages of pursuing immediate
ngiography in patients with acute limb ischemia include
elineation of the limb arterial anatomy with visualization
f both inflow and runoff vessels. Finally, thrombolytic
herapy has the advantage, compared with surgical embo-
ectomy, of clearing intra-arterial thrombus from the distal
unoff vessels, thereby potentially enhancing long-term
atency. The choice of thrombolytic versus surgical revas-
ularization depends on several factors (16). Patients with
rofound limb ischemia may not tolerate the time necessary
o perform thrombolysis. Infrainguinal or distal arterial
hrombolysis has worse outcomes than more proximal or
liofemoral lysis (141). Because of bleeding risks, thrombol-
sis may be contraindicated in some patients. Contraindi-
ations have been summarized, although these recommen-
ations are based on common practice and are not
ecessarily supported by published studies. Because of
omorbidities, surgery may be contraindicated in some
atients. Nonrandomized trials and small series have also
eported on the use of mechanical thrombectomy devices,
hich may avert the need for thrombolysis or permit the use
f decreased doses of thrombolytic drugs (Table 22).
. SURGERY FOR CLI.
ECOMMENDATIONS
lass I
. For individuals with combined inflow and outflow
disease with CLI, inflow lesions should be addressed
first. (Level of Evidence: B)
. For individuals with combined inflow and outflow
disease in whom symptoms of CLI or infection
persist after inflow revascularization, an outflow re-
vascularization procedure should be performed.
(Level of Evidence: B)
. Patients who have significant necrosis of the weight-
bearing portions of the foot (in ambulatory patients),
an uncorrectable flexion contracture, paresis of the
extremity, refractory ischemic rest pain, sepsis, or a
very limited life expectancy due to comorbid condi-
tions should be evaluated for primary amputation of
the leg. (Level of Evidence: C)
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Device and
First Author
(Reference) Year n
Conduit
n (%)
Duration
n
MTD Success,*
n (%)
Adjunctive
Procedures
Primary
Patency
(%)
Complications
(%)
asis
Hoptner (143)
1999 51 Native: 44
(86)
Grafts: 7
(14)
All acute 6 (11.8) Lysis: 5
PTA: 20
PAT: 15
SA: 3
1 month: 64
6 months: 54
Hemorrhage: 8
Emboli: 4.8
Acute occlusion: 3
Amputation: 17.7
Mortality: 8
ngioJet
Muller-Hulsbeck
(144)
2000 112 Native: 99
(86)
Grafts: 16
(14)
All acute 79 (71) Lysis: 20
PTA: 68
PAT: 11
6 months: 68
2 years: 60
3 years: 58
Embolization: 9.8
Dissection: 8
Perforation: 3.6
Amputation: 1.8
Mortality: 7
Kasirajan (145) 2001 83 Native: 52
(63)
Grafts: 31
(37)
Acute: 62
Chronic: 21
Complete: 51
(61)
Partial: 19
(23)
Lysis: 50
PTA: 47
3 months: 90
6 months: 78
Hemorrhage: 10.5
Emboli: 2.3
Dissection: 3.5
Perforation: 2.3
Amputation: 11.6
Mortality: 9.3
Silva (146) 1998 22 Native: 13 All acute 21 (95) PTA: 21 NA Hemorrhage: 10
(59) Embolism: 9
Grafts: 9 Dissection: 5
(41) Occlusion: 18
Amputation: 5
Mortality: 14
Wagner (147) 1997 50 Native: 39 All acute 26 (52) Lysis: 15 1 year: 69 Hemorrhage: 6
(78) PTA: 34 Emboli: 6
Grafts: 11 PAT: 9 Dissection: 6
(22) Perforation: 6
Amputation: 8
Mortality: 0
ydrolyser
Reekers (148) 1996 28 Native: 11 Acute: 23 23 (82) Lysis: 11 1 month: 50 Embolization: 18
(39) Chronic: 5 PTA: 20 Hemorrhage: 0
Grafts: 17 PAT: 2 Acute occlusion: 10
(61) Amputation: 11
Mortality: 0
Henry (149) 1998 41 Native: 28 All acute 34 (83) Lysis: 10 1 month: 73 Acute occlusion: 12
(68) PTA: 29 Emboli: 2.4
Grafts: 8 PAT: 17 Amputation: 0
(20) Mortality: 0
Other: 5 Mortality: 0
mplatz
Rilinger (150) 1997 40 All native All acute 30 (75) Lysis/PTA/
SA: 9
NA Hemorrhage: 2.5
Device failure: 7.5
Emboli: 0
Amputation: 5
Mortality: 0
Tadavarthy (151) 1994 14 Native: 2
(14)
Grafts: 10
(71)
Other: 2
Acute: 9
Chronic: 5
10 (71) Lysis: 4
PTA/SA: 11
6 months: 43 Hemorrhage: 14.3
Emboli: 14
Device failure: 7
Amputation: 0
Mortality: 0
Gorich (152) 1998 18 All native All acute 14 (78) Lysis: 12 NA Hemorrhage: 6
PAT: 9 Device failure: 6
Amputation: 6
Definition of success varies among studies. Reprinted from Haskal ZJ. Mechanical thrombectomy devices for the treatment of peripheral arterial occlusions. Rev Cardiovasc Med
002;3 Suppl 2:S45–S52 (152a).MTDmechanical thrombectomy device; n number of patients; NA not applicable; PAT percutaneous aspiration thrombectomy; PTA percutaneous transluminal
ngioplasty; SA  Simpson atherectomy.
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. Surgical and endovascular intervention is not indi-
cated in patients with severe decrements in limb
perfusion (e.g., ABI less than 0.4) in the absence of
clinical symptoms of CLI. (Level of Evidence: C)
The goal of surgical intervention in patients with CLI is
he elimination of clinical manifestations of severe lower
xtremity PAD, whether rest pain, ischemic ulcers, or distal
schemic gangrene. A significant improvement in inflow
ay diminish the symptoms of rest pain, but pulsatile flow
o the foot is generally necessary for the treatment of
schemic ulcers or ischemic gangrene. Therefore, if infec-
ion, ischemic ulcers, or gangrenous lesions persist and the
BI is less than 0.8 after correction of inflow, an outflow
rocedure should be performed that bypasses all major distal
tenoses and occlusions (138). Surgery for the treatment of
evere lower extremity ischemia (as for endovascular treat-
ent) must be based on specific goals, such as the relief of
est pain or healing of ulcers, prior revascularization at-
empts, the type of procedure required to accomplish the
oals, and the patient’s overall ability to successfully recover
rom the effort. In patients with combined inflow and
utflow disease, inflow problems must be corrected first.
NFLOW PROCEDURES: AORTOILIAC OCCLUSIVE DISEASE.
ECOMMENDATIONS
lass I
. When surgery is to be undertaken, aortobifemoral
bypass is recommended for patients with symptom-
atic, hemodynamically significant, aorto-bi-iliac dis-
ease requiring intervention. (Level of Evidence: A)
. Iliac endarterectomy, patch angioplasty, or aortoiliac
or iliofemoral bypass in the setting of acceptable
aortic inflow should be used for the treatment of
unilateral disease or in conjunction with femoral-
femoral bypass for the treatment of a patient with
bilateral iliac artery occlusive disease if the patient is
not a suitable candidate for aortobifemoral bypass
grafting. (Level of Evidence: B)
. Axillofemoral-femoral bypass is indicated for the
treatment of patients with CLI who have extensive
aortoiliac disease and are not candidates for other
types of intervention. (Level of Evidence: B)
The creation of an in situ or reversed greater saphenous
ein bypass to a tibial vessel is the most commonly per-
ormed limb salvage procedure. This type of bypass can be
erformed under general or regional (or, more rarely, local)
nesthesia and is generally well tolerated. There are, how-
ver, specific factors that may modify the result of this
rocedure, most notably, the type of conduit and the
utflow tract beyond the distal anastomosis.Nearly all studies that have compared vein to prosthetic
onduit for arterial reconstruction of the lower extremity
ave demonstrated the superior patency of vein (115–118).
n its absence, polytetrafluoroethylene or Dacron (polyester
ber) may be used with an expected lower but acceptable
atency rate for above-knee bypasses. Patency of prosthetic
rafts is significantly lower once the knee joint is crossed
85). When vein length is inadequate, a composite sequen-
ial graft that consists of a prosthetic graft to the above-knee
opliteal artery and a jump graft of autogenous vein to the
istal vessel may be used. If no other option exists, the use
f a prosthetic with an adjunctive procedure, such as
rteriovenous fistula or vein interposition or cuff, may
mprove patency, although this has not been proven. The
east-diseased tibial or pedal artery with continuous flow to
he foot should be used as the outflow vessel for the
onstruction of a distal bypass, because equivalent results
an be achieved with all tibial and even pedal arteries
153,154).
UTFLOW PROCEDURES: INFRAINGUINAL DISEASE.
ECOMMENDATIONS
lass I
. Bypasses to the above-knee popliteal artery should be
constructed with autogenous saphenous vein when
possible. (Level of Evidence: A)
. Bypasses to the below-knee popliteal artery should be
constructed with autogenous vein when possible.
(Level of Evidence: A)
. The most distal artery with continuous flow from
above and without a stenosis greater than 20% should
be used as the point of origin for a distal bypass.
(Level of Evidence: B)
. The tibial or pedal artery that is capable of providing
continuous and uncompromised outflow to the foot
should be used as the site of distal anastomosis.
(Level of Evidence: B)
. Femoral-tibial artery bypasses should be constructed
with autogenous vein, including the ipsilateral
greater saphenous vein, or if unavailable, other
sources of vein from the leg or arm. (Level of Evi-
dence: B)
. Composite sequential femoropopliteal-tibial bypass
and bypass to an isolated popliteal arterial segment
that has collateral outflow to the foot are both
acceptable methods of revascularization and should
be considered when no other form of bypass with
adequate autogenous conduit is possible. (Level of
Evidence: B)
. If no autogenous vein is available, a prosthetic
femoral-tibial bypass, and possibly an adjunctive
procedure, such as arteriovenous fistula or vein in-
terposition or cuff, should be used when amputation
is imminent. (Level of Evidence: B)
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. Prosthetic material can be used effectively for by-
passes to the below-knee popliteal artery when no
autogenous vein from ipsilateral or contralateral leg
or arms is available. (Level of Evidence: B)
There are numerous patterns of aortoiliac occlusive dis-
ase and procedures to surgically treat them. Most com-
only, patients demonstrate diffuse disease of the infrarenal
orta and iliac vessels, with the lesions of greatest hemody-
amic consequence located in the iliac arteries. The most
ffective surgical procedure for the treatment for this pattern
f atherosclerotic occlusive disease is aortobifemoral bypass.
ortobifemoral grafting is associated with an operative
ortality of 3.3% and a morbidity of 8.3% (93). Major
orbidity is most commonly due to MI (0.8% to 5.2%) or
enal failure (0% to 4.6%) (155). The expected patency of
ortobifemoral bypass as the sole procedure for the treat-
ent of CLI is excellent (93,155).
If the aortoiliac lesions are confined to the area of the
ortic bifurcation, localized aortoiliac endarterectomy may
e considered. This procedure is effective but is uncom-
only performed because few patients have such a limited
anifestation of atherosclerosis. Nonetheless, when the
peration is indicated, the results demonstrate good pa-
ency, in the range of 48% to 77% at 10 years (156).
For patients with adequate aortic flow but stenoses or
cclusions of both iliac vessels who are not considered
cceptable candidates for aortobifemoral bypass, a some-
hat less invasive approach may be appropriate. If 1 iliac
rtery can be made widely patent by angioplasty and stent
lacement, endarterectomy, or a unilateral iliofemoral by-
ass, a femoral-femoral bypass can be constructed. In the
bsence of an inflow stenosis within the donor iliac arterial
egment, this procedure can effectively improve flow to both
ower extremities. Unilateral iliac stenoses or occlusions that
annot be treated effectively by angioplasty and stent place-
ent can be treated by iliac artery endarterectomy, aorto-
liac bypass, aortofemoral bypass, or iliofemoral bypass if the
rigin of the iliac artery is free of disease.
The surgical treatment of unilateral iliac disease by
ortoiliac, iliofemoral, or femoral-femoral bypass graft
lacement provides excellent results for the restoration of
nflow into the lower extremity. Ipsilateral bypasses that
riginate from the aorta or proximal iliac artery have a
-year patency rate in the range of 90% (95,157). Femoral-
emoral bypass grafting yields a 3-year patency rate that
anges from 60% to 80% and a 5-year patency rate of 60%
o 90% (158,159).
Patients with severe infrarenal aortic atherosclerosis who
re at high cardiovascular or surgical risk for open aorto-
ifemoral bypass may be treated with axillofemoral-femoral
ypass. Because this graft is based on the axillary artery,
reoperative assessment of bilateral arm blood pressures,
uplex ultrasound flow assessments, and/or imaging of the mortic arch and great vessels to the origin of the donor vessel
hould be obtained.
Axillofemoral and axillobifemoral grafts are significantly
nferior to aortobifemoral bypass grafts or aortoiliac endar-
erectomy for the treatment of severe diffuse aortoiliac
isease. The 5-year patency rate for axillofemoral grafts
anges from 19% to 50% (160,161). The results of axillobi-
emoral bypass are somewhat better, with 5-year patency
ates that range from 50% to 76% (162).
OSTSURGICAL CARE.
ECOMMENDATIONS
lass I
. Unless contraindicated, all patients undergoing re-
vascularization for CLI should be placed on anti-
platelet therapy (see Sections 2.4.2 and 2.6.1.6 in the
full-text guidelines), and this treatment should be
continued indefinitely. (Level of Evidence: A)
. Patients who have undergone placement of aortobi-
femoral bypass grafts should be followed up with
periodic evaluations that record any return or pro-
gression of ischemic symptoms, the presence of fem-
oral pulses, and ABIs. (Level of Evidence: B)
. If infection, ischemic ulcers, or gangrenous lesions
persist and the ABI is less than 0.8 after correction of
inflow, an outflow procedure should be performed
that bypasses all major distal stenoses and occlusions.
(Level of Evidence: A)
. Patients who have undergone placement of a lower
extremity bypass with autogenous vein should un-
dergo for at least 2 years periodic examinations that
record any return or progression of ischemic symp-
toms; a physical examination, with concentration on
pulse examination of the proximal, graft, and outflow
vessels; and duplex imaging of the entire length of the
graft, with measurement of peak systolic velocities
and calculation of velocity ratios across all lesions.
(Level of Evidence: A)
. Patients who have undergone placement of a syn-
thetic lower extremity bypass graft should undergo
periodic examinations that record any return of isch-
emic symptoms; a pulse examination of the proximal,
graft, and outflow vessels; and assessment of ABIs at
rest and after exercise for at least 2 years after
implantation. (Level of Evidence: A)
To maximize the benefit of revascularization and to
inimize the risk of cardiovascular ischemic events (MI and
troke), all postoperative patients with lower extremity PAD
hould receive cardiovascular risk-reduction therapy and an
ral antiplatelet medication, usually aspirin or clopidogrel.
Optimally, risk-reduction therapies will be initiated preop-
ratively and continued for the patient’s lifetime. There are
inimal data to suggest that anticoagulation with warfarin
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umbers of patients, and thus the overall database is inconclu-
ive as yet (163,164). One retrospective analysis of patients who
ad undergone infrainguinal bypass suggested that the use of
n ACE inhibitor might decrease mortality (165). To maintain
ptimal outcomes, patients should undergo periodic graft
urveillance for at least 2 years after placement. For vein grafts,
uplex imaging of the donor and recipient arteries, proximal
nd distal anastomoses, and the entire graft length is of benefit
or the detection of grafts with reduced flow secondary to
ntraluminal lesions. Duplex imaging is of limited benefit for
he detection of lesions within synthetic grafts. Therefore, the
eriodic recording of ABIs is sufficient.
. Algorithms
. Diagnostic and Treatment Pathways. The diagnosis of
ower extremity PAD should be considered in individuals who
re either “at risk” for lower extremity PAD and in those who
resent with lower extremity ischemic symptoms (Fig. 3).
pecific clinical information should be used to identify these
t-risk individuals who merit pursuit of an objective lower
xtremity PAD diagnosis by measurement of an ABI exami-
ation or by use of alternative PAD testing strategies (Figs. 3
o 5). Clinical data that should guide this assessment include
he presence of atherosclerosis risk factors (especially age,
moking, and diabetes), clinical history (a history of athero-
clerotic coronary artery, carotid artery, or renal artery disease
nd lower extremity symptoms), and an abnormal lower
xtremity pulse examination. Subsequent diagnostic testing
nd therapeutic interventions are dependent on the severity
nd acuity of the presenting limb symptoms (Figs. 4 to 8). Use
f lower extremity symptoms and ABI data should then be
sed to initiate therapeutic interventions to decrease cardiovas-
ular ischemic risk; diminish claudication symptoms; and
romptly identify individuals with CLI or those who are at risk
or amputation. Algorithms for the diagnosis and treatment of
AD are presented for individuals with PAD who are asymp-
omatic or who present with atypical symptoms (Fig. 4),
laudication (Figs. 5 and 6), CLI (Fig. 7), and acute limb
schemia (Figs. 8 and 9).
II. RENAL ARTERIAL DISEASE
. Prevalence and Natural History
enal artery stenosis (RAS) is both a common and progressive
isease in patients with atherosclerosis and a relatively uncom-
on cause of hypertension (166,167). From a limited epide-
iological database, it is estimated that atherosclerotic RAS
ay affect as many as 6.8% of people aged 65 years and older
168). However, atherosclerotic RAS is common in cohorts
hat have clinically evident atherosclerosis in other arterial
irculations. For example, 22% to 59% of patients with PAD
ave hemodynamically significant RAS (as defined by a ste-
osis greater than 50%) (169–179). In individuals with histo-
ies of proven MI, 12% of postmortem examinations demon-
trate the presence of an RAS of 75% or greater. Despite theigh prevalence of RAS in these atherosclerotic subgroups, it
emains controversial as to which lesions are associated with
mportant clinical sequelae.
. Clinical Clues to the Diagnosis of RAS
ECOMMENDATIONS
lass I
. The performance of diagnostic studies to identify
clinically significant RAS is indicated in patients with
the onset of hypertension before the age of 30 years.
(Level of Evidence: B)
. The performance of diagnostic studies to identify
clinically significant RAS is indicated in patients with
the onset of severe hypertension [as defined in the
Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure: the JNC 7 report (187)] after
the age of 55 years. (Level of Evidence: B)
. The performance of diagnostic studies to identify
clinically significant RAS is indicated in patients
with the following characteristics: (a) accelerated
hypertension (sudden and persistent worsening of
previously controlled hypertension); (b) resistant
hypertension (defined as the failure to achieve
goal blood pressure in patients who are adhering
to full doses of an appropriate 3-drug regimen
that includes a diuretic); or (c) malignant hyper-
tension (hypertension with coexistent evidence of
acute end-organ damage; i.e., acute renal failure,
acutely decompensated congestive heart failure,
new visual or neurological disturbance, and/or
advanced [grade III to IV] retinopathy). (Level of
Evidence: C)
. The performance of diagnostic studies to identify
clinically significant RAS is indicated in patients
with new azotemia or worsening renal function
after the administration of an ACE inhibitor or an
angiotensin receptor blocking agent. (Level of Ev-
idence: B)
. The performance of diagnostic studies to identify
clinically significant RAS is indicated in patients with
an unexplained atrophic kidney or a discrepancy in
size between the 2 kidneys of greater than 1.5 cm.
(Level of Evidence: B)
. The performance of diagnostic studies to identify
clinically significant RAS is indicated in patients with
sudden, unexplained pulmonary edema (especially in
azotemic patients). (Level of Evidence: B)
lass IIa
. The performance of diagnostic studies to identify
clinically significant RAS is reasonable in patients
with unexplained renal failure, including individuals
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transplantation). (Level of Evidence: B)
lass IIb
. The performance of arteriography to identify signif-
icant RAS may be reasonable in patients with mul-
igure 3. Steps toward the diagnosis of peripheral arterial disease (PA
xertional, but that does not consistently resolve with rest, consistently
riteria. †The five “Ps” are defined by the clinical symptoms and signs t
nd paralysis (with polar being a sixth “P”).tivessel coronary artery disease and none of theclinical clues (Fig. 10) or PAD at the time of
arteriography. (Level of Evidence: B)
. The performance of diagnostic studies to identify
clinically significant RAS may be reasonable in pa-
tients with unexplained congestive heart failure or
refractory angina (see Section 3.5.2.4 of the full-text
*“Atypical” leg pain is defined by lower extremity discomfort that is
t exercise at a reproducible distance, or meet all “Rose questionnaire”
ggest potential limb jeopardy: pain, pulselessness, pallor, paresthesias,D).
limiguidelines). (Level of Evidence: C)
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rovide relative indications for application of more specific
iagnostic testing strategies. Such diagnostic testing strate-
ies should be performed when establishment of the RAS
iagnosis is likely to offer information that can beneficially
e linked to an effective patient-specific treatment strategy.
igure 4. Diagnosis and treatment of asymptomatic peripheral arterial dis
eserved for use in symptomatic patients in whom anatomic diagnostic data
ciatica, radiculopathy; muscle strain; neuropathy; compartment syndrome.
AD-specific (limb ischemic) endpoints. Primary treatment of diabetes m
ngiotensin-converting enzyme (ACE) inhibition in individuals without cla
as been extrapolated from other “at risk” populations. Adapted with per
laudication. N Engl J Med 2001;344:1608–21 (179a). Copyright © 2001 M
gbA1c  hemoglobin A; JNC-7  Seventh Report of the Joint National
lood Pressure; LOE  level of evidence; NCEP ATP III  National Cee Figure 10 for a summary.. Diagnostic Methods
ECOMMENDATIONS
lass I
. Duplex ultrasonography is recommended as a screen-
ing test to establish the diagnosis of RAS. (Level of
PAD) and atypical leg pain. *Duplex ultrasonography should generally be
uired for care. †Other causes of leg pain may include: lumbar disk disease,
not yet proven that treatment of diabetes mellitus will significantly reduce
should be continued according to established guidelines. #The benefit of
tion has not been specifically documented in prospective clinical trials, but
on from Hiatt WR. Medical treatment of peripheral arterial disease and
chusetts Medical Society. All rights reserved. ABI ankle-brachial index;
mittee on the Prevention, Detection, Evaluation, and Treatment of High
terol Education Program Adult Treatment Panel III.ease (
is req
‡It is
ellitus
udica
missi
assa
ComEvidence: B)
23
4
C
1
2
3
F
a
†
c
o
I II.
1271JACC Vol. 47, No. 6, 2006 Hirsch et al.
March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PAD. Computed tomographic angiography (in individuals
with normal renal function) is recommended as a
screening test to establish the diagnosis of RAS.
(Level of Evidence: B)
. Magnetic resonance angiography is recommended as
a screening test to establish the diagnosis of RAS.
(Level of Evidence: B)
. When the clinical index of suspicion is high and the
results of noninvasive tests are inconclusive, catheter
angiography is recommended as a diagnostic test to
igure 5. Diagnosis of claudication and systemic risk treatment. *It is not y
rterial disease (PAD)-specific (limb ischemic) endpoints. Primary treatme
The benefit of angiotensin-converting enzyme (ACE) inhibition in indiv
linical trials, but has been extrapolated from other “at risk” populations. AB
f the Joint National Committee on the Prevention, Detection, Evaluation,
II  National Cholesterol Education Program Adult Treatment Panel Iestablish the diagnosis of RAS. (Level of Evidence: B)lass III
. Captopril renal scintigraphy is not recommended as a
screening test to establish the diagnosis of RAS.
(Level of Evidence: C)
. Selective renal vein renin measurements are not
recommended as a useful screening test to establish
the diagnosis of RAS. (Level of Evidence: B)
. Plasma renin activity is not recommended as a useful
screening test to establish the diagnosis of RAS.
ven that treatment of diabetes mellitus will significantly reduce peripheral
diabetes mellitus should be continued according to established guidelines.
without claudication has not been specifically documented in prospective
ankle-brachial index; HgbA1c  hemoglobin A; JNC-7  Seventh Report
reatment of High Blood Pressure; LOE level of evidence; NCEP ATPet pro
nt of
iduals
I 
and T(Level of Evidence: B)
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activity after captopril administration) is not recom-
mended as a useful screening test to establish the
diagnosis of RAS. (Level of Evidence: B)
Renal artery stenosis is best diagnosed with an imaging
odality. The ideal tool should evaluate both the main
nd accessory renal arteries, assess the hemodynamic
ignificance of the demonstrated lesions, identify the site
nd severity of the stenosis, and identify associated
erirenal pathology, including the presence of an abdom-
nal aortic aneurysm or renal or adrenal masses. Direct
maging modalities such as duplex ultrasound, CTA, and
RA are best suited to serve as effective diagnostic
creening methods. The choice of imaging procedure will
epend on the availability of the diagnostic tool, the
xperience and local accuracy of the chosen modality, and
atient characteristics (e.g., body size, renal function,
ontrast allergy, and presence of prior stents or metallic
bjects that may serve as contraindications to MRA or
igure 6. Treatment of claudication. *Inflow disease should be suspected in
ruit and should be confirmed by noninvasive vascular laboratory diagnostic
nfrapopliteal stenoses (the presence of occlusive lesions in the lower extre
o the pedal vessels). PAD  peripheral arterial disease.TA techniques). nUMMARY OF NONINVASIVE RENAL ARTERY DIAGNOSTIC IMAGING
TRATEGIES. There are relative advantages and disadvan-
ages to each of the aforementioned imaging modalities.
aptopril renography has been validated in a large
umber of patients but is limited in value to a subset of
ll potential renovascular patients and is of limited value
n patients with significant azotemia, bilateral RAS, or
AS to a single functioning kidney. Duplex renal sonog-
aphy, because of the critical role of the sonographer, is
ccurate in experienced laboratories and is thus ideally
erformed in high-volume accredited laboratories. The
iagnostic accuracy of these ultrasound-based examina-
ions is further limited in patients with large body habitus
r intestinal gas obscuring visualization of the entirety of
he renal artery. Computed tomographic angiography
urrently provides higher spatial resolution than MRA
nd may be more readily available; however, the require-
ent to use iodinated contrast makes it an unattractive
odality in patients with impaired renal function.
adolinium-enhanced MRA provides excellent and less-
viduals with gluteal or thigh claudication and femoral pulse diminution or
nce of aortoiliac stenoses †Outflow disease represents femoropopliteal and
rterial tree below the inguinal ligament from the common femoral arteryindi
evideephrotoxic characterization of the renal arteries, sur-
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PADigure 7. Diagnosis and treatment of critical limb ischemia (CLI). *Based on patient comorbidities. †Based on anatomy or lack of conduit. ‡Risk factor
ormalization: immediate smoking cessation, treat hypertension per the Seventh Report of the Joint National Committee on Prevention, Detection,
valuation, and Treatment of High Blood Pressure guidelines; treat lipids per National Cholesterol Education Program Adult Treatment Panel III
uidelines; treat diabetes mellitus (HgbA1c [hemoglobin A] less than 7%; Class IIa). It is not yet proven that treatment of diabetes mellitus will significantly
educe peripheral arterial disease (PAD)-specific (limb ischemic) end points. Primary treatment of diabetes mellitus should be continued according to
stablished guidelines. ABI ankle-brachial index; CTA computed tomographic angiography; ECG electrocardiogram; MRAmagnetic resonance
ngiography; PVR  pulse volume recording; TBI  toe-brachial index; TEE  transesophageal echocardiography; US  ultrasound.
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ut it remains the most costly renal artery examination. It
s far less useful in patients who have had a metallic renal
rtery stent placed because of the inability to image inside
f the stent to detect restenosis. Comparisons of
ontrast-enhanced 3-dimensional MRA and multidetec-
or CTA with digital subtraction catheter angiography in
igure 8. Diagnosis of acute limb ischemia. Adapted from J Vasc Surg 26,
utherford RB, Baker JD, Ernst C, et al., Recommended standards for
eports dealing with lower extremity ischemia: revised version, 517–38,
opyright 1997, with permision from Elsevier (180a). ABI  ankle-
rachial index; CTA  computed tomographic angiography; ECG 
lectrocardiogram; MRA  magnetic resonance angiography; PVR 
ulse volume recording; TBI  toe-brachial index; TEE  transesopha-
eal echocardiography.large number of arterial segments have demonstratedqually high sensitivities for detection of hemodynami-
ally significant stenoses for MRA and CTA (greater
han 90%), with excellent interobserver and intermodality
greement (kappa equals 0.88 to 0.90) (180).
. Catheter Angiography. The indications for catheter-
ased contrast renal angiography include (a) individuals in
hom there are prespecified indications to suspect clinically
mportant RAS (“clinical clues”) in whom definitive diag-
ostic noninvasive images cannot be obtained and (b)
ndividuals in whom these prespecified clinical indications
nd patient consent have been documented and in whom
oncomitant angiographic access has been obtained for
eripheral angiography or coronary angiography. Catheter-
ased contrast angiography is associated with a low rate of
erious adverse outcomes.
. Renin.
. SELECTIVE RENAL VEIN RENIN STUDIES. The utility of
enal vein renin measurements depends on the ability to
ifferentiate the unilateral elevation of renin concentration
rom the renal vein that drains the kidney with renal artery
isease from the systemic plasma renin levels and/or renal vein
enin levels collected from the contralateral (normal) kidney.
he test may have more utility in establishing an indication for
ephrectomy in patients with renal artery occlusion than in
dentifying patients with RAS who may derive benefit from
evascularization (181); for pediatric patients with questionably
evere RAS before revascularization; or for patients with very
arked aortoiliac-renal atherosclerosis, in whom revasculariza-
ion could carry unusually high risk.
. PLASMA RENIN ACTIVITY: CAPTOPRIL TEST. The overall
ensitivity of this test is 61%, with a specificity of 86% for
he detection of RAS; however, this test is less accurate in
atients who are volume expanded or who have chronic
enal failure, bilateral renal artery disease, or disease to a
olitary functioning kidney. Plasma renin activity is not
ecommended as a useful screening test to establish the
iagnosis of RAS.
. Treatment of Renovascular Disease: Renal Artery
tenosis
reatment of renal arterial disease should serve to aid in the
ormalization of blood pressure and to preserve renal
unction. Both medical (pharmacological) and revascular-
zation strategies should be considered for patients with
ocumented renal arterial disease. A treatment algorithm is
rovided in Figure 11.
. Medical Treatment.
ECOMMENDATIONS
lass I
. Angiotensin-converting enzyme inhibitors are effec-
tive medications for treatment of hypertension asso-
ciated with unilateral RAS. (Level of Evidence: A)
23
4
c
h
a
t
s
l
a
w
h
p
f
o
c
r
c
a
t
P
B
2
A
R
C
1
F
d 1997,
P
1275JACC Vol. 47, No. 6, 2006 Hirsch et al.
March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PAD. Angiotensin receptor blockers are effective medica-
tions for treatment of hypertension associated with
unilateral RAS. (Level of Evidence: B)
. Calcium-channel blockers are effective medications
for treatment of hypertension associated with unilat-
eral RAS. (Level of Evidence: A)
. Beta-blockers are effective medications for treatment
of hypertension associated with RAS. (Level of Evi-
dence: A)
Multiple studies have now shown that ACE inhibitors and
alcium-channel blockers are effective in the treatment of
ypertension in the presence of RAS (182–186). These results
ddress primarily the treatment of hypertension, but diminu-
ion in the progression of renal disease has also been demon-
trated. There is also evidence that alternative therapies, based
argely on chlorothiazide, hydralazine, and beta-blockers, also
ppear effective to achieve target blood pressures in individuals
ith RAS. Although the angiotensin II receptor blockers also
igure 9. Treatment of acute limb ischemia. Adapted from J Vasc Surg 26
ealing with lower extremity ischemia: revised version, 517–38, Copyright
VR  pulse volume recording; US  ultrasound.ave an evidence base of efficacy for normalization of bloodressure in individuals with RAS, their effects need to be tested
urther in large randomized trials. There are currently few
bjective clinical clues that permit selection of specific patient
ohorts that would best be treated by medical therapy versus
enal arterial revascularization, which remains an area of active
linical investigation. Individuals with atherosclerotic disease
nd hypertension should be treated according to the goals of
he Seventh Report of the Joint National Committee on
revention, Detection, Evaluation, and Treatment of High
lood Pressure (187).
. Indications for Revascularization.
. ASYMPTOMATIC STENOSIS.
ECOMMENDATIONS
lass IIb
. Percutaneous revascularization may be considered for
erford RB, Baker JD, Ernst C, et al. Recommended standards for reports
with permission from Elsevier (180a). PAD  peripheral arterial disease;, Ruthtreatment of an asymptomatic bilateral or solitary
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RAS. (Level of Evidence: C)
. The usefulness of percutaneous revascularization of
an asymptomatic unilateral hemodynamically signif-
icant RAS in a viable kidney is not well established
and is presently clinically unproven. (Level of Evi-
dence: C)
There are no well-controlled prospective randomized
nvestigations to measure the relative risk and benefit of
ndovascular interventions (or associated medical thera-
ies) in individuals with asymptomatic renal artery dis-
ase, and thus, the role of such interventions remains
ontroversial. Recommendations regarding the role of
ercutaneous revascularization of asymptomatic renal
isease are made largely on the basis of expert opinion
igure 10. Clinical clues to the diagnosis of renal artery stenosis. *For defi
he Seventh Report of the Joint National Committee on Prevention, Det
AMA 2003;289:2560–72 (187). †For example, atrophic kidney due t
ngiotensin-converting enzyme; ARB  angiotensin receptor blocking age
esonance angiography; RAS  renal artery stenosis.nd are not based on evidence that treatment of asymp-omatic RAS improves any renal or systemic outcome,
ncluding renal preservation, blood pressure, or cardio-
ascular morbidity or mortality. Therefore, these recom-
endations must be individualized for the patient by
ach treating physician.
. HYPERTENSION.
ECOMMENDATIONS
lass IIa
. Percutaneous revascularization is reasonable for pa-
tients with hemodynamically significant RAS and
accelerated hypertension, resistant hypertension, ma-
lignant hypertension, hypertension with an unex-
plained unilateral small kidney, and hypertension
of hypertension, please see Chobanian AV, Bakris GL, Black HR, et al.
, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.
onic pyelonephritis is not an indication for RAS evaluation. ACE 
T  computed tomography; LOE  level of evidence; MRA  magneticnition
ection
o chr
nt; Cwith intolerance to medication. (Level of Evidence: B)
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PADThe current evidence base suggests that patients with
evere atherosclerotic RAS and accelerated, resistant, and
alignant hypertension may expect to receive some clinical
enefit, including improved blood pressure control, the need
or fewer medications, or both. However, “cure” of hyper-
ension is rare, improvement in blood pressure control is
ommon, and a moderate fraction of individuals do not
chieve measurable benefit (see Table 36 of the full-text
uidelines).
. PRESERVATION OF RENAL FUNCTION.
ECOMMENDATIONS
lass IIa
. Percutaneous revascularization is reasonable for pa-
tients with RAS and progressive chronic kidney
disease with bilateral RAS or a RAS to a solitary
functioning kidney. (Level of Evidence: B)
lass IIb
. Percutaneous revascularization may be considered for
patients with RAS and chronic renal insufficiency
igure 11. Indications for renal revascularization. *Viable means kidney line
fficacy in alleviating renal arterial stenosis (RAS) due to atherosclerosis
ndividuals in whom less invasive percutaneous RAS interventions are not fe
level of evidence; PTA  percutaneous transluminal angioplasty.with unilateral RAS. (Level of Evidence: C)Revascularization is effective in stabilizing or improving
enal function in patients with symptomatic atheroscle-
otic RAS (188 –193). Several factors may argue against
enal revascularization or predict poorer outcomes, in-
luding the presence of proteinuria greater than 1 g every
4 hours, renal atrophy, severe renal parenchymal disease,
nd severe diffuse intrarenal arteriolar disease. Moreover,
he adverse consequences of renal atheroembolization at
he time of surgical revascularization have been docu-
ented (194). Similarly, potentially severe atheroembo-
ization may be provoked by renal percutaneous revascu-
arization methods (195).
. IMPACT OF RAS ON CONGESTIVE HEART FAILURE AND
NSTABLE ANGINA.
ECOMMENDATIONS
lass I
. Percutaneous revascularization is indicated for pa-
tients with hemodynamically significant RAS and
recurrent, unexplained congestive heart failure or
sudden, unexplained pulmonary edema (see text).
gth greater than 7 cm. †It is recognized that renal artery surgery has proven
bromuscular dysplasia. Currently, however, its role is often reserved for
. CHF congestive heart failure; CRI chronic renal insufficiency; LOEar len
and fi
asible(Level of Evidence: B)
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. Percutaneous revascularization is reasonable for pa-
tients with hemodynamically significant RAS and
unstable angina (see text). (Level of Evidence: B)
The potential physiological benefits of renal stent place-
ent include reperfusion of the ischemic kidney(s), result-
ng in a reduction in the stimulus to renin production, which
ecreases angiotensin and aldosterone production, thereby
ecreasing peripheral arterial vasoconstriction and the ten-
ency to develop an expanded extracellular fluid volume.
mprovement in renal perfusion enhances glomerular filtra-
ion and therefore promotes natriuresis. Finally, in patients
ith a solitary kidney or bilateral RAS, the ability of the
atient to tolerate long-term administration of angiotensin
ntagonist medications may be facilitated by relief of a
emodynamic renal artery obstruction. The recommenda-
ions in these guidelines are intended to apply to individuals
ith refractory heart failure or unstable angina in whom
onrenal exacerbating factors have been evaluated and in
hom there are reasonable clinical indications to suggest the
resence of RAS (e.g., systemic atherosclerosis), as is more
ully described in the full-text version of the guidelines.
. Catheter-Based Interventions.
ECOMMENDATIONS
lass I
. Renal stent placement is indicated for ostial athero-
sclerotic RAS lesions that meet the clinical criteria
for intervention. (Level of Evidence: B)
. Balloon angioplasty with bailout stent placement if
necessary is recommended for fibromuscular dyspla-
sia lesions. (Level of Evidence: B)
Percutaneous transluminal renal balloon angioplasty is
he treatment of choice for symptomatic RAS caused by
bromuscular dysplasia (188,196–198). However, in ath-
rosclerotic RAS, balloon angioplasty alone is associated
ith a lower procedural success rate and a higher restenosis
ate (189,199–205). Aorto-ostial stenoses represent the
ost common atherosclerotic lesions and are prone to
ascular recoil due to confluent plaque that extends from the
all of the aorta into the ostium of the renal artery. These
therosclerotic aorto-ostial lesions are generally considered
nsuitable for treatment by balloon angioplasty alone
197,198,206).
Stent placement has consistently proven superior to
alloon angioplasty in the treatment of renal artery athero-
clerotic lesions (207,208). For renal artery atherosclerotic
esions, the larger the poststent minimal lumen diameter, as
easured by quantitative vascular angiography, the better
he late stent patency (209). Similar to coronary stents,
arger-diameter renal arteries have lower restenosis rates
han smaller-diameter vessels (210,211). p. Surgery for RAS.
ECOMMENDATIONS
lass I
. Vascular surgical reconstruction is indicated for pa-
tients with fibromuscular dysplastic RAS with clini-
cal indications for interventions (same as for PTA),
especially those exhibiting complex disease that ex-
tends into the segmental arteries and those having
macroaneurysms. (Level of Evidence: B)
. Vascular surgical reconstruction is indicated for pa-
tients with atherosclerotic RAS and clinical indica-
tions for intervention, especially those with multiple
small renal arteries or early primary branching of the
main renal artery. (Level of Evidence: B)
. Vascular surgical reconstruction is indicated for pa-
tients with atherosclerotic RAS in combination with
pararenal aortic reconstructions (in treatment of aor-
tic aneurysms or severe aortoiliac occlusive disease).
(Level of Evidence: C)
. RESULTS OF OPERATIVE THERAPY. Surgical treatment of
enovascular hypertension affords good clinical outcomes
212–216). The risk of surgery increases in patients who
equire concomitant aortic reconstruction, in patients with
enal insufficiency, and when aortic grafts are used as a
ource of the bypass graft. The need for reoperation has
een reported in 5% to 15% and survival in 65% to 81% of
atients (212–216).
V. MESENTERIC ARTERIAL DISEASE
egardless of cause, intestinal ischemia is rare, and there are no
andomized or controlled trials of diagnosis or therapy for
ntestinal ischemia. Important gaps thus exist in our knowledge
f the natural history of intestinal ischemia, and yet the primary
iagnoses responsible for most cases have been known for
ecades. Numerous series documenting the results of surgical
reatment have been reported, and the clinical course of patient
ase series treated by percutaneous intervention has also been
ocumented. These largely retrospective clinical reviews form
he basis for our knowledge of and recommendations for
reatment of intestinal ischemia.
. Acute Intestinal Ischemia
. Acute Intestinal Ischemia Caused by Arterial Ob-
truction.
. ETIOLOGY. Acute obstructive intestinal ischemia occurs
hen the intestinal arteries are suddenly blocked to such a
egree that all or part of the intestine has insufficient
erfusion for viability. The many possible causes include
mbolism from cardiac or proximal arterial sources and
rterial thrombosis (217–222). Regardless of the cause,
atients with acute intestinal ischemia present with severe
bdominal pain that is initially out of proportion to any
hysical findings that may be present.
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ECOMMENDATIONS
lass I
. Patients with acute abdominal pain out of proportion
to physical findings and who have a history of
cardiovascular disease should be suspected of having
acute intestinal ischemia. (Level of Evidence: B)
. Patients who develop acute abdominal pain after
arterial interventions in which catheters traverse the
visceral aorta or any proximal arteries or who have
arrhythmias (such as atrial fibrillation), or recent MI
should be suspected of having acute intestinal isch-
emia. (Level of Evidence: C)
lass III
. In contrast to chronic intestinal ischemia, duplex
sonography of the abdomen is not an appropriate
diagnostic tool for suspected acute intestinal isch-
emia. (Level of Evidence: C)
LINICAL PRESENTATION. Approximately two thirds of pa-
ients with acute intestinal ischemia are women, with a
edian age of 70 years. Most patients have a history of
re-existing cardiovascular disease (217–219,222). Abdom-
nal pain is always present; its nature, location, and duration
re variable, but most commonly, the pain is anterior,
eriumbilical, and sufficiently severe that medical attention
s sought immediately. Initially, signs of peritoneal irritation
re absent, which is classically referred to as “pain out of
roportion to physical findings.”
ABORATORY FINDINGS. Laboratory evaluation most fre-
uently shows leukocytosis and lactic acidosis, and amylase
s elevated in approximately 50% of patients; approximately
5% of patients have occult blood in the stool. Abdominal
adiographs most frequently show some dilated loops of
ntestine. There are no specific laboratory or plain radio-
raph findings for acute intestinal ischemia.
LTRASOUND. Although duplex ultrasound scanning is capa-
le of identifying occlusive lesions of the intestinal arteries,
n practice, it is not very helpful. The abdominal distention
nd fluid frequently present with acute ischemia preclude
uccessful scanning in most patients. Because of the need for
mergent treatment in acute ischemia and the time required
o attempt duplex scanning, this test is contraindicated.
OMPUTED TOMOGRAPHIC (CT) SCANNING. Because CT scan-
ing for evaluation of abdominal pain requires administra-
ion of intravenous iodinated contrast material, which may
ffect later arteriography, this test is not the best initial
xamination for suspected acute intestinal ischemia, al-
hough it is frequently performed before consideration of
he mesenteric ischemia diagnosis.
RTERIOGRAPHY. Arteriography is the most helpful diagnos-
ic test in patients suspected of having acute intestinal aschemia; however, its use is controversial because of the
ime required for its performance in the emergency setting.
n patients suspected of having intestinal ischemia, arteriog-
aphy can be diagnostic and can differentiate occlusive from
onocclusive ischemia. The decision for arteriography is
robably best individualized in patients suspected of having
cute intestinal ischemia. For those with a very acute
resentation, a high likelihood of arterial obstruction, and
uspected bowel infarction, immediate laparotomy by a
urgeon capable of intestinal revascularization is the best
pproach. In patients with acute onset in whom angiogra-
hy can be performed rapidly and without delay, this is a
easonable approach. For those with a more delayed pre-
entation or a high likelihood of nonocclusive ischemia,
nitial arteriography is indicated. In these cases, the advan-
ages of the additional information provided by arteriogra-
hy outweigh the time required for its performance.
. NATURAL HISTORY. All series of acute intestinal isch-
mia patients include some who had a history of chronic
bdominal pain and weight loss. The frequency with which
hronic intestinal ischemia caused by arterial obstruction
ecomes acute intestinal ischemia (presumably by thrombo-
is) is unknown.
. SURGICAL TREATMENT.
ECOMMENDATION
lass I
. Surgical treatment of acute obstructive intestinal
ischemia includes revascularization, resection of ne-
crotic bowel, and, when appropriate, a “second look”
operation 24 to 48 hours after the revascularization.
(Level of Evidence: B)
Surgical treatment consists of laparotomy, revasculariza-
ion of the ischemic intestine either by embolectomy or by
ypass grafting, assessment of the viability of the intestine
fter revascularization, resection of nonviable intestine, and
ntensive care. Scheduled “second look” operations, 24 to 48
ours after the initial procedure, are the best way to avoid
oth excessive resection of potentially viable bowel and
ailure to resect nonviable intestine.
. ENDOVASCULAR TREATMENT.
ECOMMENDATION
lass IIb
. Percutaneous interventions (including transcatheter
lytic therapy, balloon angioplasty, and stenting) are
appropriate in selected patients with acute intestinal
ischemia caused by arterial obstructions. Patients so
treated may still require laparotomy. (Level of Evi-
dence: C)
Despite limited data, percutaneous treatment (lytic ther-
py; balloon angioplasty or stenting or both) of the arterial
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ith the standard operative approach (223–225). However,
ecause most patients with acute intestinal ischemia have at
east some nonviable intestine at the time of presentation,
ost will still require laparotomy, and surgical assessment of
ntestinal viability may be required even if percutaneous
herapy is successful in relieving the obstruction. Reestab-
ishment of flow to infarcted bowel may cause a sudden
ystemic release of endotoxins, which may be associated
ith the sudden onset of disseminated intravascular coagu-
ation, adult respiratory distress syndrome, and sudden
ardiovascular collapse. Therefore, in the presence of in-
arcted bowel or markedly elevated lactic acid levels, initial
ercutaneous treatment should be weighed against surgical
ptions in which control of the venous outflow (and the
ndotoxins) from the infarcted bowel segment can be
chieved.
. Acute Nonocclusive Intestinal Ischemia.
. ETIOLOGY.
ECOMMENDATIONS
lass I
. Nonocclusive intestinal ischemia should be suspected
in patients with low flow states or shock, especially
cardiogenic shock, who develop abdominal pain.
(Level of Evidence: B)
. Nonocclusive intestinal ischemia should be suspected
in patients receiving vasoconstrictor substances and
medications (e.g., cocaine, ergot, vasopressin, or nor-
epinephrine) who develop abdominal pain. (Level of
Evidence: B)
. Nonocclusive intestinal ischemia should be suspected
in patients who develop abdominal pain after coarc-
tation repair or after surgical revascularization for
intestinal ischemia caused by arterial obstruction.
(Level of Evidence: B)
Acute intestinal ischemia sufficient to produce infarction
lso occurs in the absence of fixed arterial obstruction. The
ost frequent setting is severe systemic illness with systemic
hock, usually as a result of reduced cardiac output
217,226–230). In this situation, the intestinal ischemia has
een shown to be the result of severe and prolonged
ntestinal arterial vasospasm. Intestinal vasospasm sufficient
o produce ischemia/infarction also occurs as a result of
ocaine ingestion and ergot poisoning (231,232). Therapeu-
ic drugs may produce intestinal ischemia from vasospasm,
specially when vasopressors are used in high doses to treat
irculatory shock.
Intestinal ischemia can also occur as a result of mesenteric
rterial spasm after repair of aortic coarctation (233) and
ccasionally occurs after revascularization procedures for
hronic mesenteric ischemia (228). The mechanism of this
pparently paradoxical spasm is unknown. r. DIAGNOSIS.
ECOMMENDATIONS
lass I
. Arteriography is indicated in patients suspected of
having nonocclusive intestinal ischemia whose con-
dition does not improve rapidly with treatment of
their underlying disease. (Level of Evidence: B)
There are no physical findings or laboratory tests specific
or nonocclusive intestinal ischemia, although it should be
uspected whenever patients with circulatory shock, espe-
ially cardiogenic shock, develop abdominal pain or disten-
ion and in patients treated with ergot, as well as in persons
sing cocaine or amphetamines who have abdominal pain.
rteriography is the “gold standard” for diagnosis. It can
emonstrate the characteristic mesenteric arterial vasospasm
nd allow direct intra-arterial instillation of vasodilator
edications (227,229,232).
. TREATMENT.
ECOMMENDATIONS
lass I
. Treatment of the underlying shock state is the most
important initial step in treatment of nonocclusive
intestinal ischemia. (Level of Evidence: C)
. Laparotomy and resection of nonviable bowel is
indicated in patients with nonocclusive intestinal
ischemia who have persistent symptoms despite
treatment. (Level of Evidence: B)
lass IIa
. Transcatheter administration of vasodilator medica-
tions into the area of vasospasm is indicated in
patients with nonocclusive intestinal ischemia who
do not respond to systemic supportive treatment and
in patients with intestinal ischemia due to cocaine or
ergot poisoning. (Level of Evidence: B)
Initial treatment of nonocclusive intestinal ischemia should
e directed at treatment of the underlying shock state. The
ost intensive hemodynamic monitoring possible, including
ppropriate fluid/pharmacological therapy to improve cardiac
utput/peripheral perfusion, is the most reliable way to relieve
he inappropriate vasospasm. Administration of vasodilators by
ercutaneously placed catheters at the site of inappropriate
asospasm has been associated with relief of vasospasm/
schemic symptoms in multiple patients (226). Transcatheter
dministration of vasodilators is especially appropriate in non-
cclusive mesenteric ischemia caused by drugs such as ergot or
ocaine, in which systemic shock may not coexist (234).
bdominal symptoms/findings that persist after relief of intes-
inal arterial vasospasm are an indication for laparotomy/
esection of necrotic intestine.
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. Etiology. Although atherosclerotic disease of the celiac
nd mesenteric vessels is common, the clinical presentation
f chronic intestinal ischemia is rare. It is nearly uniformly
aused by atherosclerosis (235). Classic clinical approaches
o the diagnosis of intestinal ischemia have often suggested
hat this syndrome requires occlusion or stenosis of at least
of the 3 intestinal arteries; however, this is not entirely
rue (236,237). Well-documented cases of intestinal isch-
mia occur as a result of single-vessel disease, virtually
lways of the superior mesenteric artery. Patients in whom
ome of the normal collateral intestinal arterial connections
ave been interrupted by previous surgery are especially
ulnerable to single-vessel occlusions.
Patients with chronic intestinal ischemia are most often
emale (70%) and classically complain of severe abdominal
ain induced by eating. The pattern of pain is quite variable,
owever, and the relationship to food is not always clear, at
east by history. What is clear is that patients voluntarily
astly reduce their food intake, so that weight loss occurs,
nd this may be profound. Vomiting, diarrhea, and consti-
ation are present in a minority of patients. A majority have
history of cardiovascular disease, and 30% to 50% have had
revious operations for atherosclerotic disease, most fre-
uently coronary and lower extremity bypass (238,239).
. Diagnosis.
ECOMMENDATIONS
lass I
. Chronic intestinal ischemia should be suspected in
patients with abdominal pain and weight loss without
other explanation, especially those with cardiovascu-
lar disease. (Level of Evidence: B)
. Duplex ultrasound, CTA, and gadolinium-enhanced
MRA are useful initial tests for supporting the
clinical diagnosis of chronic intestinal ischemia.
(Level of Evidence: B)
. Diagnostic angiography, including lateral aortogra-
phy, should be obtained in patients suspected of
having chronic intestinal ischemia for whom nonin-
vasive imaging is unavailable or indeterminate. (Level
of Evidence: B)
Because there are many common causes of abdominal
ain and weight loss, and because chronic intestinal
schemia is rare, diagnosis is delayed in most patients. At
resent, there are no diagnostic tests that establish the
iagnosis definitively. Rather, it is the combination of the
ypical clinical presentation of abdominal pain and
eight loss, with other evidence of cardiovascular disease,
ombined with the finding of intestinal arterial obstruc-
ion in the absence of any other obvious cause of the
ymptoms that should lead to consideration of the
iagnosis. Duplex scanning of visceral vessels is techni-
ally difficult but can be accomplished in more than 85% rf subjects in the elective setting. The test has an overall
ccuracy of approximately 90% for detection of greater
han 70% diameter stenoses or occlusions of the celiac
nd superior mesenteric arteries when performed in
ighly experienced laboratories (240 –242). Both
ontrast-enhanced CTA and gadolinium-enhanced
RA are well suited for visualizing the typical athero-
clerotic lesions at the origins of the intestinal arteries,
lthough they are less suited for visualizing the more
istal intestinal arteries and for diagnosis of some of the
ore unusual causes of intestinal ischemia. Arteriograms
rovide definitive diagnosis of intestinal arterial lesions,
lthough not chronic intestinal ischemia. Lateral aortog-
aphy is best suited for display of the typical origin
esions, which may not be apparent on frontal projec-
ions. The presence of an enlarged “Arc of Riolan” (an
nlarged collateral vessel connecting the left colic branch of the
nferior mesenteric artery with the superior mesenteric artery)
s an arteriographic sign of proximal mesenteric arterial ob-
truction that is visible on anteroposterior aortograms.
. Natural History. Significant atherosclerotic obstruc-
ion of the intestinal arteries is present in 6% to 10% of
nselected autopsies and in 14% to 24% of patients
ndergoing abdominal arteriography. Development of
ymptomatic intestinal ischemia in patients with asymp-
omatic intestinal arterial obstruction after abdominal
urgery for other reasons has been described (243). The
atural history of symptomatic chronic intestinal isch-
mia is known in part. An unknown percentage of
atients progress to acute intestinal ischemia. The re-
ainder have progressive weight loss with ultimate death
rom inanition.
. Interventional Treatment.
ECOMMENDATION
lass I
. Percutaneous endovascular treatment of intestinal
arterial stenosis is indicated in patients with chronic
intestinal ischemia. (Level of Evidence: B)
A large number of reports in the literature have docu-
ented that percutaneous interventional treatment of intes-
inal arterial obstructions is possible with a high technical
uccess rate and few complications in properly selected cases
244–249). Most procedures have been performed to treat
ntestinal arterial stenoses, with few attempting to treat
cclusions. To date, there have been no prospective thera-
eutic trials, and follow-up information is limited. Several
eports of concurrent series treated by angioplasty/stenting
r surgery indicate that recurrences after percutaneous
rocedures have been more frequent than after open surgery,
ut many of the recurrences can be managed by percutane-
us interventions (250). The results of several series are
isted in Table 42 of the full-text guidelines. The reported
ecurrence rates mandate that patients treated with angio-
p
s
r
5
R
C
1
C
1
C
1
c
m
(
t
t
f
t
f
r
v
V
B
A
s
a
l
L
a
p
i
t
b
s
o
A
T
t
a
a
(
(
a
B
1
n
f
t
f
m
f
T
A
A
A
A
C
S
C
I
C
P
P
A
o
f
1282 Hirsch et al. JACC Vol. 47, No. 6, 2006
ACC/AHA Guidelines for the Management of PAD March 21, 2006:1239–312lasty and stents undergo careful follow-up. As with open
urgery, recurrent symptoms have nearly always indicated
ecurrent arterial obstruction.
. Surgical Treatment.
ECOMMENDATIONS
lass I
. Surgical treatment of chronic intestinal ischemia is
indicated in patients with chronic intestinal ischemia.
(Level of Evidence: B)
lass IIb
. Revascularization of asymptomatic intestinal arterial
obstructions may be considered for patients undergo-
ing aortic/renal artery surgery for other indications.
(Level of Evidence: B)
lass III
. Surgical revascularization is not indicated for pa-
tients with asymptomatic intestinal arterial obstruc-
tions, except in patients undergoing aortic/renal artery
surgery for other indications. (Level of Evidence: B)
Surgical treatment of chronic intestinal ischemia is ac-
omplished by endarterectomy or bypass grafting, with the
ajority of surgeons preferring the latter approach
239,251–258). In chronic cases, the overall operative mor-
ality and durability of revascularization described by mul-
iple contemporary reports are listed in Table 42 in the
ull-text guidelines. Long-term patency and relief of symp-
oms are the rule, with few recurrences; however, long-term
ollow-up is mandatory. Essentially all symptomatic recur-
ences are the result of recurrent stenosis or occlusion of
isceral arteries or the reconstructions.
able 23. Dimensions of Normal Arteries
Artery
Female
Mean Diameter,
cm, Range SD, cm, Rang
bdominal aorta, supraceliac 2.10–2.31 0.27
bdominal aorta, suprarenal 1.86–1.88 0.09–0.21
bdominal aorta, infrarenal 1.66–2.16 0.22–0.32
bdominal aorta, infrarenal 1.19–1.87 0.09–0.34
eliac 0.53 0.03
uperior mesenteric 0.63 0.04
ommon iliac 0.97–1.02 0.15–0.19
nternal iliac 0.54 0.15
ommon femoral 0.78–0.85 0.07–0.11
opliteal NA NA
osterior tibial NA NA
dapted from J Vasc Surg, 13, Johnston K, Rutherford RB, Tilson MD, Shah DM, H
n Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting S
or Cardiovascular Surgery, 452–8, Copyright 1991, with permission from the Society for
CT  computed tomography; NA  not available; SD  standard deviation.. ANEURYSMS OF THE ABDOMINAL AORTA, ITS
RANCH VESSELS, AND THE LOWER EXTREMITIES
lthough their etiology may be substantially different in
ome cases, arterial aneurysms share many of the same
therosclerotic risk factors and pose similar threats to life,
imb, and vital organ function as occlusive arterial disease.
ike occlusive disease, the presence of most common
neurysms can be suspected on the basis of an attentive
hysical examination and subsequently confirmed by non-
nvasive, widely available imaging studies. Just as important,
here are now a variety of therapeutic options that include
oth traditional open surgery and endovascular techniques,
uch that relatively few large aneurysms should merely be
bserved until morbid events occur.
. Definition
here is abundant information concerning normal diame-
ers of the abdominal aorta and its branches in healthy
dults that indicates enlargement with age and body size
nd larger diameters in men than in women (Table 23)
259 –261). Generally, an abdominal aortic aneurysm
AAA) is considered to be present when the minimum
nteroposterior diameter of the aorta reaches 3.0 cm.
. Abdominal Aortic and Iliac Aneurysms
. Prevalence. The prevalence of AAAs varies with a
umber of demographic factors, including advancing age,
amily history, male gender, and tobacco use. In general,
he prevalence of AAAs 2.9 to 4.9 cm in diameter ranges
rom 1.3% for men aged 45 to 54 years up to 12.5% for
en 75 to 84 years of age. Comparable prevalence figures
or women are 0% and 5.2%, respectively (Table 24).
Male
Assessment Method
Mean Diameter,
cm, Range SD, cm, Range
2.50–2.72 0.24–0.35 CT
1.98–2.27 0.19–0.23 CT
1.99–2.39 0.30–0.39 CT, intravenous
arteriography
1.41–2.05 0.04–0.37 B-mode ultrasound, CT,
intravenous
arteriography
0.53 0.03 B-mode ultrasound
0.63 0.04 B-mode ultrasound
1.17–1.23 0.20 CT
0.54 0.15 Arteriography
0.78–1.12 0.09–0.30 CT, B- or M-mode
ultrasound
0.9 0.2 B-mode ultrasound
0.3 0.01 M-mode ultrasound
, Stanley JC. Suggested standards for reporting on arterial aneurysms. Subcommittee
ds, Society for Vascular Surgery and North American Chapter, International Societye
ollier L
tandarVascular Surgery and the American Association for Vascular Surgery (261a).
Am
n
t
r
b
s
T
W
V
N
T
T
J
*
1283JACC Vol. 47, No. 6, 2006 Hirsch et al.
March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PAD. GENERALIZED ARTERIOMEGALY. Generalized arterio-
egaly reflects a systemic alteration of the elastic compo-
ent of the arterial wall that results in dilation and elonga-
able 24. Prevalence of Abdominal Aortic Aneurysms in Populat
Country/Study
First
Author Reference
Number
Screened Age,
estern Australia Jamrozik (262) 12 203 65–
80–
65–
eterans Affairs
Cooperative
Study
Lederic (263) 126 196* 50–
50–
50–
orway Singh (264) 6386 25–
45–
55–
65–
75–
55–
65–
75–
he Netherlands Pleumeekers (265) 5283† Older th
Older th
he Netherlands Boll (266) 2419‡ 60–
apan Adachi (267) 1591 —
52 745 plus prior report of 73 451. †Of 10 215 eligible. ‡Of 2914 eligible.
CAD  coronary artery disease; PAD  peripheral arterial disease; OR  oddsion of many arteries. Patients with localized AAAs are relatively unlikely to have generalized arteriomegaly (268),
ut the familial pattern of generalized arteriomegaly is
imilar. In one series, there was a family history of aneu-
ased Screening Studies
Criteria
Prevalence/
Gender, % Relative Risk
Larger than 3.0 cm 4.8/Male Higher risk:
Current or ex-smokers
Larger than 3.0 cm 10.8/Male Established PAD, CAD
Larger than 5.0 cm 0.69/Male Waist-hip ratio larger
than 0.9
Lower risk:
Mediterranean born vs.
Australian born
(OR 0.6)
Regular vigorous
exercise
Larger than 4.0 cm 1.3/Male and
female
Higher risk:
Increased age per 7 yrs
(OR 1.7)
Larger than 4.9 cm 0.45/Male
and female
Smoking history
(OR 5.17)
Family history (OR 1.9)
Larger than 5.4 cm 0.27/Male
and female
Established
atherosclerosis (OR
1.6)
Lower risk:
Female (OR 0.18; 2.7%
of total)
Black race (OR 0.59)
Diabetes mellitus
(OR 0.50)
Larger than 2.9 cm 8.9/Male Higher risk:
2.2/Female Increased age
Larger than 2.9 cm 1.9/Male
0/Female
6.0/Male
Smoker older than 40
yrs versus never-
smoker (OR 8.0)
1.1/Female
12.8/Male
2.8/Female
18.5/Male
4.8/Female
Larger than 3.9 cm 1.1/Male
0.1/Female
4.1/Male
0.7/Female
8.6/Male
1.0/Female
4 3.4 to 3.6 cm or
distal dilation
greater than 49%
2.8/Male,
0.5/female
Higher risk:
Smoker
High serum cholesterol
Established
cardiovascular disease
4 Larger than 4.0 cm 1.6/Male,
0.3/female
Larger than 2.9 cm 8.1/Male
Larger than 4.9 cm 1.7/Male
— 0.3/Maleion-B
yrs
69
83
83
79
79
79
84
54
64
74
84
64
74
84
an 5
an 5
80
ratio.ysms in 10% (4/40) of patients with peripheral aneurysms,
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f patients with generalized arteriomegaly (269).
. Etiology. Most aortic and peripheral aneurysms repre-
ent a manifestation of aortic medial degeneration, which
as complex biological mechanisms. Data (see full-text
uidelines) suggest that many aneurysms form in response
o altered tissue metalloproteinases that diminish the integ-
ity of the arterial wall.
. HEREDITARY RISK FACTORS. A family history of AAAs is
articularly relevant for male siblings of male probands, in
hom the relative risk for AAA is as high as 18% (270),
hich suggests a single dominant gene effect. (See Table 45
f the full-text guidelines.) First-degree male relatives of
atients with AAA have 2 to 4 times the normal risk for
AA. Female first-degree relatives appear to be at similar
isk, but the data are less certain.
. ATHEROSCLEROTIC RISK FACTORS.
ECOMMENDATIONS
lass I
. In patients with AAAs, blood pressure and fasting
serum lipid values should be monitored and con-
trolled as recommended for patients with atheroscle-
rotic disease. (Level of Evidence: C)
. Patients with aneurysms or a family history of aneu-
rysms should be advised to stop smoking and be
offered smoking cessation interventions, including
behavior modification, nicotine replacement, or bu-
propion. (Level of Evidence: B)
Patients with AAAs have a significantly higher preva-
ence of hypertension, smoking, MI, heart failure, and
arotid artery disease or lower extremity PAD than do age-
nd gender-matched controls. The lipoprotein(a) serum
evel, an indicator of atherosclerosis, is also elevated in
atients with AAA, independent of other cardiovascular
isk factors and the extent of atherosclerosis (271).
. COLLAGENASE, ELASTASE, AND METALLOPROTEASES. The
triking histological feature of aortic aneurysms is destruc-
ion of the media and elastic tissue. Excessive proteolytic
nzyme activity in the aortic wall may promote deterioration
f structural matrix proteins, such as elastin and collagen
272). Smooth muscle cells derived from patients with
AAs display increased migration, perhaps related to over-
roduction of the matrix metalloproteinase MMP-2, which
ay lead to extracellular matrix remodeling and medial
isruption (273). Abnormal biochemical elastolytic and
ctive proteolytic activity has also been identified in aneu-
ysmal aortas (274).
The association between AAAs and chronic obstructive
ulmonary disease has been attributed to elastin degradation
aused by tobacco smoking. Among 4404 men 65 to 73
ears of age with a 4.2% prevalence of AAA, 7.7% of those
ith chronic obstructive pulmonary disease had aortic an-urysms (275). The overall mean annual expansion rate was
.7 mm per year irrespective of chronic obstructive pulmo-
ary disease but was 4.7 mm per year among patients treated
ith corticosteroid agents compared with 2.6 mm per year
mong those who were not treated (p less than 0.05).
. INFLAMMATORY ANEURYSMS. Inflammatory AAAs rep-
esent a unique clinical entity, typically consisting of an
AA that is associated with an unusually thickened aneu-
ysm wall, shiny white perianeurysmal fibrosis, and intense
dherence of adjacent intra-abdominal structures. Abnor-
al accumulation of macrophages and cytokines in aneu-
ysmal aortic tissue supports an association with inflamma-
ion (276,277). In a case-control study, there were no
istinctions between patients with inflammatory aneurysms
nd those with noninflammatory aneurysms with respect to
isk factors, treatment requirements, or prognosis, but
atients with inflammatory aneurysms were more often
ymptomatic and had a higher erythrocyte sedimentation
ate, larger aneurysm diameter, and more retroperitoneal
nflammatory reaction (278).
The triad of chronic abdominal pain, weight loss, and
levated erythrocyte sedimentation rate in a patient with
AA is highly suggestive of an inflammatory aneurysm.
nflammatory aortic or iliac aneurysms were present in
.5% of the 2816 patients who underwent elective AAA
epair at the Mayo Clinic from 1955 to 1985 (279). More
han 90% of the patients with inflammatory aneurysms
ere smokers, and clinical evidence of peripheral arterial
cclusive disease and coronary artery disease was found in
7% and 39%, respectively. Compared with patients with
oninflammatory atherosclerotic aneurysms, those with
nflammatory aneurysms were more likely to have symp-
oms (66% vs. 20%, p less than 0.0001), weight loss
20.5% vs. 10%, p less than 0.05), a higher erythrocyte
edimentation rate (73% vs. 33%, p less than 0.0001), and
higher operative mortality rate (7.9% vs. 2.4%, p less
han 0.002).
. Natural History. The natural history of arterial aneu-
ysms is distinguished by gradual and/or sporadic expan-
ion in their diameter and by the accumulation of mural
hrombus caused by turbulent blood flow at their periph-
ry. These features contribute to the 3 most common
omplications of aneurysms, that is, rupture, thrombo-
mbolic ischemic events, and the compression or erosion
f adjacent structures, which often are quite specific to
heir location.
. AORTIC ANEURYSM RUPTURE.
ECOMMENDATIONS
lass I
. Patients with infrarenal or juxtarenal AAAs measur-
ing 5.5 cm or larger should undergo repair to elimi-
nate the risk of rupture. (Level of Evidence: B)
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PAD. Patients with infrarenal or juxtarenal AAAs measur-
ing 4.0 to 5.4 cm in diameter should be monitored by
ultrasound or CT scans every 6 to 12 months to
detect expansion. (Level of Evidence: A)
lass IIa
. Repair can be beneficial in patients with infrarenal or
juxtarenal AAAs 5.0 to 5.4 cm in diameter. (Level of
Evidence: B)
. Repair is probably indicated in patients with supra-
renal or type IV thoracoabdominal aortic aneurysms
larger than 5.5 to 6.0 cm. (Level of Evidence: B)
. In patients with AAAs smaller than 4.0 cm in diam-
eter, monitoring by ultrasound examination every 2
to 3 years is reasonable. (Level of Evidence: B)
lass III
. Intervention is not recommended for asymptomatic
infrarenal or juxtarenal AAAs if they measure less
than 5.0 cm in diameter in men or less than 4.5 cm in
able 25. Rupture and Survival Rates for Patients With Abdomi
First Author Reference Year
No. of
Patients
Bas
ase series
Bengtsson (282) 1993 155 Med
Perko (283) 1993 63 Sma
Larg
eq
Galland (284) 1998 267 Sma
4 to
Jones (285) 1998 25 5 to
32 6 cm
Scott (286) 1998 218 3 to
4.5
Conway (281) 2001 23 5.5
62 6 to
21 Larg
Biancari (287) 2002 41 2.5
ollective reviews
Hollier (288) 1992 349 Sma
90 Larg
Hallin (289) 2001 54 048 Sma
4 to
Larg
andomized trials
UK Small Aneurysm
Trial (nonoperated
cohort)
(290) 1998 213 4 to
169 4.5
145 4.9
UK Small Aneurysm
Trial (nonoperated
cohort)
(291) 1999 NA 3 to
NA 4 to
NA 5.6
A  not available; UK  United Kingdom.diameter in women. (Level of Evidence: A) dAneurysm size remains the single most important pre-
ictor not only for aneurysm rupture but also for unrelated
eath from other cardiopulmonary events (280,281). Data
uggest that the eventual risk for rupture is approximately
0% for aneurysms larger than 5.0 cm in diameter, 40% for
hose at least 6.0 cm in diameter, and greater than 50% for
neurysms that exceed 7.0 cm in diameter (Table 25).
Conversely, the rupture rate for truly small aneurysms
hat are less than 4.0 cm in diameter is quite low, perhaps
ecause aged patients with such small aneurysms ordinarily
o not survive long enough for this complication to occur.
engtsson et al. have recommended only 1 annual follow-up
can for aneurysms less than 3.5 cm in diameter, because the
nrelated mortality rate in such patients is so high that
elatively few live long enough to incur sufficient aneurysm
rowth to warrant elective surgical treatment (292). Pro-
pective nonrandomized studies have indicated that small
neurysms may be safely monitored by annual or semiannual
maging scans with a low risk for rupture, provided elective
epair is advised once a diameter of at least 5.0 cm has been
ortic Aneurysms, Since 1990
Aneurysm
eter
Follow-Up
Interval
Aneurysm
Rupture Rate
Survival
Rate
cm Median, 3.4 yrs 14% 30%
an 6 cm Less than 5% NA
an or
6 cm
10% to 15% NA
an 4 cm 5 yrs 4% NA
m 5 yrs 21% NA
m 3 yrs 28% NA
rger 3 yrs 41% NA
m 7 yrs 2.1% per year and/or
operation
NA
cm 7 yrs 10% per year and/or
operation
NA
cm 10 yrs 22% 39%
10 yrs 34% 32%
an 7 cm 10 yrs 52% 5%
m Median, 7.3 yrs 7.3% 59%
an 5 cm 5 yrs 4.6% NA
an 5 cm 5 yrs 30% NA
an 4 cm 4 yrs 2% NA
4 yrs 10% NA
an 5 cm 4 yrs 22% NA
m Mean, 4.6 yrs NA 75%
cm Mean, 4.6 yrs NA 72%
cm Mean, 4.6 yrs NA 64%
m 7 yrs 2.1% NA
m 7 yrs 4.6% NA
larger 7 yrs 20% NAnal A
eline
Diam
ian, 4
ller th
er th
ual to
ller th
5.5 c
5.9 c
or la
4.4 c
to 5.9
to 5.9
7 cm
er th
to 4 c
ller th
er th
ller th
5 cm
er th
4.4 c
to 4.8
to 5.5
3.9 c
5.5 c
cm orocumented (286, 293).
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ACC/AHA Guidelines for the Management of PAD March 21, 2006:1239–312ANDOMIZED TRIALS. Prospective randomized trials compar-
ng early intervention versus expectant observation for in-
rarenal abdominal aortic aneurysms measuring 4.0 to 5.4
m in diameter have been conducted in the United King-
om (UK) and by the U.S. Department of Veterans Affairs
VA) during the past decade (291,294–296). By protocol,
lective surgical treatment was not offered to patients who
ere allocated to the nonoperative cohort in each trial until
heir aneurysms exceeded 5.4 cm on serial imaging studies.
elected data from both investigations are summarized in
able 26, using updated information from the UK trial at a
ean follow-up interval of 8 years (296) compared with 4.6
ears when its findings first were disclosed in 1998. Not
urprisingly, the principal demographic difference between
he 2 trials is the fact that whereas women accounted for
7% of the patients in the UK study, they represented only
.8% of the VA population. Thirty-day operative mortality
ates (UK, 5.4%; VA, 2.1%) were competitive with those
rom other multicenter studies. Endografts were used in 27
atients in the surgical limb of the UK trial (4.8%) but in
ust 2 patients in the VA trial.
At a mean of 4.9 years of follow-up, early aneurysm repair
as produced no significant benefits with respect to the
ncidence of either aneurysm-related deaths or deaths due to
ll causes in the VA trial. These are the same conclusions
hat originally were reached at a mean follow-up of 4.6 years
n the UK trial (290). Although the UK surgical cohort now
as a lower overall mortality rate than the nonoperative
ohort (p equals 0.03) at a mean follow-up of 8 years, this
nding has been attributed in part to a higher rate of
moking cessation in the early-surgery group (296). The
nnual rupture rate was negligible (0.6%) for observed
neurysms in the VA trial and was 3.2% in the UK trial.
upture was more likely to occur in women in the UK trial
odds ratio 4.0; 95% confidence interval [CI] 2.0 to 7.9; p
ess than 0.001), accounting for 14% of all deaths in women
ompared with 4.6% of all deaths in men (p less than 0.001).
neurysm size at the time of randomization did not
nfluence the risk for rupture in the UK trial or the
ong-term mortality rate in either trial, but this may reflect
he promptness with which intervention was performed
henever aneurysms reached a diameter of at least 5.5 cm.
ore than 60% of the patients in the nonoperative limb of
ach of these trials currently have undergone aneurysm
epair because of documented enlargement, including 81%
f the patients whose aneurysms were 5.0 to 5.4 cm in
iameter when they were recruited into the VA trial.
No randomized trial has yet addressed the size at which
uprarenal, pararenal, or type IV thoracoabdominal aortic
neurysms should be repaired to prevent rupture. Because of
heir higher risk for postoperative death, renal insufficiency,
nd other surgical complications, however, there has been a
onsensus that elective intervention should be considered
or these aneurysms at a slightly larger diameter than for
nfrarenal aortic aneurysms. t. COMMON ILIAC ANEURYSMS. Isolated common iliac an-
urysms are unusual in the absence of a proximal aortic
neurysm, and comparatively little information is available
ith respect to their natural history. Approximately one
hird to one half of common iliac aneurysms are bilateral,
nd 50% to 85% are asymptomatic at the time of their
iscovery (298,299). According to a collective review of 3
linical series, aneurysm rupture usually occurs at a diameter
f 5.0 cm or larger, whereas common iliac aneurysms that
re less than 3.0 cm in diameter almost never rupture (299).
herefore, isolated common iliac aneurysms that are smaller
able 26. Outcomes of Early Elective Repair Versus
onoperative Surveillance of Asymptomatic Abdominal
ortic Aneurysms*
UK Trial (2002) VA Trial (2002)
otal patients 1090 1136
arly elective repair 563 569
Open 536 567
Endovascular 27 2
onoperative
surveillance
527 567
en 902 1127
omen 188 9
ge 69 plus or minus
4 years
68 plus or minus
6 years
perative mortality rate
(surgical cohorts)
5.4% (30 days) 2.1% (30 days);
2.7% (in-
hospital)
ollow-up period Range 6 to 10
years; mean
8 years
Range 3.5 to 8.0
years; mean
4.9 years
urvival rate
Surgical cohort 57% 75%
Nonoperative cohort 52% (p equals
0.03)
78%
neurysm rupture rate
(nonoperative
cohorts)
3.2% Annually 0.6% Annually
Men Odds ratio 1.0
(reference set)
NA
Women Odds ratio 4.0;
95% CI 2.0 to
7.9 (p less than
0.001)
NA
ventual aneurysm
repair
Surgical cohort 520 (92%) 527 (93%)
Nonoperative cohort 327 (62%) 349 (62%)
nfluence of aneurysm
diameter
(nonoperative
cohorts)
Survival rate 4.0 to 4.4 cm: 57% 4.0 to 4.4 cm: 79%
4.5 to 4.8 cm: 54% 4.5 to 4.9 cm: 78%
4.9 to 5.5 cm: 43% 5.0 to 5.4 cm: 68%
Eventual repair rate NA 4.0 to 4.4 cm: 27%
4.5 to 4.9 cm: 53%
5.0 to 5.4 cm: 81%
Results of 2 prospective randomized trials conducted in the United Kingdom (UK)
290,296) and by the United States Department of Veterans Affairs (VA) (297).
CI  confidence interval; NA  not available.han 3.0 cm probably can be safely followed up with serial
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PADoninvasive imaging. Contrast-enhanced CT scans or mag-
etic resonance imaging studies appear to be better suited
or this purpose than ultrasonography because many com-
on iliac aneurysms are situated deep in the pelvis.
. Diagnosis.
. SYMPTOMATIC AORTIC OR ILIAC ANEURYSMS.
ECOMMENDATIONS
lass I
. In patients with the clinical triad of abdominal
and/or back pain, a pulsatile abdominal mass, and
hypotension, immediate surgical evaluation is indi-
cated. (Level of Evidence: B)
. In patients with symptomatic aortic aneurysms, re-
pair is indicated regardless of diameter. (Level of
Evidence: C)
Pain is the most frequent complaint in patients with
ymptomatic AAAs and usually is located in the hypogas-
rium or the lower part of the back. Pain is typically steady,
asting for hours to days at a time, and has a gnawing
uality. Aneurysm pain is not affected by movement, al-
hough patients may be more comfortable in certain posi-
ions, such as with the knees flexed. Expansion and impend-
ng rupture are heralded by the development of new or
orsening pain, characteristically constant, severe, and lo-
ated in the back or lower part of the abdomen, sometimes
ith radiation into the groin, buttocks, or legs. Rupture is
ssociated with abrupt onset of back pain, abdominal pain,
nd tenderness. Unless they are hypotensive because of
lood loss, many patients with ruptured aneurysms have a
alpable, pulsatile abdominal mass. It must be remembered,
owever, that the pathognomonic triad of abdominal/back
ain, pulsatile abdominal mass, and hypotension occurs in
nly about one third of cases (300). The symptoms of a
uptured aneurysm may mimic those of renal colic, diver-
iculitis, or a gastrointestinal hemorrhage, thus leading to a
isdiagnosis that can cost valuable time.
. ASYMPTOMATIC AORTIC OR ILIAC ANEURYSMS. Patients
ith even small AAAs have a high prevalence of risk factors
or and clinical manifestations of atherosclerotic cardiovas-
ular disease. Up to 13% of patients with aortic aneurysms
ave multiple aneurysms elsewhere (301), and 25% to 28%
f those with thoracic aortic aneurysms have concomitant
AAs (302,303). Accordingly, patients in whom an aortic
neurysm is discovered at either level should undergo an
ppropriate examination of the entire aorta to detect aneu-
ysms in other locations.
. PHYSICAL EXAMINATION. A comprehensive physical ex-
mination should include palpation of the abdomen and the
ower extremity arteries in an attempt to detect widened
ulses that suggest the presence of aneurysms. Palpation of
AAs is safe and has not been reported to precipitateupture. Perhaps the best evidence regarding the accuracy of rbdominal palpation comes from 15 studies of patients who
ere not previously known to have AAAs but were screened
ith both an abdominal examination and ultrasound scans
304). The pooled sensitivity of abdominal palpation in-
reased significantly with aortic diameter (p less than 0.001),
anging from 29% for AAAs of 3.0 to 3.9 cm to 50% for
AAs of 4.0 to 4.9 cm and 76% for AAAs measuring 5.0
m or more by ultrasonography. In a 3-year retrospective
tudy of 198 patients with AAAs that was conducted by
lcorn et al. (305) in a general hospital setting, 48% of the
neurysms had been discovered clinically, 37% represented
ncidental findings during the radiographic investigation of
nother condition, and 15% were encountered during un-
elated abdominal operations. Not surprisingly, the average
ize of palpable AAAs was larger than that of nonpalpable
AAs (6.4 plus or minus 1.2 cm vs. 4.9 plus or minus 1.4
m, p less than 0.001).
. SCREENING HIGH-RISK POPULATIONS.
ECOMMENDATIONS
lass I
. Men 60 years of age or older who are either the
siblings or offspring of patients with AAAs should
undergo physical examination and ultrasound screen-
ing for detection of aortic aneurysms. (Level of Evi-
dence: B)
lass IIa
. Men who are 65 to 75 years of age who have ever
smoked should undergo a physical examination and
1-time ultrasound screening for detection of AAAs.
(Level of Evidence: B)
Aortic diameter can be measured accurately by ultrasound
maging in more than 97% of subjects (306,307). Screening
y this method has the potential to reduce the incidence of
ortic rupture. In a cohort of 52 745 military veterans aged
0 to 79 years who had no history of aneurysms, AAAs
easuring 4.0 cm or more in diameter were detected by
ltrasound screening in 613 participants (1.2%). When this
ohort was combined with a similar cohort of 73 451
eterans in the same age range, the odds ratios for major risk
actors were as follows: 1.71 per 7 years of age, 0.18 for
emale gender, 0.53 for black race, 1.94 for a family history
f AAA, 5.07 for smoking, 0.52 for diabetes, and 1.66 for
therosclerotic diseases. The excess prevalence associated
ith smoking accounted for 75% of all AAAs 4.0 cm or
arger in the combined population of 126 196 veterans.
In another population-based study, 67 800 men aged 65
o 74 years were randomly allocated to receive an invitation
or an abdominal ultrasound scan (308). Men in whom
ortic aneurysms at least 3.0 cm in diameter were detected
ere followed up with repeat scans for a mean of 4.1 years.
urgical treatment was considered when the diameter
eached 5.5 cm, if expansion occurred at a rate of more than
1
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80%) of the 33 839 men in the invited group agreed to
creening, and 1333 aneurysms were detected. There were
5 aneurysm-related deaths (absolute risk 0.19%) in the
nvited group and 113 (0.33%) in the control group (risk
eduction 42%, 95% CI 22% to 58%, p equals 0.0002),
ncluding a 53% reduction of risk (95% CI 30% to 64%)
mong those who actually underwent screening. During the
years in which this trial was conducted, there were 47
ewer deaths related to AAAs in the screening group than in
he control group, but the additional costs incurred were 2.2
illion British pounds (approximately $3.5 million U.S.
ollars). The hazard ratio for AAA was 0.58 (95% CI 0.42
o 0.78). Over 4 years, the mean incremental cost-
ffectiveness ratio for screening was 28 400£/$45 000 per
ife-year that was gained, a figure that is equivalent to about
6 000£/$57 000 per quality-adjusted life-year. After 10
ears, this figure was estimated to decline to approximately
000£/$12 500 per life-year gained (309).
Selected screening of populations with a high prevalence
f AAA (e.g., males 60 years or older who have a family
istory of AAA, in whom the prevalence is approximately
8%) and the use of a limited ultrasound scan are more
ost-effective than conventional abdominal imaging of un-
elected populations. The United States Preventive Services
ask Force meta-analysis supports the concept that screen-
ng for AAA and surgical repair of large AAAs (5.5 cm or
ore) in men aged 65 to 75 years who have ever smoked
inclusive of both current and former smokers) leads to
ecreased AAA-specific mortality when abdominal ultra-
onography is performed in a setting with adequate quality
ssurance (i.e., in an accredited facility with credentialed
echnologists). The data do not support the application of
AA screening for men who have never smoked or for
omen.
. Observational Management.
. BLOOD PRESSURE CONTROL AND BETA-BLOCKADE.
ECOMMENDATIONS
lass I
. Perioperative administration of beta-adrenergic
blocking agents, in the absence of contraindications,
is indicated to reduce the risk of adverse cardiac
events and mortality in patients with coronary artery
disease undergoing surgical repair of atherosclerotic
aortic aneurysms. (Level of Evidence: A)
lass IIb
. Beta-adrenergic blocking agents may be considered
to reduce the rate of aneurysm expansion in patients
with aortic aneurysms. (Level of Evidence: B)
Perioperative administration of beta-adrenergic blockers
educes the risk of adverse cardiac events and death in
atients who undergo AAA surgery (310,311). Long-term reta-adrenergic blockade has slowed the rate of thoracic
ortic dilation and decreased the incidence of aortic com-
lications in patients with Marfan syndrome. Retrospective
tudies have suggested that beta-adrenergic antagonist
gents might reduce the risk of AAA expansion and
upture. One prospective randomized trial found that the
xpansion rate of AAAs was not attenuated by beta-
drenergic blockers.
. FOLLOW-UP SURVEILLANCE. A number of prospective
onrandomized studies that were reported before the dis-
losures from the UK Small Aneurysm Trial and the VA
neurysm Detection and Management (ADAM) Trial
ere made suggested annual ultrasound surveillance for
neurysms measuring less than 4.0 cm in diameter and
ltrasound scans every 6 months for those 4.0 to 4.9 cm in
iameter, with a recommendation for elective aneurysm
epair in appropriate surgical candidates whenever an AAA
eached a size of at least 5.0 cm. One such study of 99
atients documented a mean expansion rate of 2.2 mm in
he first year of observation, 2.8 mm in the second year, and
.8 mm in the third year for aneurysms that initially were
maller than 4.0 cm. The corresponding growth rates for
neurysms measuring 4.0 to 4.9 cm were 2.7, 4.2, and 2.2
m (312). Given the usual slow rate of expansion for truly
mall aneurysms, however, some studies have recommended
hat those measuring less than 4.0 cm in diameter can safely
e followed up with ultrasound scans every 2 to 3 years.
. Open Aortic Aneurysm Repair. The management of
atients who have AAAs that are sufficiently large to
epresent a predictable risk for fatal rupture is guided by
everal considerations. First, the survival rate of this patient
opulation generally is acknowledged to be significantly
ower than that of a normal population of the same age
313–316). Second, it has long been recognized that coro-
ary artery disease and its consequences represent the
eading causes of late death in these patients, superseding
ven the mortality rate that can be attributed directly to
noperated aneurysms (317,318). Therefore, in addition to
heir importance regarding early surgical risk, these obser-
ations have long-term implications with respect to the
dentification and treatment of underlying coronary disease
efore the elective repair of aortic aneurysms. Finally, the
mergence of new technology for transfemoral endovascular
epair of AAAs with a variety of commercially available U.S.
ood and Drug Administration–approved stent grafts now
rovides an alternative to open surgical treatment in patients
ith aneurysms that warrant repair on the basis of their size
r expansion rate. Thus, management of aortic aneurysms
ust be tailored to the individual patient.
. INFRARENAL AAAS.
REOPERATIVE CARDIAC EVALUATION. A number of studies
ave demonstrated that the perioperative and long-term
ortality rates in conjunction with open aortic aneurysmepair are highest among patients who have symptomatic
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ongestive heart failure), intermediate in those who have
hronic stable angina and/or a history of remote MI, and
owest among those who have no indication of coronary
isease whatsoever (319–323). Several large clinical series
ave reported that the mortality rate for open aortic aneu-
ysm repair can be reduced to less than 2% in a setting in
hich approximately 5% to 15% of patients undergo pre-
iminary coronary artery intervention (324–327). However,
he role of revascularization in the context of contemporary
edical management appears to be less than has been
ssumed traditionally. Intensive medical therapy and coro-
ary revascularization (including percutaneous coronary in-
ervention and coronary artery bypass grafting), when of-
ered to individuals anticipated to undergo AAA repair or
ower extremity revascularization surgery, had equal post-
perative rates of cardiovascular ischemic events in a recent
rospective investigation (328). A comprehensive discussion
f this topic may be found in a previous guidelines docu-
ent sponsored by the ACC/AHA (89).
PEN SURGICAL APPROACHES. Open aortic aneurysm repair
an be performed with a midline transabdominal approach
r an extraperitoneal incision in the left flank. There is no
lear consensus, however, regarding the superiority of either
f these incisions on the basis of prospectively randomized
tudies.
ARLY MORTALITY AND COMPLICATION RATES. In a collective
eview of nearly 40 000 reported cases, Blankensteijn et al.
oncluded that the operative mortality rate for elective open
ortic aneurysm repair varied according to whether the
ndividual case series were prospective or retrospective in
esign and whether they were population-based or hospital-
ased (329). Such factors undoubtedly account for some of
he variability in the representative early outcomes that are
ummarized in Table 27. Mortality rates from single centers
enerally were in the range of 4% to 5% during the 1980s,
hereas information that has been published during the
990s contains several series in which the mortality rate has
eclined to less than 2%. In comparison, regional or
ulticenter studies in the U.S. and elsewhere generally have
een associated with slightly higher mortality rates, ranging
rom 5% to 7%. The operative mortality rate for open repair
f ruptured AAAs is uniformly grim, however, ranging from
0% to 70% regardless of whether it has been reported from
ingle-center case series, collective reviews, regional or
ulticenter studies, or large national databases.
During the past 15 years, a growing number of studies
ave demonstrated an inverse relationship between the
ortality rate for aortic aneurysm repair and both the
nnual hospital volume and the experience of individual
urgeons with these procedures. Representative data show-
ng these relationships for intact and ruptured aneurysms are
ummarized in Table 28. Other studies have reconfirmed
hese observations with respect to hospital volume
341,348), surgeon experience (336), or both (349). Man- ceim et al. (338) and Dimick et al. (347) have estimated that
he operative mortality rate for elective aneurysm repair is
educed by approximately 50% in high-volume hospitals in
he U.S., and Wen et al. (335) have calculated that there is
6% reduction in the relative odds for death with every 10
dditional elective cases that are added to the annual
ospital volume in Ontario. Pearce et al. (340) discovered
hat a doubling of the annual surgeon volume was associated
ith an 11% reduction in the relative risk for death after
ortic aneurysm repair in Florida, and Dardik et al. (339)
ave determined that hospital charges are significantly lower
n conjunction with the repair of either intact or ruptured
ortic aneurysms by high-volume surgeons in Maryland.
. JUXTARENAL, PARARENAL, AND SUPRARENAL AORTIC AN-
URYSMS. Aneurysms involving the upper abdominal aorta
enerally are classified according to their relationship to the
enal arteries. Juxtarenal aneurysms arise distal to the renal
rteries but in very close proximity to them; pararenal
neurysms involve the origin of 1 or both renal arteries;
uprarenal aneurysms encompass the visceral aortic segment
ontaining the superior mesenteric and celiac arteries, and
pecifically are termed type IV thoracoabdominal aneurysms
f they extend upward to the crus of the diaphragm (352).
rrespective of the incision that is used for their exposure,
he principal technical consideration that is common to
ost of these aneurysms is that they require a period of
ortic cross-clamping above the renal arteries.
Juxtarenal aneurysms represent the only exception to the
equirement for suprarenal aortic cross-clamping, because
ome of these aneurysms are associated with an adequate cuff of
elatively normal aorta for proximal control just below the renal
rteries. Even when suprarenal cross-clamping is required, it is
nly for the period of time that is necessary to construct the
roximal anastomosis of the replacement graft near the unin-
olved renal arteries. This feature undoubtedly accounts for the
bservation that operative mortality and morbidity rates for
uxtarenal aortic aneurysms are higher than those for standard
nfrarenal aneurysms but lower than those for aneurysms that
xtend above the renal arteries.
Selected but representative data regarding the operative
ortality and complication rates for all upper abdominal
ortic aneurysms involving the renal arteries are presented in
able 29.
. Endovascular Aortic Aneurysm Repair.
. INTRODUCTION. Endovascular AAA repair can elimi-
ate the need for a major transabdominal procedure, can be
erformed under regional or even local anesthesia, and
learly represents a major advance in the management of
atients with AAAs who have severe cardiopulmonary
isease or other risk factors, such as advanced age, morbid
besity, or a hostile abdomen from multiple previous oper-
tions. Since its feasibility had been demonstrated in such
atients, endovascular repair also has been offered at many
enters to low- or average-risk patients who have no
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ent. This has resulted in a distinct shift in the paradigm
or management of infrarenal aortic aneurysms in some
eographic areas during a relatively short period of time.
ccording to statewide data from New York, for example,
3% of patients who underwent AAA repair received
ndografts in 2002 compared with 40% in 2001 (363).
Most contemporary stent grafts are supported by a
etallic skeleton that is secured to the fabric of the graft
uring the manufacturing process to maintain linear stabil-
ty once the device has been implanted and to avoid kinking
hat can result in graft limb occlusion with unsupported
able 27. Operative Mortality Rates for Open Repair of Intact A
First Author Reference (
ase series
Sicard (330)
Lloyd (331) 19
Starr (318) 19
Aune (315) 20
Hertzer (327) 20
Menard (332) 20
andomized trials
UK Small Aneurysm Trial
(surgical cohort)
(290)
U.S. Veterns Affairs Small Aneurysm
Trial (surgical cohort)
(297)
ollective reviews
Zarins (333) 19
Blankensteijn (329) 19
egional or multicenter studies
Kazmers (Veterans Affairs) (334) 19
Wen (Ontario Aneurysm Study) (335) 19
Kantonen (Finland Vascular Registry) (336)
Koskas (French AURC) (314) 19
Bradbury (Edinburgh Vascular
Registry)
(337) 19
Manheim (California statewide) (338) 19
Dardik (Maryland statewide) (339) 19
Pearce (Florida statewide) (340) 19
Sollano (New York statewide) (341) 19
Kazmers (Veterans Affairs) (342) 20
Axelrod (Veterans Affairs) (343) 20
.S. hospital databases
Lawrence (National Hospital
Discharge Survey)
(344) 19
Heller (National Hospital Discharge
Survey)
(345) 20
Huber (Nationwide Inpatient Sample) (346) 20
Dimick (Nationwide Inpatient Sample) (347) 20
URC  Association for Academic Research in Vascular Surgery; UK  United Krafts. To better accommodate the aortoiliac anatomy and dacilitate graft deployment, the majority of modern en-
ografts also are modular in construction. The absence of an
dequate length of relatively normal aorta below the renal
rteries historically has excluded patients from consideration
or endovascular repair because of the high risk for proximal
ttachment failure, graft migration, and endoleak.
In an attempt to overcome the risk of distal migration and
roximal attachment failure, a growing number of new
evices now incorporate barbed hooks that are sufficiently
ong to secure the metallic frame of the stent graft to the
isceral segment of the aorta above the renal arteries. In
ggregate, modular externally supported bifurcation en-
inal Aortic Aneurysms, Since 1995
ear
Period) No. of Patients
Mortality
Rate (%)
995 145 1.4
980–1995) 1000 2.4
983–1989) Men: 490 5.1
Women: 92 4.3
Total: 582 5.0
985–1999) Age less than 66 yrs: 118 1.7
Age 66 yrs and older: 333 6.0
Total: 451 4.9
989–1998) 1135 1.2
990–2000) Low risk: 444 0.0
High risk: 128 4.7
Total: 572 1.0
998 563 5.8
002 569 2.7
987–1992) 2162 2.1
985–1997) Prospective population: 692 8.2
Prospective hospital: 1677 7.4
Retrospective population: 21 409 3.8
Retrospective hospital: 12 019 3.8
Subset analyses: 1857 3.5
991–1993) 3419 4.9
988–1992) 5492 3.8
997 929 5.1
989) 1107 4.8
976–1996) 492 6.1
982–1994) 35 130 7.6
990–1995) 2335 3.5
992–1996) 13 415 5.7
990–1995) 9847 5.5
991–1995) 5833 4.5
997–1998) 1001 3.7
994) 32 387 8.4
979–1997) 358 521 5.6
994–1996) 16 450 4.2
996–1997) 13 887 3.8
.bdom
Y
Study
1
96 (1
96 (1
01 (1
02 (1
03 (1
1
2
97 (1
98 (1
96 (1
96 (1
1
97 (1
98 (1
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99 (1
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99 (1
01 (1
01 (1
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02 (1ografts are more widely applicable, less prone to migrate
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PADrom their sites of attachment, and more likely to remain
atent than was the case with the first generation of
nsupported endografts only a few years ago. Some aspects
f endovascular aneurysm repair remain problematic, how-
ver, and will require further refinements in the future. In
ddition to the vexing problem of metal fatigue (364,365),
hese include anatomic limitations and intrasac endoleaks.
able 28. Volume/Outcome Relationships for Open Abdominal
First Author Reference
Year
(Study Period)
No. of
Patients
ntact aneurysms
Hannan (New
York statewide)
(350) 1992 (1982–1987) 6042
Katz (Michigan
statewide)
(351) 1994 (1980–1990) 8185
Kazmers (Veterans
Affairs)
(334) 1996 (1991–1993) 3419
Dardik (Maryland
statewide)
(339) 1999 (1990–1995) 2335
uptured aneurysms
Katz (Michigan
statewide)
(351) 1994 (1980–1990) 1829
Dardik (Maryland
statewide)
(339) 1998 (1990–1995) 527
A  not available; NS  nonsignificant.
able 29. Operative Mortality and Postoperative Complication R
horacoabdominal Aortic Aneurysms, Since 1990
First Author Reference
Year
(Study Period)
No. o
Patient
ararenal or
suprarenal
Nypaver (353) 1993 (1985–1992) 53
Faggioli (354) 1998 50
Jean-Claude (355) 1999 (1977–1997) 257
Anagnostopoulos (356) 2001 (1986–1999) 65
ype IV
thoracoabdominal
Cox (357) 1992 (1966–1991) 42
Svensson (358) 1993 (1960–1991) 346
Coselli (359) 1995 (1984–1993) 35
Schwartz (360) 1996 (1977–1994) 58
Dunning (361) 1999 (1995–1998) 26
Martin (362) 2000 (1989–1998) 165A  not available.NATOMIC LIMITATIONS. Because of the inflexibility of exter-
ally supported grafts, this segment of the aorta must not be
everely angulated. This requirement may impose a gender
ias in patient selection because, in addition to the fact that
heir small external iliac arteries often present problems with
espect to vascular access, women also appear to have a
igher prevalence of short, angulated aneurysm necks than
c Aneurysm Repair in the United States Since 1990
Overall
ortality
ate (%)
Annual Volume
Hospital Surgeon
7.6 Low: 12%; medium: 6.8%; Low: 11%; medium: 7.3%;
high: 5.6% high: 5.6%
7.5 Low: 8.9%; high: 6.2% NA
(p less than 0.001)
4.9 Low: 6.7%; high: 4.2% NA
(p less than 0.05)
3.5 Low: 4.3%; medium:
4.2%; high: 2.5%
(p equals 0.08)
Very low: 9.9%; low: 4.9%;
medium: 2.8%; high: 2.9%
50 Low: 54%; high: 46%
(p equals 0.0026)
NA
47 Low: 46%; medium: 49%;
high: 47% (p equals NS)
Low: 51%; medium: 47%;
high: 36% (p equals 0.05)
for Open Repair of Pararenal, Suprarenal, and/or Type IV
Mortality Rate
(%)
Postoperative Complication Rate (%)
Renal Paraplegia Other
3.8 Transient: 23;
dialysis: 5.7
NA NA
12 NA NA NA
5.8 Transient: 30;
sustained: 9.3;
dialysis: 7.0
0.4 31
0 Total: 42;
dialysis: 9.2;
permanent: 1.5
0 NA
Total: 31;
elective: 12;
urgent: 55
NA Total: 11;
elective: 4.3;
urgent: 20
NA
5.8 Total: 22 4.3 NA
14 (Reoperations) None permanent 2.9 NA
5.3 Transient: 31;
sustained: 28;
dialysis: 8.8;
permanent: 1.9
1.8 42
12 Dialysis: 3.8 3.8 42
Total: 11;
elective: 7.2;
urgent: 22
Transient: 19;
dialysis: 14;
permanent: 3.0
3.6 56Aorti
M
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ACC/AHA Guidelines for the Management of PAD March 21, 2006:1239–312en (366,367). Considering all of these criteria, Carpenter
t al. reported that a disproportionate number of women
ere excluded from endograft repair because of anatomic
imitations (60% of women vs. 30% of men; p equals
.0009) (368). Becker et al. (369) also found that signifi-
antly fewer women qualified for endovascular aneurysm
epair (26% of women vs. 41% of men), and Mathison et al.
370) were forced to abandon more attempted endograft
rocedures in women (17%) than in men (2.1%, p less than
.01). Wolf et al. described comparable eligibility rates for
ndograft repair in women (49%) and men (57%), but the
omen in this series had a higher incidence of intraopera-
ive complications than men (31% vs. 13%, p less than 0.05)
nd required more adjunctive arterial reconstructions (42%
s. 21%, p less than 0.05) to correct those complications
371).
NTRASAC ENDOLEAKS. Type I endoleaks are caused by in-
ompetent proximal or distal attachment sites, produce high
ntrasac pressure that can lead to rupture, and should be
epaired with intraluminal extender cuffs or conversion to an
pen procedure as soon as they are discovered. Type II
ndoleaks are the result of retrograde flow from branch
essels (e.g., lumbar arteries and the inferior mesenteric
rtery), occur in as many as 40% of patients at some point in
ime after endograft implantation, and often may be cor-
ected by selective arterial catheterization and therapeutic
mbolization. More than half of type II endoleaks will seal
pontaneously, however, and although isolated examples of
neurysm rupture on the basis of persistent type II en-
oleaks have been reported (372,373), they do not yet
ppear to influence the risk for rupture during 18 to 36
onths of surveillance in large series of patients (374,375).
ype III endoleaks are caused by midgraft defects from
abric tears or the junctional disruption of modular graft
omponents, especially if these components are buckled as
he excluded aneurysm sac shrinks and foreshortens. Type
II endoleaks are considered to have the same potential for
elayed aneurysm rupture as type I endoleaks and therefore
hould be repaired promptly at the time of their discovery.
ype IV endoleaks are the result of high graft porosity and
iffuse leakage through its interstices, usually occur within
0 days of implantation, and are rare compared with the
requency of other endoleaks. Finally, the term “endoten-
ion” has been applied to those circumstances in which the
xcluded sac continues to enlarge and appears to remain
ressurized despite the absence of any visible endoleaks on
ontrast-enhanced CT scans.
In summary, it is largely because of the uncertainties
elated to intrasac endoleaks that clinical investigators and
he Food and Drug Administration consider follow-up
maging to be mandatory every 6 to 12 months for any
atient whose aortic aneurysm is treated with an endovas-
ular stent graft (376,377).
. PREOPERATIVE CARDIAC EVALUATION. The preopera-
ive cardiac evaluation before endovascular aneurysm repair tay be dictated by patient selection, because severe cardiac
isease already will have been documented in many patients
ho are treated at centers where endografting is restricted to
igh-risk cases. Perhaps for this reason, relatively little
ublished information is available on this topic. On the
asis of admittedly incomplete data, elective endovascular
ortic aneurysm repair in unselected patients probably
hould be considered as an “intermediate or low surgical risk
rocedure” according to the previous ACC/AHA Guideline
pdate for Perioperative Cardiovascular Evaluation for
oncardiac Surgery (89).
. EARLY MORTALITY AND COMPLICATION RATES. Table
0 contains representative data regarding the procedural
ortality rate for endovascular aneurysm repair, the inci-
ence of early endoleaks, and the risk for immediate
onversion to an open operation. This information has been
ollected from case series, from Food and Drug
dministration- and industry-sponsored device trials in the
.S., and from the European collaborators registry on
tent-graft techniques for abdominal aortic aneurysm repair
EUROSTAR), a cooperative archive for endograft data
hat are submitted voluntarily by nearly 60 participating
enters. The study periods for the references that are cited in
able 30 help to identify the generation of devices that were
nder investigation, and they also provide points of refer-
nce during an era in which rapid advances in technology
end to make the preceding iteration of stent grafts and
elivery systems obsolete as soon as new devices are
ntroduced.
The early mortality rate for endograft repair generally has
een less than 3%, but May et al. (385) have shown this to
e substantially lower than the mortality rate for a concur-
ent series of open procedures. The comparative safety of
ndograft repair is difficult to assess because it often is
ifficult to determine from published reports whether aortic
tent grafts were offered only to high-risk surgical patients
r to a mix of high-risk, average-risk, and low-risk patients.
everal EUROSTAR studies have demonstrated that both
arly mortality rates and nonfatal complication rates were
ignificantly higher among patients who were deemed to be
nfit for open repair or general anesthesia (396,399,401), as
ell as among those who needed adjunctive procedures in
ddition to the placement of an aortic stent graft (396).
onsequently, the perceived margin of safety for endovas-
ular aneurysm repair in truly high-risk candidates may be
lightly overestimated by results from nonuniform patient
opulations. Irrespective of case mix, however, the compar-
tively low early mortality rate for endograft repair of aortic
neurysms in New York State deserves close attention.
ccording to data reported by Anderson et al., the mortality
ate for endograft procedures was significantly lower than
or open procedures in New York during both 2001 (1.1%
s. 3.6%, p equals 0.0018) and 2002 (0.8% vs. 4.2%, p less
han 0.0001) (363).
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PADImmediate conversion to an open operation presently is
ecessary in only 1% of patients, and approximately half of
ll early endoleaks appear to resolve spontaneously within a
eriod of 30 days. Several reports have indicated that
ndovascular procedures have fewer early complications
han open operations, require less intensive care, and are
ssociated with correspondingly shorter lengths of stay in
he hospital (402–404). Nevertheless, these and other stud-
es (405–407) also have suggested that the total costs of
ndovascular repair probably exceed those for open repair,
specially when the expense of subsequent follow-up imag-
able 30. Representative Early Results for Endovascular Repair o
First Author
(Study/Sponsor) Reference
Year
(Study Period) No. of Patien
ase series
Becquemin (378) 2000 (1995–1999) Endo: 73;
Open: 195
Chuter (379) 2000 (1996–1999) High risk: 116
Zarins (380) 2000 (1996–2000) 149
Blum (381) 2001 (1994–2001) 1994–1996; 111
1996–1997: 159
1998–2001: 28
Becker (369) 2001 (1994–2001) 305
Fairman (382) 2001 (1998–1999) 75
Holzenbein (383) 2001 173
Howell (384) 2001 215
Mathison (370) 2001 (1994–2000) 305
May (385) 2001 (1995–1998) Endo: 148;
Open: 135
Sicard (386) 2001 (1997–2000) Endo: 260;
Open: 210
Abraham (373) 2002 (1998–2001) 116
Dattilo (387) 2002 (1994–2000) 362
Sampram (388) 2003 (1996–2002) 703
Ouriel (389) 2003 (1996–2002) 606 Men;
98 Women
Shames (390) 2003 (1999–2001) 302 Men;
42 Women
Anderson (New York
State)
(363) 2004 (2000–2002) Endo: 1,706;
Open: 3,063
evice trials
Zarins (AneuRx,
Medtronic)
(391) 2000 (1997–1998) 425
Beebe (Vanguard,
Boston Scientific)
(392) 2001 (1997–1998) Endo: 268;
Open: 98
Greenberg (Zenith,
Cook)
(393) 2001 (1995–2000) 528
Faries (Talent,
Medtronic/
AVE-WorldMedical)
(394) 2002 (1999–2001) 368
Matsumura (Excluder;
WL Gore &
Associates)
(395) 2003 (2000–2002) Endo: 235;
Open: 99
UROSTAR registry
Buth (396) 2000 (1994–1999) 1554
Harris (397) 2000 (1996–2000) 2464
Vallabhaneni (398) 2001 (1994–2000) 2812
Buth (399) 2002 (1996–2001) 3075
Peppelenbosch (400) 2004 (1996–2002) 1962 (4.0 to 5.4
1528 (5.5 to 6.4
902 (over 6.4 cm
ndo  endovascular repair; EUROSTAR  European collaborators registry on stent-graft technng, further intervention, and secondary hospital admissions ss added to the base cost ($6000 to $12 000 U.S. dollars) of
ost endografts. Despite the shorter length of stay and
arlier return to normal activity associated with aortic
ndografting, this procedure does not appear to be associ-
ted with superior late functional outcome or longer quality-
djusted life expectancy compared with open surgical treat-
ent (408,409).
ECHNICAL SUCCESS RATES. The technical success rate is a
seful way to express endograft results because it condenses
number of events into a single outcome value that
rdinarily is calculated with the life-table method. Table 31
rarenal Abdominal Aortic Aneurysms Since 2000
Immediate Open
Conversion (%)
Endoleaks (%) Procedural
Mortality Rate
(%)Total Persistent
None 23 9.6 2.7
None NA 10 1.7
1.30 36 18 1.3
3.6 (1994–1996) 14 (1994–1996) NA Total: 8.1
0.6 (1996–1997) 3.1 (1996–1997)
None (1998–2001) 11 (1998–2001)
1.30 23 17 2.6
None 44 20 0
1.2 4.6 (Type I) NA 2.8
None 42 11 0
1.3 23 NA 2.6
0.7 6.8 5.4 2.7 (Endo);
5.9 (Open)
0.8 13 3 1.9 (Endo);
2.9 (Open)
None 15 11 0.9
1.40 NA NA 1.5
NA NA NA 1.7
NA NA NA 1.3 (Men);
3.1 (Women)
0.5 (Men); NA NA 1.5 (Men);
14 (Women) 2.3 (Women)
NA NA NA 1.1 (Endo);
4.0 (Open)
1.20 Centers 38;
core lab 50
13 1.4
1.90 5.70 2.7 1.5 (Endo);
3.1 (Open)
0.80 16 5.5 0.2
1.10 12 4.8 1.9
None 22 17 0.9 (Endo);
0 (Open)
1.70 16 0.9 2.6
1.30 17 8.3 3.2
NA NA NA 2.9
1.70 17 NA 2.5
1.1 (4.0 to 5.4 cm);
1.4 (5.5 to 6.4 cm);
2.3 (over 6.4 cm)
3.7 (4.0 to 5.4 cm);
6.8 (5.5 to 6.4 cm);
9.9 (over 6.4 cm),
all Type I
NA 1.6 (4.0 to 5.4 cm)
2.6 (5.5 to 6.4 cm);
4.1 (over 6.4 cm)
or abdominal aortic aneursym repair; NA  not available.f Inf
ts
cm);
cm);
)ummarizes the early and intermediate-term technical suc-
c
l
m
f
e
q
t
5
d
a
f
8
t
v
fi
A
p
b
r
i
c
k
a
u
w
e
p
e
r
m
e
m
o
A
R
C
1
2
T
C
D
E
E nt-gra
1294 Hirsch et al. JACC Vol. 47, No. 6, 2006
ACC/AHA Guidelines for the Management of PAD March 21, 2006:1239–312ess rates from 10 recent reports. These data suggest that
onger follow-up will be necessary to determine the relative
erit of endovascular repair compared with open operations
or AAAs. In comparison, the technical success rate for
ndograft repair of isolated iliac aneurysms appears to be
uite favorable according to the scant follow-up information
hat is available. Scheinert et al. (410) described a series of
3 such aneurysms in 48 patients with successful endograft
eployment in 98%, no persistent or secondary endoleaks,
nd patency rates of 95% and 88% at 3 and 4 years of
ollow-up, respectively.
. Prevention of Aortic Aneurysm Rupture. Aside from
heir infrequent other complications (e.g., peripheral or
isceral embolism, aortocaval or primary aortoenteric
stula), the single most compelling reason to repair
AAs is to prevent fatal rupture. The first step in this
rocess is to identify the presence of these aneurysms,
eginning with a thorough physical examination or their
ecognition as an incidental finding on unrelated abdom-
nal imaging studies. This is especially important in
ertain high-prevalence populations, such as those with
able 31. Technical Success Rates For Endograft Repair of Infra
First Author
(Device/Vendor) Reference
Year
(Study Period) No. of Pat
ase series
Becquemin (378) 2000 (1995–1999) Endo: 73;
Open: 107
Chuter (379) 2000 (1996–1999) High risk: 1
Howell (411) 2000 56
Blum (381) 2001 (1994–2001) 111 (1994–
159 (1996–
28 (1998–2
Ohki (412) 2001 (1992–2000) 239
evice trials
Zarins
(AneuRx/Medtronic)
(380) 2000 (1997–1998) 398
Beebe
(Vanguard/Boston
Scientific)
(392) 2001 (1997–1998) 240
Criado
(Talent/Medtronic
WorldMedical)
(413) 2001 (1997–2001) High risk: 1
Low risk: 1
UROSTAR
Buth (396) 2000 (1994–1999) 1554
Laheij (414) 2000 (1996–1999) 1023
ndo  endovascular repair; EUROSTAR  European collaborators registry on stenown popliteal aneurysms or a family history of aorticneurysms. The next step is to establish, on the basis of
ltrasonography or CT/magnetic resonance scanning,
hether a particular aortic aneurysm already is large
nough to warrant intervention or instead should be
laced under periodic surveillance to determine its rate of
xpansion. Ultimately, once an infrarenal aortic aneurysm
eaches an appropriate size for graft replacement, a choice
ust be made between a traditional open operation or
ndovascular repair. Like all other aspects of aneurysm
anagement, this decision requires a balanced judgment
f relative risks.
. MANAGEMENT OVERVIEW.
ECOMMENDATIONS
lass I
. Open repair of infrarenal AAAs and/or common iliac
aneurysms is indicated in patients who are good or
average surgical candidates. (Level of Evidence: B)
. Periodic long-term surveillance imaging should be
performed to monitor for an endoleak, to document
Abdominal Aortic Aneurysms, Since 2000
Criteria for Technical
Success
Technical Success Rate
Early Late
No endoleaks; no
reintervention
74% (p equals 0.001);
94% (1 yr)
Successful deployment;
no endoleaks
86% (2 weeks)
NA 83% Primary;
85% secondary
(6 months)
;
;
Successful deployment;
no endoleaks
82% (1994–1996);
96% (1996–1997);
89% (1998–2001)
Successful deployment;
no endoleaks
89%
Survival free of
aneurysm rupture,
open conversion, or
reintervention for
endoleaks or graft
thrombosis
88% (18 months)
Successful deployment;
no endoleaks; graft
patent; no deaths
89% (30 days)
Successful deployment;
no endoleaks
High risk: 86%
(96% at 30 days);
low risk: 88%
(97% at 30 days)
Successful deployment;
no endoleaks; no
deaths
72% (30 days)
Freedom from any
secondary
intervention
1 yr; 89%; 3 yrs;
67%; 4 yrs; 62%
ft techniques for abdominal aortic aneurysm repair; NA  not available.renal
ients
16
1996)
1997)
001)
27;
51shrinkage or stability of the excluded aneurysm sac,
C1
C
1
F
r
s
t
a
c
t
a
r
c
U
a
a
b
a
w
t
i
a
T
d
C
r
o
d
o
H
s
p
a
C
R
C
1
C
1
c
o
t
b
n
s
a
p
f
l
o
A
r
w
g
p
s
4
v
t
i
u
1
l
a
c
c
r
w
f
w
c
b
l
t
a
a
D
1
f
i
a
1295JACC Vol. 47, No. 6, 2006 Hirsch et al.
March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PADand to determine the need for further intervention in
patients who have undergone endovascular repair of
infrarenal aortic and/or iliac aneurysms. (Level of
Evidence: B)
lass IIa
. Endovascular repair of infrarenal aortic and/or com-
mon iliac aneurysms is reasonable in patients at high
risk of complications from open operations because
of cardiopulmonary or other associated diseases.
(Level of Evidence: B)
lass IIb
. Endovascular repair of infrarenal aortic and/or com-
mon iliac aneurysms may be considered in patients at
low or average surgical risk. (Level of Evidence: B)
An overview of the management of AAAs is depicted in
igure 12. This algorithm incorporates the results of the
andomized UK and VA trials and takes into account the
till relatively limited information that is available regarding
he long-term outcome of endograft repair for infrarenal
neurysms. It must be conceded from the outset that there
ould be honest scientific disagreement regarding a few of
he recommended pathways that are illustrated in this
lgorithm. Some clinicians may think that infrarenal aneu-
ysms should continue to be repaired at a size of only 5.0
m, whereas others could believe that the conclusions of the
K and VA trials are not directly applicable to aortic
neurysms that involve the renal arteries and that these
neurysms should be even larger than 5.5 cm in diameter
efore elective surgical treatment is advised, to warrant its
dditional risks. In addition, there undoubtedly are many
ho consider the present technology of endovascular repair
o be at a state of development that justifies its general use
n low-risk and average-risk patients and in those who
ppear to be at high risk for conventional open operations.
here is nothing unfavorable about its early safety to
iscourage this opinion. As an example from northern
alifornia and Nevada, proctored endovascular aneurysm
epair was undertaken at 22 community hospitals in a series
f 257 patients, only 29% of whom had medical contrain-
ications to conventional operations, with 2 immediate
pen conversions and a 30-day mortality rate of 1.2% (415).
owever, this report shares the current liability of many
tudies concerning aortic stent grafts; the mean follow-up
eriod for these patients is only 9.6 months, during which
nother 8% of them have required reintervention.
. Visceral Artery Aneurysms
ECOMMENDATIONS
lass I
. Open repair or catheter-based intervention is indicated
for visceral aneurysms measuring 2.0 cm in diameter or
larger in women of childbearing age who are not ppregnant and in patients of either gender undergoing
liver transplantation. (Level of Evidence: B)
lass IIa
. Open repair or catheter-based intervention is proba-
bly indicated for visceral aneurysms 2.0 cm in diam-
eter or larger in women beyond childbearing age and
in men. (Level of Evidence: B)
Visceral aneurysms are insidious because they usually
annot be detected by physical examination, are easily
verlooked on plain roentgenograms unless mural calcifica-
ion is present, and occur so infrequently that they may not
e fully appreciated during incidental CT/magnetic reso-
ance imaging scanning. Not surprisingly, therefore, several
tudies have indicated that approximately half of all visceral
rtery aneurysms present with rupture (Table 32). In com-
arison, spontaneous rupture appears to be an unusual event
or renal artery aneurysms, possibly because exceptionally
arge renal artery aneurysms may be discovered on the basis
f nonacute symptoms, such as hypertension or hematuria.
lthough rare under any circumstances, both visceral and
enal artery aneurysms most commonly occur in multiparous
omen (416,417). Furthermore, some studies have sug-
ested that the incidence of splenic artery aneurysms is
articularly high among patients who have portal hyperten-
ion or a history of previous liver transplantation (418–
20). The mortality rate for surgical repair of ruptured
isceral aneurysms is sufficiently ominous (25% or higher)
hat patients who have these risk factors probably should be
nvestigated for visceral artery aneurysms in the presence of
nexplained abdominal symptoms.
. Management Options. An array of open surgical and
aparoscopic approaches has been reported for visceral artery
neurysms, with varying mortality rates depending on the
linical setting. Percutaneous catheter-based therapy with
oil embolization leading to thrombosis of visceral aneu-
ysms has been described for elective patients and for those
ho present with acute rupture. The technical success rate
or these nonsurgical options ranges from 67% to 100%,
ith few fatalities or complications (250,426,427). One
oncern that should be recognized related to the catheter-
ased management of visceral artery aneurysms is the
imited ability to assess the end organ after aneurysm
reatment. This is in contrast to open surgical visceral artery
neurysm repair, in which the end organ may be visualized
nd assessed.
. Lower Extremity Aneurysms
. Etiology. As illustrated in Figures 20 and 21 of the
ull-text guideline, the diameters of peripheral arteries
ncrease approximately 20% to 25% between the ages of 20
nd 70 years (260,428). Coexistent AAAs have been re-
orted in 85% of patients with femoral aneurysms (429) and
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emoral or popliteal aneurysms are present in 3% to 7% of
atients who have AAAs.
Figure 12. Management of abdominal aortic aneurysms. Natural History. Unlike AAAs, the natural history of
xtremity-artery aneurysms is not one of expansion and
upture but one of thromboembolism or thrombosis.
 computed tomography; MR  magnetic resonance.. CT
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PADECOMMENDATION
lass I
. In patients with femoral or popliteal aneurysms,
ultrasound (or CT or magnetic resonance) imaging is
recommended to exclude contralateral femoral or
popliteal aneurysms and AAA. (Level of Evidence: B)
. POPLITEAL ARTERY ANEURYSMS. Popliteal aneurysms ac-
ount for 70% of all aneurysms in the lower extremities and
ave an estimated incidence of 0.1% to 2.8% (431,432).
pproximately 5% of small aortic aneurysms are discovered
ecause of lower extremity ischemia caused by distal embo-
ization of mural thrombus (433). However, thromboem-
olic complications are much more common with popliteal
neurysms, which often are bilateral and also may be
ssociated with aneurysms involving the aorta and the
emoral and superficial femoral arteries (Table 33).
The unfavorable consequences of popliteal aneurysms
uggest that even when asymptomatic with good distal
unoff, they should be repaired electively, although there is
lack of prospective studies to support an unqualified
ecommendation in this regard, especially for aneurysms
easuring less than 2.0 cm in diameter. In fact, there is a
ublished consensus that small popliteal aneurysms rarely
ecome symptomatic and that elective surgical intervention
hould be considered only for those measuring at least 2.0
m in diameter (431,440,441).
. FEMORAL ARTERY ANEURYSMS. Femoral artery aneu-
ysms may be discovered incidentally as a pulsatile mass in
he thigh, or they may present with distal ischemia, and
ven more rarely, with rupture and bleeding.
able 32. Presentation and Mortality Rates for Visceral Artery A
First Author Reference Year
Patients and/or
Aneurysms, n
Symp
or R
Pr
ll visceral
Carmeci (421) 2000 31 74%
(20 Women)
Carr (422) 2001 26/34 Rupt
plenic
Trastek (416) 1982 100 17%;
(87 Women)
Lee (420) 1999 34
(21 Women)
Rupt
uperior
mesenteric
Stone (423) 2002 21
(7 Women)
52%;
(50%
enal
Tham (424) 1983 83/89 None
Henriksson (425) 1985 21/34 None
(16 Women)
A  not available.. Management. sECOMMENDATIONS
lass I
. Patients with a palpable popliteal mass should un-
dergo an ultrasound examination to exclude popliteal
aneurysm. (Level of Evidence: B)
. Patients with popliteal aneurysms 2.0 cm in diameter
or larger should undergo repair to reduce the risk of
thromboembolic complications and limb loss. (Level
of Evidence: B)
. Patients with anastomotic pseudoaneurysms or symp-
tomatic femoral artery aneurysms should undergo re-
pair. (Level of Evidence: A)
Class IIa
. Surveillance by annual ultrasound imaging is sug-
gested for patients with asymptomatic femoral artery
true aneurysms smaller than 3.0 cm in diameter.
(Level of Evidence: C)
. In patients with acute ischemia and popliteal artery
aneurysms and absent runoff, catheter-directed
thrombolysis or mechanical thrombectomy (or both)
is suggested to restore distal runoff and resolve
emboli. (Level of Evidence: B)
. In patients with asymptomatic enlargement of the
popliteal arteries twice the normal diameter for age
and gender, annual ultrasound monitoring is reason-
able. (Level of Evidence: C)
. In patients with femoral or popliteal artery aneu-
rysms, administration of antiplatelet medication may
be beneficial. (Level of Evidence: C)
. POPLITEAL ANEURYSMS. A popliteal mass should be
ysms
tic and/
red on
ation
Initial
Treatment
Complications
With Observation
Alone
Mortality
Rate
Open: 25; NA 3%
endo: 9
42% Open: 19 14% Ruptured Total: 12%;
ruptured: 25%
uptured Open: 81 None at 7.4 yrs 1%
44% Open: 34 NA Elective: 0%;
ruptured: 40%
ruptured
en)
Open: 13;
endo: 3
None
(mean, 1.8 cm)
Elective: 0%;
ruptured: 38%
Open: 14 None 0%
Open: 8 None 0%neur
toma
uptu
esent
ured:
3% r
ured:
38%
of mtudied by duplex ultrasonography to distinguish an
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atient has a history of other arterial aneurysms involving
he contralateral lower extremity or the abdominal aorta.
onoperative observation with periodic noninvasive sur-
eillance may be appropriate if the aneurysm measures
ess than 2.0 cm in diameter or contains no thrombus or
f the patient is at high surgical risk or has limited
ongevity because of medical comorbidities. If symptoms
evelop or the aneurysm enlarges on follow-up duplex
cans, the risk of thromboembolic complications and
imb loss then must be weighed against whatever factors
riginally may have influenced the decision to postpone
urgical treatment.
In the setting of acute ischemia related to popliteal
rtery aneurysm thrombosis or thromboembolism,
atheter-directed thrombolytic therapy is useful to re-
stablish patency of the popliteal and tibial trunks, which
llows for more effective definitive aneurysm treatment
nd limb salvage. Largely because of previous and often
nrecognized emboli, one of the obstacles to a successful
urgical outcome is the absence of adequate arterial
utflow in the calf and foot. Because limb salvage rates
an be correlated directly with the number of available
unoff vessels, as much thrombus as possible must be
leared from the tibioperoneal and plantar arteries in
onjunction with bypass grafting to exclude the popliteal
neurysm from the circulation. In the past, this has been
one strictly with thromboembolectomy balloon cathe-
ers in the operating room, often after preoperative
rteriograms or MRA scans have failed to determine
hether a target vessel for revascularization even is
resent. Some series now have been reported, however, in
hich preoperative intra-arterial thrombolytic therapy
as been a valuable adjunct for restoring runoff in the
resence of recent thromboembolic events (270,436,
able 33. Presentation and Complication Rates for Popliteal Ane
First
Author Reference Year
Patients and/or
Aneurysms, n
Bilateral
Popliteal or
Other
Aneurysms
ase series
Dawson (434) 1991 50/71 42% Bilateral;
32% other
Carpenter (435) 1994 33/54 62% Bilateral;
61% other
Dawson (436) 1994 42/42 NA
Lowell (437) 1994 106/161 52% Bilateral
(103 Men)
Schroder (438) 1996 217/349 61% Bilateral
Duffy (431) 1998 24/40 66% Bilateral
(23 Men)
ollective
reviews
Dawson (439) 1997 1673/2445
(95% Men)
50% Bilateral;
37% other
A  not available.37,442). tThe algorithm presented in Figure 13 summarizes the
anagement options for either symptomatic or asymp-
omatic popliteal aneurysms. In the presence of mural
hrombus, the diameter of a popliteal aneurysm will
ppear to be smaller on an arteriogram than its true
iameter on duplex ultrasound or CT imaging, but the
alue of an arteriogram is to determine the adequacy of
ibioperoneal outflow and whether the use of catheter-
irected thrombolytic therapy should be considered to
estore runoff. The decision to proceed with elective
urgical treatment in the absence of limb-threatening
schemia is not predicated on aneurysm size alone. It
ust also take into account the overall clinical situation,
he severity of symptoms in the leg, and the surgical or
ndovascular facilities that are available.
. FEMORAL ANEURYSMS. The cause of femoral artery
neurysms may be arterial degeneration (i.e., true aneu-
ysms) or false aneurysms related to previous vascular
econstructions or arterial injury. Femoral artery pseudo-
neurysm represents a pulsatile mass that is contained by
ncomplete elements of the arterial wall and surrounding
ubcutaneous/fibrous tissue and may result from disrup-
ion of a previous femoral suture line, femoral artery
ccess for a catheter-based procedure, or injury resulting
rom puncture due to self-administered drug abuse.
egardless of the cause, a pulsatile groin mass should
e evaluated by duplex ultrasound and/or contrast-
nhanced CT scan. The clinical presentation of true
emoral artery aneurysms is summarized in Table 34
443). Most reports encourage a policy of elective surgi-
al treatment for symptomatic patients if their opera-
ive risk is low and the patient has a reasonable life
xpectancy. In 2 series, however, nonoperative observa-
ion has been used twice as often as elective interven-
s, Since 1990
ymptoms Before
Presentation
Initial
Surgical
Treatment
Complications
With
Observation
Alone
Related
Amputation
Rate
NA 65% 54% NA
%; 39% Ischemic 83% NA 11%
ll asymptomatic None 60% 7%
42% 31% 22% 7%
45% 63% 47% NA
58% 75% None None
(smaller than 2 cm)
67% NA 36% NAurysm
S
61
Aion for asymptomatic femoral aneurysms and appears
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March 21, 2006:1239–312 ACC/AHA Guidelines for the Management of PADo be associated with a relatively low risk for complica-
ions during follow-up periods of 28 to 52 months
393,444). Therefore, the stable femoral artery aneurysm
resents a therapeutic dilemma, because its complication
ate appears to be substantially lower than that for
opliteal aneurysms of similar size. A wide range of
Figure 13. Diagnostic and treatment algorithm
able 34. Clinical Presentation of Femoral Aneurysms
First
Author Reference
No. of
Patients
Aneurysms
(n)
Male:
Female
(n)
Bilateral
(%)
utler (445) 45 63 40:5 47
diseshiah (446) 16 27 15:1 62
aird (447) 30 36 30:0 20
raham (429) 100 172 100:0 72
apienza (448) 22 31 21:1 41eprinted from Vascular Surgery (5th ed), Graham L, Femoral and popliteal aneurysms, 1
AAA  abdominal aortic aneurysm; PAA  popliteal artery aneurysm.ormal dimensions makes it difficult to determine an
rbitrary size at which true femoral aneurysms should be
epaired. By convention, femoral aneurysms measuring
.0 cm or larger appear most likely to cause compressive
ymptoms and therefore also are most likely to be treated
urgically. Although the presence of mural thrombus
popliteal mass. CT  computed tomography.
/PAA
ciated
(%)
Asymptomatic
(%)
Presenting
Symptoms
Complications at
Presentation
1/27 29 Local: 29% Acute thrombosis: 16%;
chronic thrombosis: 16%
rupture: 14%
5/31 70 Embolization: 4%
thrombosis: 7%
rupture: 15%
0/17 27 Local: 23%
ischemic: 50%
Acute thrombosis/
embolization: 13%;
rupture: 0%
5/44 40 Local pain: 11%
mass: 16%
venous: 8%
ischemic: 42%
Embolization: 8%
acute thrombosis: 1%
chronic thrombosis: 1%
rupture: 2%
0/— 64 Local: 5%
ischemic: 35%forAAA
Asso
5
2
4
8
5345–56, Copyright 2000, with permission from Elsevier (443).
c
e
r
o
c
i
r
p
p
e
w
a
e
u
n
a
C
R
R
C
1
2
C
1
2
p
s
I
i
t
r
c
d
A
c
a
i
F
R
e
a
f
e
T
C
C
C
D
F
F
H
H
K
K
L
P
P
S
S
S
W
1300 Hirsch et al. JACC Vol. 47, No. 6, 2006
ACC/AHA Guidelines for the Management of PAD March 21, 2006:1239–312onceivably could represent a risk for distal emboli unless
lective repair is performed, the actual magnitude of this
isk is unknown.
Anastomotic pseudoaneurysms occur with an incidence
f 2% to 5%, are encountered most commonly as a late
omplication of synthetic aortofemoral bypass grafting,
nevitably continue to enlarge if left untreated, and may
equire arteriography before repair. Infected femoral
seudoaneurysms may occur as the result of arterial
uncture during drug abuse and must be treated by
xtensive operative debridement, often in conjunction
ith either autogenous in situ reconstruction or extra-
natomic bypass grafts to avoid CLI. Skin erosion or
xpanding rupture into adjacent soft tissue obviously is an
nstable situation for which urgent surgical repair is
ecessary irrespective of the etiology of the femoral artery
neurysm or pseudoaneurysm.
igure 14. Spontaneous closure rates of selected pseudoaneurysms.
eprinted from J Vasc Surg, 25, Toursarkissian B, Allen BT, Petinec D,
t al., Spontaneous closure of selected iatrogenic pseudoaneurysms
nd arteriovenous fistulae, 803– 8, Copyright 1997, with permission
rom Elsevier (448a). AVF  arteriovenous fistula; PSA  pseudoan-
urysm.
able 35. Ultrasound-Guided Compression of Femoral Pseudoan
First Author Reference Patients (n) Closu
hatterjee (449) 38 3
oughlan (450) 10
ox (451) 100 9
ean (452) 77 5
eld (453) 15 1
ellmeth (454) 29 2
ajarizadeh (455) 57 5
ertz (456) 41 3
azmers (457) 33 2
umins (458) 60 5
angella (459) 36 2
aulson (460) 48 3
erkins (461) 13 1
chaub (462) 124 10
orrell (462) 11 1
teinkamp (463) 98 9
eatherford (464) 11 8. CATHETER-RELATED FEMORAL ARTERY PSEUDOANEU-
YSMS.
ECOMMENDATIONS
lass I
. Patients with suspected femoral pseudoaneurysms
should be evaluated by duplex ultrasonography.
(Level of Evidence: B)
. Initial treatment with ultrasound-guided compres-
sion or thrombin injection is recommended in pa-
tients with large and/or symptomatic femoral artery
pseudoaneurysms. (Level of Evidence: B)
lass IIa
. Surgical repair is reasonable in patients with femoral
artery pseudoaneurysms 2.0 cm in diameter or larger
that persist or recur after ultrasound-guided com-
pression or thrombin injection. (Level of Evidence: B)
. Re-evaluation by ultrasound 1 month after the orig-
inal injury can be useful in patients with asymptom-
atic femoral artery pseudoaneurysms smaller than 2.0
cm in diameter. (Level of Evidence: B)
Although a pulsatile mass is an obvious indication that a
seudoaneurysm may be present, a diagnostic duplex scan
hould be obtained whenever the diagnosis is even suspected.
n the absence of antithrombotic therapy, several studies have
ndicated that catheter-related pseudoaneurysms that are less
han 2.0 cm in diameter tend to heal spontaneously and usually
equire no treatment. Figure 14 illustrates the spontaneous
losure rate of selected pseudoaneurysms that were not imme-
iately repaired, 90% of which resolved within 2 months.
ccordingly, small asymptomatic pseudoaneurysms probably
an be managed conservatively unless they are still present on
follow-up duplex scan 2 months later.
At the opposite extreme, large pseudoaneurysms can rupture
nto the retroperitoneal space or the upper thigh or cause
sms
) Surgery (n) Comments
1 FemoStop used
1
2 10 Recurrences, 1 to 35 days
14 Size less than 4 cm; twice as successful
at closure
2
—
2 2 Recurrences, 2 to 10 days
3 Large catheter sheath size problematic
3 2 Pseudoaneurysm ruptures
— 7 Recurrences
— 3 Recurrences
—
—
5
1
2eury
re (n
7
9
4
6
0
7
4
6
5
2
7
7
0
4
0
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djacent femoral vein or the femoral nerve. Urgent surgical
epair clearly is necessary if any of these serious complications
ccur, and until recently, it was the mainstay of treatment for
ost catheter-related femoral artery injuries. Many reports
ow have demonstrated, however, that the majority of uncom-
licated pseudoaneurysms can be managed nonoperatively
ith either ultrasound-guided compression therapy or the
njection of miniscule amounts of thrombin directly into the
seudoaneurysm cavity. Problems with ultrasound-guided
able 36. Thrombin-Injection Closure of Femoral Pseudoaneury
First Author Reference Patients Thrombin Dose (U) Clos
Hughes (468) 9 1000 to 2000
Kang (469) 21 500 to 1000
La Perna (467) 70 1000
Liau (470) 5 1000
Mohler (471) 91 500 to 1000
Reeder (472) 26 50 to 450
Sacket (473) 30 100 to 2000
Taylor (474) 29 600Figure 15. Diagnostic and treatment algorithm for femoral psompression therapy include pain at the site of compression,
ong compression times, and incomplete closure, each of which
s more problematic with large pseudoaneurysms. Table 35
ontains information from 17 series of patients who underwent
ltrasound-guided compression therapy with a primary success
ate of 86% and surgical treatment in only 4.9%. Recurrences
sually responded to further compression and most frequently
ere associated with pseudoaneurysms that exceeded 4.0 cm in
ize in patients who had required larger-diameter delivery
heaths or periprocedural anticoagulation.
n) Surgery (n) Comments
0 1 recurrence at 4 days
1
2 94% overall success rate
Success maintained in patients with antithrombotic
medications
0
0 98% overall success rate
Second injection required for 3 patients
0 1 recurrence at 4 days
3
1sms
ure (
8
20
66
5
87
25
27eudoaneurysm. AV  arteriovenous; US  ultrasound.
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m may be successfully obliterated by the injection of throm-
in, 100 to 3000 international units, under ultrasound guid-
nce. Table 36 contains data from seven institutional series in
hich thrombin injection was performed for catheter-related
emoral pseudoaneurysms. In aggregate, the success rate was
3%, and only 4.1% of the patients needed operations. Throm-
in injection can be complicated by distal arterial thromboem-
olism in less than 2% of cases and rarely by pulmonary
mbolism. The recurrence rate is approximately 5% after an
nitial injection, but recurrent pseudoaneurysms can be safely
einjected with a high rate of success (465–467).
The algorithm illustrated in Figure 15 presents an ap-
roach to the management of catheter-related femoral
rtery pseudoaneurysms that is consistent with the current
iterature on this topic (16).
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